[Skip to nav](https://www.moffitt.org/research-science/researchers/taiga-nishihori#menu-mobile) [Skip to content](https://www.moffitt.org/research-science/researchers/taiga-nishihori#main-content)
[ ![Moffitt Cancer Center](https://www.moffitt.org/globalassets/images/logos/moffitt-logo-full-white.svg) ](https://www.moffitt.org/ "Moffitt Cancer Center")
Schedule
[New Patients](https://www.moffitt.org/eforms/patientregistrationform/ "New Patients") [Referring Physicians](https://www.moffitt.org/eforms/referapatient/ "Referring Physicians")
[ Find a Doctor ](https://www.moffitt.org/find-a-doctor/ "Find a Doctor")
Patient Portal
[Log In](https://mymoffitt.iqhealth.com/ "Log In") [Enroll](https://mymoffitt.iqhealth.com/self-enroll/)
[ Careers ](https://www.moffitt.org/careers/ "Careers")
[ Locations ](https://www.moffitt.org/locations-directions/ "Locations")
[ 1-888-663-3488 ](tel:1-888-663-3488 "Call 1-888-663-3488")
English
[English](https://www.moffitt.org/research-science/researchers/taiga-nishihori/ "English") [Spanish](https://www.moffitt.org/es/research-science/researchers/taiga-nishihori/ "Spanish")
[ ](https://www.moffitt.org/research-science/researchers/?campaign=567103 "Donate") Search
  * [Cancer Types & Treatments](https://www.moffitt.org/research-science/researchers/taiga-nishihori)
    * [ Cancers ](https://www.moffitt.org/cancers/)
      * [Acute Lymphocytic Leukemia (ALL)](https://www.moffitt.org/cancers/acute-lymphocytic-leukemia-all/ "Acute Lymphocytic Leukemia \(ALL\)")
      * [Acute Myeloid Leukemia (AML)](https://www.moffitt.org/cancers/acute-myelogenous-leukemia/ "Acute Myeloid Leukemia \(AML\)")
      * [Acute Promyelocytic Leukemia (APL)](https://www.moffitt.org/cancers/acute-promyelocytic-leukemia-apl/ "Acute Promyelocytic Leukemia \(APL\)")
      * [Adrenal Cancer](https://www.moffitt.org/cancers/adrenal-cancer/ "Adrenal Cancer")
      * [Anal Cancer](https://www.moffitt.org/cancers/anal-cancer/ "Anal Cancer")
      * [Appendiceal (Appendix) Cancer](https://www.moffitt.org/cancers/appendiceal-appendix-cancer/ "Appendiceal \(Appendix\) Cancer")
      * [Astrocytoma](https://www.moffitt.org/cancers/astrocytoma/ "Astrocytoma")
      * [Basal Cell Carcinoma](https://www.moffitt.org/cancers/basal-cell-carcinoma/ "Basal Cell Carcinoma")
      * [Bladder Cancer](https://www.moffitt.org/cancers/bladder-cancer/ "Bladder Cancer")
      * [Bone Metastasis](https://www.moffitt.org/cancers/bone-metastasis/ "Bone Metastasis")
      * [Brain Cancer](https://www.moffitt.org/cancers/brain-cancer/ "Brain Cancer")
      * [Brain Tumor](https://www.moffitt.org/cancers/brain-tumor/ "Brain Tumor")
      * [Brain Metastases](https://www.moffitt.org/cancers/brain-metastases/ "Brain Metastases")
      * [Breast Cancer](https://www.moffitt.org/cancers/breast-cancer/ "Breast Cancer")
      * [Cervical Cancer](https://www.moffitt.org/cancers/cervical-cancer/ "Cervical Cancer")
      * [Cholangiocarcinoma (Bile Duct Cancer)](https://www.moffitt.org/cancers/cholangiocarcinoma-bile-duct-cancer/ "Cholangiocarcinoma \(Bile Duct Cancer\)")
      * [Chronic Lymphocytic Leukemia (CLL)](https://www.moffitt.org/cancers/chronic-lymphocytic-leukemia/ "Chronic Lymphocytic Leukemia \(CLL\)")
      * [Colon Cancer](https://www.moffitt.org/cancers/colon-cancer/ "Colon Cancer")
      * [Colorectal Cancer](https://www.moffitt.org/cancers/colorectal-cancer/ "Colorectal Cancer")
      * [Chronic Myeloid Leukemia (CML)](https://www.moffitt.org/cancers/chronic-myelogenous-leukemia-cml/ "Chronic Myeloid Leukemia \(CML\)")
      * [Cutaneous Lymphoma (CTCL)](https://www.moffitt.org/cancers/cutaneous-t-cell-lymphoma/ "Cutaneous Lymphoma \(CTCL\)")
      * [Diffuse Large B-Cell Lymphoma](https://www.moffitt.org/cancers/diffuse-large-b-cell-lymphoma/ "Diffuse Large B-Cell Lymphoma")
      * [Ductal Carcinoma In Situ](https://www.moffitt.org/cancers/ductal-carcinoma-in-situ/ "Ductal Carcinoma In Situ")
      * [Endometrial (Uterine) Cancer](https://www.moffitt.org/cancers/endometrial-uterine-cancer/ "Endometrial \(Uterine\) Cancer")
      * [Esophageal Cancer](https://www.moffitt.org/cancers/esophageal-cancer/ "Esophageal Cancer")
      * [Follicular Lymphoma](https://www.moffitt.org/cancers/follicular-lymphoma/ "Follicular Lymphoma")
      * [Gallbladder Cancer](https://www.moffitt.org/cancers/gallbladder-cancer/ "Gallbladder Cancer")
      * [Gastrointestinal Carcinoid Tumor](https://www.moffitt.org/cancers/gastrointestinal-carcinoid-tumor/ "Gastrointestinal Carcinoid Tumor")
      * [GIST (Gastrointestinal Stromal Tumor)](https://www.moffitt.org/cancers/gist-gastrointestinal-stromal-tumor/ "GIST \(Gastrointestinal Stromal Tumor\)")
      * [Glioblastoma](https://www.moffitt.org/cancers/glioblastoma/ "Glioblastoma")
      * [Head and Neck Cancer](https://www.moffitt.org/cancers/head-and-neck-cancer/ "Head and Neck Cancer")
      * [HER2 Positive Breast Cancer](https://www.moffitt.org/cancers/her2-positive-breast-cancer/ "HER2 Positive Breast Cancer")
      * [Hodgkin Lymphoma](https://www.moffitt.org/cancers/hodgkin-lymphoma/ "Hodgkin Lymphoma")
      * [Inflammatory Breast Cancer](https://www.moffitt.org/cancers/inflammatory-breast-cancer/ "Inflammatory Breast Cancer")
      * [Invasive Ductal Carcinoma](https://www.moffitt.org/cancers/invasive-ductal-carcinoma/ "Invasive Ductal Carcinoma")
      * [Kidney (Renal Cell) Cancer](https://www.moffitt.org/cancers/kidney-renal-cell-cancer/ "Kidney \(Renal Cell\) Cancer")
      * [Leukemia](https://www.moffitt.org/cancers/leukemia/ "Leukemia")
      * [Liver (Hepatocellular) Cancer](https://www.moffitt.org/cancers/liver-hepatocellular-cancer/ "Liver \(Hepatocellular\) Cancer")
      * [Low-Grade Glioma](https://www.moffitt.org/cancers/low-grade-glioma/ "Low-Grade Glioma")
      * [Lung Cancer](https://www.moffitt.org/cancers/lung-cancer/ "Lung Cancer")
      * [Lymphomas (Hodgkin and Non-Hodgkin)](https://www.moffitt.org/cancers/lymphomas-hodgkin-and-non-hodgkin/ "Lymphomas \(Hodgkin and Non-Hodgkin\)")
      * [Mantle Cell Lymphoma](https://www.moffitt.org/cancers/mantle-cell-lymphoma/ "Mantle Cell Lymphoma")
      * [Melanoma](https://www.moffitt.org/cancers/melanoma/ "Melanoma")
      * [Meningioma](https://www.moffitt.org/cancers/meningioma/ "Meningioma")
      * [Merkel Cell Carcinoma](https://www.moffitt.org/cancers/merkel-cell-carcinoma/ "Merkel Cell Carcinoma")
      * [Mesothelioma](https://www.moffitt.org/cancers/mesothelioma/ "Mesothelioma")
      * [Metastatic Breast Cancer](https://www.moffitt.org/cancers/metastatic-breast-cancer/ "Metastatic Breast Cancer")
      * [Monoclonal Gammopathy of Undetermined Significance (MGUS)](https://www.moffitt.org/cancers/monoclonal-gammopathy-of-undetermined-significance-mgus/ "Monoclonal Gammopathy of Undetermined Significance \(MGUS\)")
      * [Multiple Myeloma-Plasma Cell Tumor](https://www.moffitt.org/cancers/multiple-myeloma-plasma-cell-tumor/ "Multiple Myeloma-Plasma Cell Tumor")
      * [Myelodysplastic Syndromes (MDS)](https://www.moffitt.org/cancers/myelodysplastic-syndromes-mds/ "Myelodysplastic Syndromes \(MDS\)")
      * [Neuroendocrine Tumor](https://www.moffitt.org/cancers/neuroendocrine-tumor/ "Neuroendocrine Tumor")
      * [Neurofibromatosis](https://www.moffitt.org/cancers/neurofibromatosis/ "Neurofibromatosis")
      * [Non-Hodgkin Lymphoma](https://www.moffitt.org/cancers/non-hodgkin-lymphoma/ "Non-Hodgkin Lymphoma")
      * [Oral Cavity (Mouth) Cancer](https://www.moffitt.org/cancers/oral-cavity-mouth-cancer/ "Oral Cavity \(Mouth\) Cancer")
      * [Insurance and Financial Information](https://www.moffitt.org/patient-family/insurance-financial-information/ "Insurance and Financial Information")
      * [Oral Cavity or Throat Cancer](https://www.moffitt.org/cancers/oral-cavity-or-throat-cancer/ "Oral Cavity or Throat Cancer")
      * [Osteosarcoma](https://www.moffitt.org/cancers/osteosarcoma/ "Osteosarcoma")
      * [Ovarian Cancer](https://www.moffitt.org/cancers/ovarian-cancer/ "Ovarian Cancer")
      * [Pancoast Tumor](https://www.moffitt.org/cancers/pancoast-tumor/ "Pancoast Tumor")
      * [Pancreatic Cancer](https://www.moffitt.org/cancers/pancreatic-cancer/ "Pancreatic Cancer")
      * [Penile Cancer](https://www.moffitt.org/cancers/penile-cancer/ "Penile Cancer")
      * [Pituitary Adenoma](https://www.moffitt.org/cancers/pituitary-adenoma/ "Pituitary Adenoma")
      * [Prostate Cancer](https://www.moffitt.org/cancers/prostate-cancer/ "Prostate Cancer")
      * [Rectal Cancer](https://www.moffitt.org/cancers/rectal-cancer/ "Rectal Cancer")
      * [Sarcoma](https://www.moffitt.org/cancers/sarcoma/ "Sarcoma")
      * [Skin Cancer (Nonmelanoma)](https://www.moffitt.org/cancers/skin-cancer-nonmelanoma/ "Skin Cancer \(Nonmelanoma\)")
      * [Skull Base Tumors](https://www.moffitt.org/cancers/skull-base-tumors/ "Skull Base Tumors")
      * [Small Intestine Cancer](https://www.moffitt.org/cancers/small-intestine-cancer/ "Small Intestine Cancer")
      * [Spinal Tumor](https://www.moffitt.org/cancers/spinal-tumor/ "Spinal Tumor")
      * [Squamous Cell Carcinoma](https://www.moffitt.org/cancers/squamous-cell-carcinoma/ "Squamous Cell Carcinoma")
      * [Smoldering Multiple Myeloma](https://www.moffitt.org/cancers/smoldering-multiple-myeloma-smm/ "Smoldering Multiple Myeloma")
      * [Stomach (Gastric) Cancer](https://www.moffitt.org/cancers/stomach-gastric-cancer/ "Stomach \(Gastric\) Cancer")
      * [Testicular Cancer](https://www.moffitt.org/cancers/testicular-cancer/ "Testicular Cancer")
      * [Throat Cancer](https://www.moffitt.org/cancers/throat-cancer/ "Throat Cancer")
      * [Thymoma](https://www.moffitt.org/cancers/thymoma/ "Thymoma")
      * [Thyroid Cancer](https://www.moffitt.org/cancers/thyroid-cancer/ "Thyroid Cancer")
      * [Tongue Cancer](https://www.moffitt.org/cancers/tongue-cancer/ "Tongue Cancer")
      * [Tracheal Cancer](https://www.moffitt.org/cancers/tracheal-cancer/ "Tracheal Cancer")
      * [Triple Negative Breast Cancer](https://www.moffitt.org/cancers/triple-negative-breast-cancer/ "Triple Negative Breast Cancer")
      * [Vaginal Cancer](https://www.moffitt.org/cancers/vaginal-cancer/ "Vaginal Cancer")
      * [Vulvar Cancer](https://www.moffitt.org/cancers/vulvar-cancer/ "Vulvar Cancer")
    * [ Treatments ](https://www.moffitt.org/treatments/)
      * [Blood Bone Marrow Transplant](https://www.moffitt.org/treatments/blood-bone-marrow-transplant/ "Blood Bone Marrow Transplant")
      * [Bloodless Medicine and Surgery](https://www.moffitt.org/treatments/bloodless-medicine-and-surgery/ "Bloodless Medicine and Surgery")
      * [Cardio-Oncology](https://www.moffitt.org/treatments/cardio-oncology/ "Cardio-Oncology")
      * [Chemotherapy](https://www.moffitt.org/treatments/chemotherapy/ "Chemotherapy")
      * [Clinical Pathways](https://www.moffitt.org/treatments/clinical-pathways/ "Clinical Pathways")
      * [Clinical Trials](https://www.moffitt.org/clinical-trials-research/clinical-trials/ "Clinical Trials")
      * [Diagnostic Services](https://www.moffitt.org/diagnostic-services/ "Diagnostic Services")
      * [Endoscopic Procedures](https://www.moffitt.org/treatments/endoscopic-procedures/ "Endoscopic Procedures")
      * [Fertility Preservation](https://www.moffitt.org/treatments/fertility-preservation/ "Fertility Preservation")
      * [Gynecologic Oncology](https://www.moffitt.org/treatments/gynecologic-oncology/ "Gynecologic Oncology")
      * [Immunotherapy](https://www.moffitt.org/treatments/immunotherapy/ "Immunotherapy")
      * [Interventional Pain Management](https://www.moffitt.org/treatments/interventional-pain-management/ "Interventional Pain Management")
      * [Interventional Radiology](https://www.moffitt.org/treatments/interventional-radiology/ "Interventional Radiology")
      * [Precision Medicine](https://www.moffitt.org/treatments/precision-medicine/ "Precision Medicine")
      * [Pharmacy](https://www.moffitt.org/treatments/pharmacy/ "Pharmacy")
      * [Radiation Therapy](https://www.moffitt.org/treatments/radiation-therapy/ "Radiation Therapy")
      * [Rehabilitation Services](https://www.moffitt.org/treatments/rehabilitation-services/ "Rehabilitation Services")
      * [Supportive Care Medicine](https://www.moffitt.org/treatments/supportive-care-medicine/ "Supportive Care Medicine")
      * [Surgical Care](https://www.moffitt.org/treatments/surgical-care/ "Surgical Care")
      * [Systemic Therapy](https://www.moffitt.org/treatments/systemic-therapy/ "Systemic Therapy")
      * [Targeted Therapy](https://www.moffitt.org/treatments/targeted-therapy/ "Targeted Therapy")
      * [Tumor Board](https://www.moffitt.org/treatments/tumor-board/ "Tumor Board")
    * [ Clinical Trials ](https://www.moffitt.org/clinical-trials-research/clinical-trials/)
      * [Am I A Candidate?](https://www.moffitt.org/clinical-trials-research/clinical-trials/am-i-a-candidate/ "Am I A Candidate?")
      * [Clinical Research Unit](https://www.moffitt.org/clinical-trials-research/clinical-trials/clinical-research-unit/ "Clinical Research Unit")
      * [Clinical Trials Administration](https://www.moffitt.org/clinical-trials-research/clinical-trials/clinical-trials-administration/ "Clinical Trials Administration")
      * [Clinical Trials: Are They Right for You?](https://www.moffitt.org/clinical-trials-research/clinical-trials/clinical-trials-are-they-right-for-you/ "Clinical Trials: Are They Right for You?")
      * [Patient Protection](https://www.moffitt.org/clinical-trials-research/clinical-trials/patient-protection/ "Patient Protection")
      * [Phase 1 Clinical Trials](https://www.moffitt.org/clinical-trials-research/clinical-trials/phase-1-clinical-trials/ "Phase 1 Clinical Trials")
    * [ Diagnostic Services ](https://www.moffitt.org/diagnostic-services/)
      * [Cancer Screenings](https://www.moffitt.org/diagnostic-services/cancer-screenings/ "Cancer Screenings")
      * [Genetic Counseling and Genetic Testing](https://www.moffitt.org/diagnostic-services/genetic-counseling-and-genetic-testing/ "Genetic Counseling and Genetic Testing")
      * [Labwork and Bloodwork](https://www.moffitt.org/diagnostic-services/labwork-and-bloodwork/ "Labwork and Bloodwork")
      * [Pathology](https://www.moffitt.org/diagnostic-services/pathology/ "Pathology")
      * [Radiology – Diagnostic Imaging and Interventional Radiology](https://www.moffitt.org/diagnostic-services/radiology-diagnostic-imaging-and-interventional-radiology/ "Radiology – Diagnostic Imaging and Interventional Radiology")
      * [Cancer Treatments](https://www.moffitt.org/treatments/ "Cancer Treatments")
    * [ ![](https://www.moffitt.org/contentassets/5f17f2115eca48a1aa7faa610608f778/clinical-trials.jpg) Search Clinical Trials  Moffitt participates in over 400 clinical trials. Find a trial that is right for you. ](https://www.moffitt.org/clinical-trials-research/clinical-trials/ "Search Clinical Trials")
  * [Patients & Families](https://www.moffitt.org/research-science/researchers/taiga-nishihori)
    * [ Patient & Family ](https://www.moffitt.org/patient-family/)
    * [ Preparing For Your Appointment ](https://www.moffitt.org/patient-family/preparing-for-your-appointment/)
      * [Patient and Family Orientation](https://www.moffitt.org/patient-family/preparing-for-your-appointment/patient-and-family-orientation/ "Patient and Family Orientation")
      * [Medical Records](https://www.moffitt.org/patient-family/preparing-for-your-appointment/medical-records/ "Medical Records")
      * [Appointment Reminder Service](https://www.moffitt.org/patient-family/preparing-for-your-appointment/appointment-reminder-service/ "Appointment Reminder Service")
      * [MyMoffitt Patient Portal](https://www.moffitt.org/patient-family/preparing-for-your-appointment/mymoffitt-patient-portal/ "MyMoffitt Patient Portal")
      * [New Cancer Diagnosis](https://www.moffitt.org/patient-family/preparing-for-your-appointment/new-cancer-diagnosis/ "New Cancer Diagnosis")
      * [Online Registration Frequently Asked Questions](https://www.moffitt.org/patient-family/preparing-for-your-appointment/online-registration-frequently-asked-questions/ "Online Registration Frequently Asked Questions")
      * [Scheduling Your Appointment](https://www.moffitt.org/patient-family/preparing-for-your-appointment/scheduling-your-appointment/ "Scheduling Your Appointment")
      * [Traveling for Cancer Treatment](https://www.moffitt.org/patient-family/preparing-for-your-appointment/traveling-for-cancer-treatment/ "Traveling for Cancer Treatment")
      * [Preparing For Your Hospitalization](https://www.moffitt.org/patient-family/preparing-for-your-hospitalization/ "Preparing For Your Hospitalization")
      * [Preparing For Your Surgery](https://www.moffitt.org/patient-family/preparing-for-your-surgery/ "Preparing For Your Surgery")
      * [Visitor Policy](https://www.moffitt.org/patient-family/preparing-for-your-appointment/visitor-policy/ "Visitor Policy")
      * [Patient Rights and Responsibilities](https://www.moffitt.org/patient-family/preparing-for-your-appointment/patient-rights-and-responsibilities/ "Patient Rights and Responsibilities")
      * [What to Know About Your Appointments During Hurricane Season](https://www.moffitt.org/patient-family/hurricane/appointments-during-hurricane-season/ "What to Know About Your Appointments During Hurricane Season")
    * [ Insurance & Financial Information ](https://www.moffitt.org/patient-family/insurance-financial-information/)
      * [Copay Assistance Program](https://www.moffitt.org/patient-family/insurance-financial-information/copay-assistance-program/ "Copay Assistance Program")
      * [Financial Assistance](https://www.moffitt.org/patient-family/insurance-financial-information/financial-assistance/ "Financial Assistance")
      * [Glossary of Terms](https://www.moffitt.org/patient-family/insurance-financial-information/glossary-of-terms/ "Glossary of Terms")
      * [Health Exchange](https://www.moffitt.org/patient-family/insurance-financial-information/health-exchange/ "Health Exchange")
      * [Insurance Coverage](https://www.moffitt.org/patient-family/insurance-financial-information/insurance-coverage/ "Insurance Coverage")
      * [Medicare Coverage](https://www.moffitt.org/patient-family/insurance-financial-information/medicare-coverage/ "Medicare Coverage")
      * [Obtain a Cost Estimate](https://www.moffitt.org/patient-family/insurance-financial-information/obtain-a-cost-estimate/ "Obtain a Cost Estimate")
      * [Questions to Ask Your Insurance Company](https://www.moffitt.org/patient-family/insurance-financial-information/questions-to-ask-your-insurance-company/ "Questions to Ask Your Insurance Company")
      * [Understanding Your Bill](https://www.moffitt.org/patient-family/insurance-financial-information/understanding-your-bill/ "Understanding Your Bill")
      * [Frequently Asked Questions](https://www.moffitt.org/patient-family/insurance-financial-information/frequently-asked-questions/ "Frequently Asked Questions")
      * [Financial Information](https://www.moffitt.org/patient-family/insurance-financial-information/financial-information/ "Financial Information")
    * [ Programs & Support Services ](https://www.moffitt.org/patient-family/programs-support-services/)
      * [Advance Care Planning](https://www.moffitt.org/patient-family/programs-support-services/advance-care-planning/ "Advance Care Planning")
      * [AYA: Adolescent Young Adult Program](https://www.moffitt.org/patient-family/programs-support-services/aya-adolescent-young-adult-program/ "AYA: Adolescent Young Adult Program")
      * [Chaplaincy Spiritual Care](https://www.moffitt.org/patient-family/programs-support-services/chaplaincy-spiritual-care/ "Chaplaincy Spiritual Care")
      * [Community Resources](https://www.moffitt.org/patient-family/programs-support-services/online-resources/ "Community Resources")
      * [Counseling and Support](https://www.moffitt.org/patient-family/programs-support-services/counseling-and-support/ "Counseling and Support")
      * [Language Services](https://www.moffitt.org/patient-family/programs-support-services/language-services/ "Language Services")
      * [Nutrition](https://www.moffitt.org/patient-family/programs-support-services/nutrition/ "Nutrition")
      * [Senior Adult Oncology Program](https://www.moffitt.org/patient-family/programs-support-services/senior-adult-oncology-program/ "Senior Adult Oncology Program")
      * [Share Gratitude for Moffitt Team Members](https://www.moffitt.org/patient-family/patient-and-family-centered-care/share-gratitude-for-moffitt-team-members/ "Share Gratitude for Moffitt Team Members")
      * [Specialty Pharmacy at Moffitt](https://www.moffitt.org/patient-family/programs-support-services/specialty-pharmacy/ "Specialty Pharmacy at Moffitt")
    * [ Patient and Family Centered Care ](https://www.moffitt.org/patient-family/patient-and-family-centered-care/)
      * [Demonstrating Respect at Moffitt](https://www.moffitt.org/patient-family/patient-and-family-centered-care/demonstrating-respect-at-moffitt/ "Demonstrating Respect at Moffitt")
      * [Daisy and Sunflower Awards](https://www.moffitt.org/patient-family/patient-and-family-centered-care/daisy-and-sunflower-awards/ "Daisy and Sunflower Awards")
      * [Patient and Family Advisory Program](https://www.moffitt.org/patient-family/patient-and-family-centered-care/patient-and-family-advisory-program/ "Patient and Family Advisory Program")
      * [Patient Relations](https://www.moffitt.org/patient-family/patient-and-family-centered-care/patient-relations/ "Patient Relations")
      * [Patient Researcher Forum](https://www.moffitt.org/patient-family/patient-and-family-centered-care/patient-researcher-forum/ "Patient Researcher Forum")
      * [Patti K Halula Legacy Award](https://www.moffitt.org/patient-family/patient-and-family-centered-care/patti-k-halula-legacy-award/ "Patti K Halula Legacy Award")
      * [Share Gratitude for Moffitt Team Members](https://www.moffitt.org/patient-family/patient-and-family-centered-care/share-gratitude-for-moffitt-team-members/ "Share Gratitude for Moffitt Team Members")
    * [ Cancer Survivorship ](https://www.moffitt.org/patient-family/cancer-survivorship/)
      * [Cancer Survivorship Program](https://www.moffitt.org/patient-family/cancer-survivorship/cancer-survivorship-program/ "Cancer Survivorship Program")
    * [ International Patient Services ](https://www.moffitt.org/patient-family/international-patient-services/)
      * [Frequently Asked Questions](https://www.moffitt.org/patient-family/international-patient-services/frequently-asked-questions/ "Frequently Asked Questions")
      * [Online Consult Forms](https://www.moffitt.org/patient-family/international-patient-services/online-consult-forms/ "Online Consult Forms")
      * [Online Consults](https://www.moffitt.org/patient-family/international-patient-services/online-consults/ "Online Consults")
      * [Moffitt Outreach in Puerto Rico](https://www.moffitt.org/patient-family/international-patient-services/puerto-rico/ "Moffitt Outreach in Puerto Rico")
    * [ Moffitt Virtual Care ](https://www.moffitt.org/patient-family/moffitt-virtual-care/)
      * [All About Virtual Care](https://www.moffitt.org/patient-family/moffitt-virtual-care/all-about-virtual-care/ "All About Virtual Care")
      * [Informed Consent for Telemedicine](https://www.moffitt.org/patient-family/moffitt-virtual-care/informed-consent-for-telemedicine/ "Informed Consent for Telemedicine")
      * [New Cancer Patients](https://www.moffitt.org/patient-family/moffitt-virtual-care/new-cancer-patients/ "New Cancer Patients")
      * [Virtual Care Success Checklist](https://www.moffitt.org/patient-family/moffitt-virtual-care/virtual-care-success-checklist/ "Virtual Care Success Checklist")
    * [ Inspiring Stories ](https://www.moffitt.org/inspiring-stories/)
      * [Isabel's Story](https://www.moffitt.org/inspiring-stories/isabels-story/ "Isabel's Story")
      * [Amanda's Story](https://www.moffitt.org/inspiring-stories/amandas-story/ "Amanda's Story")
      * [Rick's Story](https://www.moffitt.org/inspiring-stories/ricks-story-my-prostate-cancer-journey/ "Rick's Story")
      * [Vondalyn's Story: From Adversity to Advocacy](https://www.moffitt.org/inspiring-stories/vondalyns-story-from-adversity-to-advocacy/ "Vondalyn's Story: From Adversity to Advocacy")
      * [Cayla’s Story: Cancer Never Cares About Anything Like That](https://www.moffitt.org/inspiring-stories/caylas-story-cancer-never-cares-about-anything-like-that/ "Cayla’s Story: Cancer Never Cares About Anything Like That")
      * [Rick's Story: Now What?](https://www.moffitt.org/inspiring-stories/ricks-story-now-what/ "Rick's Story: Now What?")
      * [Amy's Story: No Longer Alone](https://www.moffitt.org/inspiring-stories/no-longer-alone/ "Amy's Story: No Longer Alone")
      * [Zoe's Story](https://www.moffitt.org/inspiring-stories/zoeys-story/ "Zoe's Story")
      * [Erma's Story](https://www.moffitt.org/inspiring-stories/ermas-story/ "Erma's Story")
      * [Donna's Story](https://www.moffitt.org/inspiring-stories/donnas-story/ "Donna's Story")
      * [Dr. Vadaparampil's Story](https://www.moffitt.org/inspiring-stories/dr.-vadaparampils-story "Dr. Vadaparampil's Story")
      * [Mark's Story](https://www.moffitt.org/inspiring-stories/marks-story/ "Mark's Story")
      * [Heather's Story](https://www.moffitt.org/inspiring-stories/heathers-story/ "Heather's Story")
      * [Ellen's Story](https://www.moffitt.org/inspiring-stories/ellens-story/ "Ellen's Story")
      * [Dr. Tran's Story](https://www.moffitt.org/inspiring-stories/dr.-trans-story "Dr. Tran's Story")
      * [Dr. Toloza's Story](https://www.moffitt.org/inspiring-stories/dr.-tolozas-story "Dr. Toloza's Story")
      * [Dr. Silva's Story](https://www.moffitt.org/inspiring-stories/dr.-silvas-story "Dr. Silva's Story")
      * [Dr. Fernandez's Story](https://www.moffitt.org/inspiring-stories/dr.-fernandezs-story "Dr. Fernandez's Story")
      * [Dr. Robinson's Story](https://www.moffitt.org/inspiring-stories/dr.-robinsons-story "Dr. Robinson's Story")
      * [Dr. Pow-Sang's Story](https://www.moffitt.org/inspiring-stories/dr.-pow-sangs-story "Dr. Pow-Sang's Story")
      * [Mike's Volunteer Story](https://www.moffitt.org/inspiring-stories/mikes-volunteer-story/ "Mike's Volunteer Story")
      * [Mike's Story](https://www.moffitt.org/inspiring-stories/mikes-story/ "Mike's Story")
      * [Mary Beth's Story](https://www.moffitt.org/inspiring-stories/mary-beths-story/ "Mary Beth's Story")
      * [Malcolm's Story](https://www.moffitt.org/inspiring-stories/malcolms-story/ "Malcolm's Story")
      * [Lori's Story](https://www.moffitt.org/inspiring-stories/loris-story2/ "Lori's Story")
      * [Miriam's Story](https://www.moffitt.org/inspiring-stories/miriams-story/ "Miriam's Story")
      * [Nick's Story](https://www.moffitt.org/inspiring-stories/nicks-story/ "Nick's Story")
      * [Nadine's Story](https://www.moffitt.org/inspiring-stories/nadines-story/ "Nadine's Story")
      * [Nancy's Story](https://www.moffitt.org/inspiring-stories/nancys-story/ "Nancy's Story")
      * [Madison's Story](https://www.moffitt.org/inspiring-stories/madisons-story/ "Madison's Story")
      * [Lori's Story](https://www.moffitt.org/inspiring-stories/loris-story/ "Lori's Story")
      * [Lloyd's Story](https://www.moffitt.org/inspiring-stories/lloyds-story/ "Lloyd's Story")
      * [Lanse's Story](https://www.moffitt.org/inspiring-stories/lanses-story/ "Lanse's Story")
      * [Kevin's Story](https://www.moffitt.org/inspiring-stories/kevins-story/ "Kevin's Story")
      * [Dr. Mooney's Story](https://www.moffitt.org/inspiring-stories/dr.-mooneys-story "Dr. Mooney's Story")
      * [Ken's Story](https://www.moffitt.org/inspiring-stories/kens-story/ "Ken's Story")
      * [Dr. Lee's Story](https://www.moffitt.org/inspiring-stories/dr.-lees-story "Dr. Lee's Story")
      * [Dr. Kumar's Story](https://www.moffitt.org/inspiring-stories/dr.-kumars-story "Dr. Kumar's Story")
      * [Keith's Story](https://www.moffitt.org/inspiring-stories/keiths-story2/ "Keith's Story")
      * [Dr. Latifi's Story](https://www.moffitt.org/inspiring-stories/dr.-latifis-story "Dr. Latifi's Story")
      * [Keith's Story](https://www.moffitt.org/inspiring-stories/keiths-story/ "Keith's Story")
      * [Dr. Kubal's Story](https://www.moffitt.org/inspiring-stories/dr.-kubals-story "Dr. Kubal's Story")
      * [Dr. Khakpour's Story](https://www.moffitt.org/inspiring-stories/dr.-khakpours-story "Dr. Khakpour's Story")
      * [Dr. Keenan's Story](https://www.moffitt.org/inspiring-stories/dr.-keenans-story "Dr. Keenan's Story")
      * [Dr. Kanetsky's Story](https://www.moffitt.org/inspiring-stories/dr.-kanetskys-story "Dr. Kanetsky's Story")
      * [Dr. Hoffe's Story](https://www.moffitt.org/inspiring-stories/dr.-hoffes-story "Dr. Hoffe's Story")
      * [Dr. Harrison's Story](https://www.moffitt.org/inspiring-stories/dr.-harrisons-story "Dr. Harrison's Story")
      * [Dr. Gwede's Story](https://www.moffitt.org/inspiring-stories/dr.-gwedes-story "Dr. Gwede's Story")
      * [Dr. Giuliano's Story](https://www.moffitt.org/inspiring-stories/dr.-giulianos-story "Dr. Giuliano's Story")
      * [Juli's Story](https://www.moffitt.org/inspiring-stories/julis-story/ "Juli's Story")
      * [Dr. Gonzalez's Story](https://www.moffitt.org/inspiring-stories/dr.-gonzalezs-story "Dr. Gonzalez's Story")
      * [Dr. Gatenby's Story](https://www.moffitt.org/inspiring-stories/dr.-gatenbys-story "Dr. Gatenby's Story")
      * [Dr. Etame's Story](https://www.moffitt.org/inspiring-stories/dr.-etames-story "Dr. Etame's Story")
      * [Dr. Cleveland's Story](https://www.moffitt.org/inspiring-stories/dr.-clevelands-story "Dr. Cleveland's Story")
      * [John and Whitney's Story](https://www.moffitt.org/inspiring-stories/john-and-whitneys-story/ "John and Whitney's Story")
      * [Liz's Story](https://www.moffitt.org/inspiring-stories/lizs-story/ "Liz's Story")
      * [Meet Lloyd](https://www.moffitt.org/inspiring-stories/meet-lloyd/ "Meet Lloyd")
      * [Paul and Gina's Story](https://www.moffitt.org/inspiring-stories/pauls-and-ginas-story/ "Paul and Gina's Story")
      * [Marvin's Story](https://www.moffitt.org/inspiring-stories/marvins-story/ "Marvin's Story")
      * [Meet Melissa](https://www.moffitt.org/inspiring-stories/meet-melissa/ "Meet Melissa")
      * [Muriel's Story](https://www.moffitt.org/inspiring-stories/muriels-story/ "Muriel's Story")
      * [John's and David's Story](https://www.moffitt.org/inspiring-stories/johns-and-davids-story/ "John's and David's Story")
      * [Melissa's Story](https://www.moffitt.org/inspiring-stories/melissas-story/ "Melissa's Story")
      * [Dr. Alexander Anderson's Story](https://www.moffitt.org/inspiring-stories/dr.-alexander-andersons-story "Dr. Alexander Anderson's Story")
      * [Pam's Story](https://www.moffitt.org/inspiring-stories/pams-story/ "Pam's Story")
      * [Yolanda's Story](https://www.moffitt.org/inspiring-stories/yolandas-story/ "Yolanda's Story")
      * [Wilbur's Story](https://www.moffitt.org/inspiring-stories/wilburs-story/ "Wilbur's Story")
      * [Vikki's Story](https://www.moffitt.org/inspiring-stories/vikkis-story/ "Vikki's Story")
      * [Tiffany's Story](https://www.moffitt.org/inspiring-stories/tiffanys-story/ "Tiffany's Story")
      * [Theresa's Story](https://www.moffitt.org/inspiring-stories/theresas-story/ "Theresa's Story")
      * [Joanna's Story](https://www.moffitt.org/inspiring-stories/joannas-story/ "Joanna's Story")
      * [Jenifer's Story](https://www.moffitt.org/inspiring-stories/jenifers-story/ "Jenifer's Story")
      * [Jeanine's Story](https://www.moffitt.org/inspiring-stories/jeanines-story/ "Jeanine's Story")
      * [Meet Jackie](https://www.moffitt.org/inspiring-stories/meet-jackie/ "Meet Jackie")
      * [Ian's Story](https://www.moffitt.org/inspiring-stories/ians-story/ "Ian's Story")
      * [Howard's Story](https://www.moffitt.org/inspiring-stories/howards-story/ "Howard's Story")
      * [Ryan's Story](https://www.moffitt.org/inspiring-stories/ryans-story/ "Ryan's Story")
      * [Robert's Story](https://www.moffitt.org/inspiring-stories/roberts-story/ "Robert's Story")
      * [Rick's Story](https://www.moffitt.org/inspiring-stories/ricks-story/ "Rick's Story")
      * [Richard's Story](https://www.moffitt.org/inspiring-stories/richards-story/ "Richard's Story")
      * [Rena's Story](https://www.moffitt.org/inspiring-stories/renas-story/ "Rena's Story")
      * [Rebecca's Story](https://www.moffitt.org/inspiring-stories/rebeccas-story/ "Rebecca's Story")
      * [Ray's and Dr. Bui's story](https://www.moffitt.org/inspiring-stories/rays-and-dr.-buis-story "Ray's and Dr. Bui's story")
      * [Patti's Story](https://www.moffitt.org/inspiring-stories/pattis-story/ "Patti's Story")
      * [Pam and Jonathan's story](https://www.moffitt.org/inspiring-stories/pams-and-jonathans-story/ "Pam and Jonathan's story")
      * [Sarah's Story](https://www.moffitt.org/inspiring-stories/sarahs-story/ "Sarah's Story")
      * [Steve and Laura's Story](https://www.moffitt.org/inspiring-stories/steve-and-lauras-story/ "Steve and Laura's Story")
      * [Donna's Story](https://www.moffitt.org/inspiring-stories/donna/ "Donna's Story")
      * [Tommy's Story](https://www.moffitt.org/inspiring-stories/tommys-story/ "Tommy's Story")
      * [Viviana's Story](https://www.moffitt.org/inspiring-stories/vivianas-story/ "Viviana's Story")
      * [Craig's Story](https://www.moffitt.org/inspiring-stories/craigs-story/ "Craig's Story")
      * [William's Story](https://www.moffitt.org/inspiring-stories/williams-story/ "William's Story")
      * [The Wilson - Jones's Family Story](https://www.moffitt.org/inspiring-stories/the-joness-family-story/ "The Wilson - Jones's Family Story")
      * [Woodrow's Story](https://www.moffitt.org/inspiring-stories/woodrows-story/ "Woodrow's Story")
      * [Cathy's Story](https://www.moffitt.org/inspiring-stories/cathys-story2/ "Cathy's Story")
      * [Cathy's Story](https://www.moffitt.org/inspiring-stories/cathys-story/ "Cathy's Story")
      * [Carolyn's Story](https://www.moffitt.org/inspiring-stories/carolyn/ "Carolyn's Story")
      * [Beth's Story](https://www.moffitt.org/inspiring-stories/beths-story/ "Beth's Story")
      * [Benita's Story](https://www.moffitt.org/inspiring-stories/benitas-story/ "Benita's Story")
      * [Barney's Story](https://www.moffitt.org/inspiring-stories/barneys-story/ "Barney's Story")
      * [Joel's Story](https://www.moffitt.org/inspiring-stories/joels-story/ "Joel's Story")
      * [Jessica's Story](https://www.moffitt.org/inspiring-stories/jessicas-story/ "Jessica's Story")
      * [Jen's Story](https://www.moffitt.org/inspiring-stories/jens-story/ "Jen's Story")
      * [Jay's Story](https://www.moffitt.org/inspiring-stories/jays-story/ "Jay's Story")
      * [Janelle's Story](https://www.moffitt.org/inspiring-stories/janelles-story/ "Janelle's Story")
      * [Greg's Story](https://www.moffitt.org/inspiring-stories/gregs-story2/ "Greg's Story")
      * [Gayle's Story](https://www.moffitt.org/inspiring-stories/gayles-story/ "Gayle's Story")
      * [Francis' Story](https://www.moffitt.org/inspiring-stories/francis-story/ "Francis' Story")
      * [Dr. Lau's Story](https://www.moffitt.org/inspiring-stories/dr.-laus-story "Dr. Lau's Story")
      * [Dr. Roberto Diaz's Story](https://www.moffitt.org/inspiring-stories/dr.-roberto-diazs-story "Dr. Roberto Diaz's Story")
      * [Dimas' Story](https://www.moffitt.org/inspiring-stories/dimas-story/ "Dimas' Story")
      * [David and Vesta's Story](https://www.moffitt.org/inspiring-stories/david-and-vestas-story/ "David and Vesta's Story")
      * [Cydney's Story](https://www.moffitt.org/inspiring-stories/cydneys-story/ "Cydney's Story")
      * [Charles' Story](https://www.moffitt.org/inspiring-stories/charless-story/ "Charles' Story")
      * [Cammie's Story](https://www.moffitt.org/inspiring-stories/cammies-story/ "Cammie's Story")
      * [Joanne's Story](https://www.moffitt.org/inspiring-stories/joannes-story/ "Joanne's Story")
      * [Neisha's Story](https://www.moffitt.org/inspiring-stories/neishas-story/ "Neisha's Story")
      * [Greg's Story](https://www.moffitt.org/inspiring-stories/gregs-story/ "Greg's Story")
      * [Joshua's Story](https://www.moffitt.org/inspiring-stories/joshuas-story/ "Joshua's Story")
      * [Bridget's Story](https://www.moffitt.org/inspiring-stories/bridgets-story/ "Bridget's Story")
      * [Barbara's Story](https://www.moffitt.org/inspiring-stories/barbaras-story/ "Barbara's Story")
      * [Abrianna's Story](https://www.moffitt.org/inspiring-stories/abriannas-story/ "Abrianna's Story")
    * [ ![Friends supporting woman with cancer ](https://www.moffitt.org/globalassets/images/content-images/patient--family/women-cancer-640.jpg) Taking Care of Your Health  Taking Care of Your Health features cancer-related information, health tips, patient stories and more. ](https://www.moffitt.org/taking-care-of-your-health/ "Taking Care of Your Health")
  * [For Healthcare Professionals](https://www.moffitt.org/research-science/researchers/taiga-nishihori)
    * [ For Healthcare Professionals ](https://www.moffitt.org/for-healthcare-professionals/)
    * [ Clinical Programs and Services ](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/)
      * [Adolescent Young Adult (AYA) Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/adolescent-young-adult-aya-program/ "Adolescent Young Adult \(AYA\) Program")
      * [Anesthesiology and Critical Care Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/anesthesiology-program/ "Anesthesiology and Critical Care Program")
      * [BMT and Cellular Immunotherapy Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/bmt-and-cellular-immunotherapy-program/ "BMT and Cellular Immunotherapy Program")
      * [Breast Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/breast-oncology-program/ "Breast Oncology Program")
      * [Cardio-Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/cardio-oncology-program/ "Cardio-Oncology Program")
      * [Cutaneous Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/cutaneous-oncology-program/ "Cutaneous Oncology Program")
      * [Diagnostic Imaging and Interventional Radiology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/diagnostic-imaging-and-interventional-radiology-program/ "Diagnostic Imaging and Interventional Radiology Program")
      * [Endocrine Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/endocrine-oncology-program/ "Endocrine Oncology Program")
      * [Endoscopic Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/endoscopic-oncology-program/ "Endoscopic Oncology Program")
      * [Gastrointestinal Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/gastrointestinal-oncology-program/ "Gastrointestinal Oncology Program")
      * [Genetic Counseling Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/genetic-counseling-program/ "Genetic Counseling Program")
      * [Genitourinary Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/genitourinary-oncology-program/ "Genitourinary Oncology Program")
      * [Gynecologic Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/gynecologic-oncology-program/ "Gynecologic Oncology Program")
      * [Head and Neck Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/head-and-neck-oncology-program/ "Head and Neck Oncology Program")
      * [Immunotherapy Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/immunotherapy-program/ "Immunotherapy Program")
      * [Malignant Hematology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/malignant-hematology-program/ "Malignant Hematology Program")
      * [Moffitt Malignant Hematology Cellular Therapy at Memorial Healthcare System](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/moffitt-malignant-hematology-cellular-therapy-at-memorial-healthcare-system/ "Moffitt Malignant Hematology Cellular Therapy at Memorial Healthcare System")
      * [Neuro-Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/neuro-oncology-program/ "Neuro-Oncology Program")
      * [Pathology](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/pathology/ "Pathology")
      * [Pharmacy](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/pharmacy/ "Pharmacy")
      * [Radiation Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/radiation-oncology-program/ "Radiation Oncology Program")
      * [Sarcoma Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/sarcoma-program/ "Sarcoma Program")
      * [Screening Prevention](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/screening-prevention/ "Screening Prevention")
      * [Senior Adult Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/senior-adult-oncology-program/ "Senior Adult Oncology Program")
      * [Supportive Care Medicine Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/supportive-care-medicine-program/ "Supportive Care Medicine Program")
      * [Thoracic Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/thoracic-oncology-program/ "Thoracic Oncology Program")
      * [Translational Pathology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/translational-pathology/ "Translational Pathology Program")
    * [ Physician Relations ](https://www.moffitt.org/for-healthcare-professionals/physician-relations/)
    * [ Continuing Education ](https://www.moffitt.org/for-healthcare-professionals/continuing-education/)
      * [Moffitt Grand Rounds](https://www.moffitt.org/for-healthcare-professionals/continuing-education/moffitt-grand-rounds/ "Moffitt Grand Rounds")
      * [Provider Conferences](https://www.moffitt.org/for-healthcare-professionals/continuing-education/provider-conferences/ "Provider Conferences")
  * [Research](https://www.moffitt.org/research-science/researchers/taiga-nishihori)
    * [ Research Science ](https://www.moffitt.org/research-science/)
    * [ Research Programs ](https://www.moffitt.org/research-science/research-programs/)
      * [Cancer Biology and Evolution](https://www.moffitt.org/research-science/research-programs/cancer-biology-and-evolution/ "Cancer Biology and Evolution")
      * [Cancer Epidemiology](https://www.moffitt.org/research-science/research-programs/cancer-epidemiology/ "Cancer Epidemiology")
      * [Health Outcomes and Behavior](https://www.moffitt.org/research-science/research-programs/health-outcomes-behavior/ "Health Outcomes and Behavior")
      * [Immuno-Oncology](https://www.moffitt.org/research-science/research-programs/immuno-oncology/ "Immuno-Oncology")
      * [Molecular Medicine](https://www.moffitt.org/research-science/research-programs/molecular-medicine/ "Molecular Medicine")
    * [ Divisions and Departments ](https://www.moffitt.org/research-science/divisions-and-departments/)
      * [Basic Science](https://www.moffitt.org/research-science/divisions-and-departments/basic-science/ "Basic Science")
      * [BioEngineering](https://www.moffitt.org/research-science/divisions-and-departments/bioengineering/ "BioEngineering")
      * [Clinical Science](https://www.moffitt.org/research-science/divisions-and-departments/clinical-science/ "Clinical Science")
      * [Population Science](https://www.moffitt.org/research-science/divisions-and-departments/population-science/ "Population Science")
      * [Quantitative Science](https://www.moffitt.org/research-science/divisions-and-departments/quantitative-science/ "Quantitative Science")
    * [ Centers and Institutes ](https://www.moffitt.org/research-science/centers-and-institutes/)
      * [Centers of Excellence](https://www.moffitt.org/research-science/centers-and-institutes/centers-of-excellence/ "Centers of Excellence")
      * [Institutes](https://www.moffitt.org/research-science/centers-and-institutes/institutes/ "Institutes")
    * [ Community Outreach and Engagement ](https://www.moffitt.org/research-science/community-outreach-and-engagement/)
      * [About COE](https://www.moffitt.org/research-science/community-outreach-and-engagement/about-coe/ "About COE")
      * [Advisory Boards](https://www.moffitt.org/research-science/community-outreach-and-engagement/community-advisory-boards/ "Advisory Boards")
      * [Catchment Area](https://www.moffitt.org/research-science/community-outreach-and-engagement/catchment-area/ "Catchment Area")
      * [Data](https://www.moffitt.org/research-science/community-outreach-and-engagement/data/ "Data")
      * [Outreach](https://www.moffitt.org/research-science/community-outreach-and-engagement/outreach/ "Outreach")
      * [Research and Clinical Trials](https://www.moffitt.org/research-science/community-outreach-and-engagement/research-and-clinical-trials/ "Research and Clinical Trials")
      * [Get Involved With COE](https://www.moffitt.org/research-science/community-outreach-and-engagement/get-involved-with-coe/ "Get Involved With COE")
    * [ Shared Resources ](https://www.moffitt.org/research-science/shared-resources/)
      * [Analytic Microscopy](https://www.moffitt.org/research-science/shared-resources/analytic-microscopy/ "Analytic Microscopy")
      * [Biostatistics and Bioinformatics](https://www.moffitt.org/research-science/shared-resources/biostatistics-and-bioinformatics/ "Biostatistics and Bioinformatics")
      * [Cancer Pharmacokinetics and Pharmacodynamics](https://www.moffitt.org/research-science/shared-resources/cancer-pharmacokinetics-and-pharmacodynamics/ "Cancer Pharmacokinetics and Pharmacodynamics")
      * [Chemical Biology](https://www.moffitt.org/research-science/shared-resources/chemical-biology/ "Chemical Biology")
      * [Collaborative Data Services](https://www.moffitt.org/research-science/shared-resources/collaborative-data-services/ "Collaborative Data Services")
      * [Flow Cytometry](https://www.moffitt.org/research-science/shared-resources/flow-cytometry/ "Flow Cytometry")
      * [Gene Targeting](https://www.moffitt.org/research-science/shared-resources/gene-targeting/ "Gene Targeting")
      * [Molecular Genomics](https://www.moffitt.org/research-science/shared-resources/molecular-genomics/ "Molecular Genomics")
      * [Participant Research, Interventions, and Measurement Core (PRISM)](https://www.moffitt.org/research-science/shared-resources/participant-research-interventions-and-measurement-core-prism/ "Participant Research, Interventions, and Measurement Core \(PRISM\)")
      * [Proteomics and Metabolomics](https://www.moffitt.org/research-science/shared-resources/proteomics-and-metabolomics/ "Proteomics and Metabolomics")
      * [Quantitative Imaging Core](https://www.moffitt.org/research-science/shared-resources/quantitative-imaging-core/ "Quantitative Imaging Core")
      * [Small Animal Imaging Lab](https://www.moffitt.org/research-science/shared-resources/small-animal-imaging-lab/ "Small Animal Imaging Lab")
      * [Tissue](https://www.moffitt.org/research-science/shared-resources/tissue/ "Tissue")
    * [ Academic and Industry Partnerships ](https://www.moffitt.org/research-science/academic-and-industry-partnerships/)
      * [Office of Innovation](https://www.moffitt.org/research-science/academic-and-industry-partnerships/office-of-innovation/ "Office of Innovation")
      * [Academic Partnerships](https://www.moffitt.org/research-science/academic-and-industry-partnerships/academic-partnerships/ "Academic Partnerships")
    * [ Administration ](https://www.moffitt.org/research-science/administration/)
      * [Non-Therapeutic Research Office](https://www.moffitt.org/research-science/administration/non-therapeutic-research-office/ "Non-Therapeutic Research Office")
    * [ ![Research fellows in a lab](https://www.moffitt.org/contentassets/a7d26515856847ad8ebe488477e34948/research-training.jpg) Research Education and Training  We are interested in recruiting scholars who have a profound interest in preventing, treating and curing cancer. ](https://www.moffitt.org/education/research-education-and-training/ "Research Education and Training")
  * [Training & Education](https://www.moffitt.org/research-science/researchers/taiga-nishihori)
    * [ Education ](https://www.moffitt.org/education/)
    * [ Medical Education ](https://www.moffitt.org/education/medical-education/)
      * [Our Training Programs](https://www.moffitt.org/education/medical-education/our-training-programs/ "Our Training Programs")
      * [Program Staff/Contact Us](https://www.moffitt.org/education/medical-education/program-staffcontact-us/ "Program Staff/Contact Us")
      * [Salary and Benefits](https://www.moffitt.org/education/medical-education/salary-and-benefits/ "Salary and Benefits")
      * [About Tampa Bay](https://www.moffitt.org/careers/about-tampa-bay/ "About Tampa Bay")
    * [ Research Education and Training ](https://www.moffitt.org/education/research-education-and-training/)
      * [Office of Postdoctoral Affairs](https://www.moffitt.org/education/research-education-and-training/office-of-postdoctoral-affairs/ "Office of Postdoctoral Affairs")
      * [Office of Graduate Affairs](https://www.moffitt.org/education/research-education-and-training/office-of-graduate-affairs/ "Office of Graduate Affairs")
      * [Office of Undergraduate and Visiting Scholar Affairs](https://www.moffitt.org/education/research-education-and-training/office-of-undergraduate-and-visiting-scholar-affairs/ "Office of Undergraduate and Visiting Scholar Affairs")
      * [Pre-College Programs](https://www.moffitt.org/education/research-education-and-training/pre-college-programs/ "Pre-College Programs")
      * [What We Provide](https://www.moffitt.org/education/research-education-and-training/what-we-provide/ "What We Provide")
      * [Contact Us](https://www.moffitt.org/education/research-education-and-training/contact-us/ "Contact Us")
      * [About Tampa Bay](https://www.moffitt.org/careers/about-tampa-bay/ "About Tampa Bay")
      * [News](https://www.moffitt.org/education/research-education-and-training/news/ "News")
      * [Where Are They Now](https://www.moffitt.org/education/research-education-and-training/where-are-they-now/ "Where Are They Now")
    * [ Nursing Education ](https://www.moffitt.org/education/nursing-education/)
      * [Ambulatory Care Oncology Nurse Residency Program](https://www.moffitt.org/education/nursing-education/ambulatory-care-oncology-nurse-residency-program/ "Ambulatory Care Oncology Nurse Residency Program")
      * [Nurse Anesthetist](https://www.moffitt.org/education/nursing-education/nurse-anesthetist/ "Nurse Anesthetist")
      * [Nurse Practitioner](https://www.moffitt.org/education/nursing-education/nurse-practitioner/ "Nurse Practitioner")
      * [Oncology Nurse Residency Program](https://www.moffitt.org/education/nursing-education/oncology-nurse-residency-program/ "Oncology Nurse Residency Program")
      * [Registered Nurse](https://www.moffitt.org/education/nursing-education/registered-nurse/ "Registered Nurse")
    * [ Health Professional Education ](https://www.moffitt.org/education/health-professional-education/)
      * [Advanced Pharmacy Practice (APPE)](https://www.moffitt.org/education/health-professional-education/advanced-pharmacy-practice-appe/ "Advanced Pharmacy Practice \(APPE\)")
      * [Anesthesiology Assistant](https://www.moffitt.org/education/health-professional-education/anesthesiology-assistant/ "Anesthesiology Assistant")
      * [Dietetic Technician](https://www.moffitt.org/education/health-professional-education/dietetic-technician/ "Dietetic Technician")
      * [Dietitian](https://www.moffitt.org/education/health-professional-education/dietitian/ "Dietitian")
      * [Genetic Counseling](https://www.moffitt.org/education/health-professional-education/genetic-counseling/ "Genetic Counseling")
      * [Introductory Pharmacy Practice (IPPE)](https://www.moffitt.org/education/health-professional-education/introductory-pharmacy-practice-ippe/ "Introductory Pharmacy Practice \(IPPE\)")
      * [Master of Public Health Field Experience](https://www.moffitt.org/education/health-professional-education/master-of-public-health-field-experience/ "Master of Public Health Field Experience")
      * [Medical Assistants](https://www.moffitt.org/education/health-professional-education/medical-assistants/ "Medical Assistants")
      * [Nuclear Medicine](https://www.moffitt.org/education/health-professional-education/nuclear-medicine/ "Nuclear Medicine")
      * [Occupational Therapy Intern](https://www.moffitt.org/education/health-professional-education/occupational-therapy-intern/ "Occupational Therapy Intern")
      * [PGY1 Pharmacy Residency](https://www.moffitt.org/education/health-professional-education/pgy-1-residency/ "PGY1 Pharmacy Residency")
      * [PGY2 Oncology Pharmacy Residency](https://www.moffitt.org/education/health-professional-education/pgy-2-oncology-residency/ "PGY2 Oncology Pharmacy Residency")
      * [Oncology Pharmacy Technician Trainee Program](https://www.moffitt.org/education/health-professional-education/pharmacy-technician-extern/ "Oncology Pharmacy Technician Trainee Program")
      * [Physical Therapy](https://www.moffitt.org/education/health-professional-education/physical-therapy/ "Physical Therapy")
      * [Physical Therapy Assistant](https://www.moffitt.org/education/health-professional-education/physical-therapy-assistant/ "Physical Therapy Assistant")
      * [Physician Assistant](https://www.moffitt.org/education/health-professional-education/physician-assistant/ "Physician Assistant")
      * [Psychology](https://www.moffitt.org/education/health-professional-education/psychology/ "Psychology")
      * [Radiation Therapy](https://www.moffitt.org/education/health-professional-education/radiation-therapy/ "Radiation Therapy")
      * [Radiography Therapy](https://www.moffitt.org/education/health-professional-education/radiography-therapy/ "Radiography Therapy")
      * [Respiratory Therapy](https://www.moffitt.org/education/health-professional-education/respiratory-therapy/ "Respiratory Therapy")
      * [Social Work](https://www.moffitt.org/education/health-professional-education/social-work/ "Social Work")
      * [Sonography/Ultrasound Student](https://www.moffitt.org/education/health-professional-education/sonographyultrasound-student/ "Sonography/Ultrasound Student")
      * [Speech Therapy](https://www.moffitt.org/education/health-professional-education/speech-therapy/ "Speech Therapy")
      * [Wound Ostomy](https://www.moffitt.org/education/health-professional-education/wound-ostomy/ "Wound Ostomy")
    * [ Other Educational Programs ](https://www.moffitt.org/education/other-educational-programs/)
  * [Give](https://www.moffitt.org/research-science/researchers/taiga-nishihori)
    * [ Give ](https://www.moffitt.org/give/)
    * [ Why Give? ](https://www.moffitt.org/give/why-give/)
      * [About the Moffitt Foundation](https://www.moffitt.org/give/why-give/about-the-moffitt-foundation/ "About the Moffitt Foundation")
      * [FAQ](https://www.moffitt.org/give/why-give/faq/ "FAQ")
      * [Financials and Stewardship](https://www.moffitt.org/give/why-give/financials-and-stewardship/ "Financials and Stewardship")
      * [Contact the Foundation](https://www.moffitt.org/give/why-give/contact-the-foundation/ "Contact the Foundation")
      * [You Can Make a Difference](https://www.moffitt.org/give/why-give/you-can-make-a-difference/ "You Can Make a Difference")
      * [Impact Report](https://www.moffitt.org/give/your-impact/2022-annual-foundation-impact-report/ "Impact Report")
    * [ Ways to Give ](https://www.moffitt.org/give/ways-to-give/)
      * [Cash, Stock or Other Assets](https://www.moffitt.org/give/ways-to-give/cash-stock-or-other-assets/ "Cash, Stock or Other Assets")
      * [Planned Giving](https://mymoffittlegacy.org/ "Planned Giving")
      * [Philanthropic Foundation Giving](https://www.moffitt.org/give/ways-to-give/philanthropic-foundation-giving/ "Philanthropic Foundation Giving")
      * [Corporate Partnership](https://www.moffitt.org/give/ways-to-give/corporate-partnership/ "Corporate Partnership")
      * [Employer Matching Gifts](https://www.moffitt.org/give/ways-to-give/employer-matching-gifts/ "Employer Matching Gifts")
      * [Endowment Gifts](https://www.moffitt.org/give/ways-to-give/endowment-gifts/ "Endowment Gifts")
      * [Other Ways to Donate](https://www.moffitt.org/give/ways-to-give/other-ways-to-donate/ "Other Ways to Donate")
      * [Breast Cancer Funding Opportunities](https://www.moffitt.org/give/ways-to-give/breast-cancer-funding-opportunities/ "Breast Cancer Funding Opportunities")
      * [Support the Pentecost Family Myeloma Research Center](https://www.moffitt.org/give/ways-to-give/support-the-pentecost-family-myeloma-research-center/ "Support the Pentecost Family Myeloma Research Center")
      * [Partners In Discovery](https://www.moffitt.org/give/ways-to-give/partners-in-discovery/ "Partners In Discovery")
    * [ Get Involved ](https://www.moffitt.org/give/get-involved/)
      * [Become a Member](https://www.moffitt.org/give/get-involved/become-a-member/ "Become a Member")
      * [Volunteer Your Time](https://www.moffitt.org/give/get-involved/volunteer-your-time/ "Volunteer Your Time")
      * [Miles for Moffitt](https://www.moffitt.org/give/get-involved/miles-for-moffitt/ "Miles for Moffitt")
      * [Magnolia](https://www.moffitt.org/give/get-involved/magnolia/ "Magnolia")
      * [Mission Possible Sarasota Luncheon](https://www.moffitt.org/give/get-involved/mission-possible-sarasota-luncheon/ "Mission Possible Sarasota Luncheon")
      * [Discovery Series Webinars](https://www.moffitt.org/give/get-involved/discovery-series-webinars/ "Discovery Series Webinars")
      * [Fundraise for Moffitt](https://www.moffitt.org/give/get-involved/fundraise-for-moffitt/ "Fundraise for Moffitt")
    * [ ![A researcher holds a Moffitt License Plate](https://www.moffitt.org/contentassets/fff003985b6341a8b2d684da79916350/ways-to-give.jpg) Ways to Give  Cancer touches all of us. Our mission - to contribute to the prevention and cure of cancer - depends on your support.  ](https://www.moffitt.org/give/ways-to-give/ "Ways to Give")


# Taiga Nishihori, MD
![Taiga  Nishihori](https://www.moffitt.org/globalassets/images/researchers_bio/NishihoriTaiga_7659.jpg)
Taiga Nishihori, MD 
**Program:** Blood and Marrow Transplant and Cellular Immunotherapy 
**Research Program:** Molecular Medicine Program 
[Google Scholar Profile](https://scholar.google.com/citations?user=7XnjuzoAAAAJ&hl=en)
[ Contact ](https://eforms.moffitt.org/ContactResearchersForm?PERID=7659)
  * ## Overview
Dr. Nishihori's research focuses on the improvement of clinical outcomes after hematopoietic cell transplantation (HCT) and cellular immunotherapy through application of novel treatment approaches. He is interested in evaluating the outcome measures after transplant and cellular therapy for various hematologic malignancies.
### Associations
    * Blood and Marrow Transplant and Cellular Immunotherapy
    * Pentecost Family Myeloma Research Center
    * Molecular Medicine Program
### Education & Training
**Internship:**
    * US Naval Hospital Yokusuka - Intern
**Board Certification:**
    * Internal Medicine - Hematology
**Fellowship:**
    * Yale University - Medical Oncology
    * Moffitt Cancer Center - Blood and Marrow Transplantation
**Residency:**
    * Beth Israel Medical Center - Internal Medicine
    * Beth Israel Medical Center - 
    * Hokkaido University Hospital - Radiation Oncology & Diagnostic Radiology
**Medical School:**
    * Hokkaido University - MD
  * ## Research Interest
My research interests are application of novel strategies to improve hematopoietic cell transplantation (HCT) and cellular therapy outcomes in hematologic malignancies. Disease focus includes leukemia, lymphoma, multiple myeloma as well as myeloproliferative neoplasms such as myelofibrosis. He has served as data director at BMT CI department and has participated in number of studies conducted by the Center for International Blood and Marrow Transplant Research (CIBMTR). He has over 200 peer reviewed publications. He serves as a co-chair of Plasma Cell Disorders Working Committee at CIBMTR since 2023.
  * ## Participating Trials
[ Clinical Trial 20632 ](https://www.moffitt.org/clinical-trials-and-studies/clinical-trial-20632/ "Clinical Trial 20632")   
A Phase II Randomized Controlled Trial Comparing GVHD-Reduction Strategies for Allogeneic Peripheral Blood Transplantation (PBSCT) for Patients with Acute Leukemia or Myelodysplastic Syndrome: Selective Depletion of CD45RA+ Naïve T Cells (TND) vs. Post-Transplantation Cyclophosphamide (PTCy)   
Condition: Malignant Hematology   
Intervention: FK506 (Tacrolimus); MESNA (); PBSC (); Tacrolimus (); Thiotepa (Thioplex); busulfan (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate); methotrexate ()   
Status: Open 
[ Clinical Trial 22461 ](https://www.moffitt.org/clinical-trials-and-studies/clinical-trial-22461/ "Clinical Trial 22461")   
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients with Hematologic Malignancies   
Condition: Malignant Hematology   
Intervention: Alkeran (Melphalan); Melphalan (); Ossium HPC (); Radiotherapy (); busulfan (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)   
Status: Open 
[ Clinical Trial 22538 ](https://www.moffitt.org/clinical-trials-and-studies/clinical-trial-22538/ "Clinical Trial 22538")   
A Phase 1/2a Multicenter Ascending Dose Study to Evaluate the Safety of HA-1 Minor Histocompatibility Antigen-Reactive TCR-Modified T Cells (BSB-1001) in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS   
Condition: Malignant Hematology   
Intervention: Alkeran (Melphalan); BSB-1001 (); Melphalan (); Radiotherapy (); Thiotepa (Thioplex); busulfan (); fludarabine (Fludarabine phosphate)   
Status: Open 
**If you believe you are eligible for one of these trials or studies, please call  
[813-745-6100](tel:+813-745-6100) or toll-free [1-800-679-0775](tel:+1-800-679-0775). **
  * ## Publications
    * Ustun C, Zhang MJ, Peterson A, Baek A, Agha M, Alkhateeb H, Chhabra S, Coltoff A, de Lima M, Gandhi A, Ho V, Kassim A, Lin A, Gowda L, Borthakur G, DeAngelo DJ, McGuirk J, Mensah F, Nadiminti KV, Nishihori T, Pantin J, Trunk A, Uberti J, Marcucci G, Gotlib J, Akin C, Hamadani M, Pullarkat V, Valent P, Grunwald M, Juckett M, Oran B, Saber W, Burns LJ. Allogeneic haematopoietic cell transplantation in advanced systemic mastocytosis in new era: A CIBMTR study. Brit J Haematol. 2025 Sep. Pubmedid: [40983528](https://www.ncbi.nlm.nih.gov/pubmed/40983528). Pmcid: PMC12519450. 
    * Elmariah H, Kim J, Gonzalez R, DiMaggio E, Sansil S, Mishra A, Faramand R, Perez L, Lazaryan A, Mirza AS, Khimani F, Liu H, Ochoa-Bayona JL, Nieder M, Perna F, Figura N, Robinson TJ, Nishihori T, Anasetti C, Pidala JA, Bejanyan N. Phase II Trial of Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning With Haploidentical Donor Peripheral Blood Stem Cell Transplant. Am J Hematol. 2025 Sep.100(9):1665-1669. Pubmedid: [40492500](https://www.ncbi.nlm.nih.gov/pubmed/40492500). 
    * Schmitz J, Gaskill E, Price S, Cao B, Kim J, Baluch A, Klinkova O, Faramand R, Mishra A, Perez L, Khimani F, Lazaryan A, Ochoa-Bayona JL, Liu H, Mirza AS, Nieder M, Anasetti C, Nishihori T, Pidala JA, Bejanyan N, Elmariah H. Letermovir reduces cytomegalovirus in HLA-matched and mismatched allogeneic hematopoietic cell transplant patients receiving post-transplant cyclophosphamide. Bone Marrow Transplant. 2025 Oct.60(10):1383-1386. Pubmedid: [40617898](https://www.ncbi.nlm.nih.gov/pubmed/40617898). 
    * Gaskill E, Albanyan O, Naqvi SMH, Mo Q, Belfon A, Nishihori T, Faramand R, Lazaryan A, Hansen DK, Khimani F, Mishra A, Nieder M, Perez L, Liu H, Pidala J, Anasetti C, Bejanyan N, Elmariah H. Impact of Obesity and Weight-Based Chemotherapy Dosing Adjustments on Outcomes of Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia. Transplant Cell Ther. 2025 Oct. Pubmedid: [41115629](https://www.ncbi.nlm.nih.gov/pubmed/41115629). 
    * Wudhikarn K, Herr MM, Chen M, Martens MJ, Baird JH, Gowda L, Rangarajan HG, Abid MB, Kharfan-Dabaja MA, Williams KM, Ganguly S, Young JH, Sharma A, Fatobene G, Jain T, Kanakry CG, Modi D, Grover NS, Salem B, Batista MV, Vergidis P, Yin DE, Beitinjaneh AM, Kelkar AH, Nishihori T, Holter-Chakrabarty J, Gergis U, Smith M, El Boghdadly Z, Dandoy CE, Murthy HS, Huppler AR, Perales MA, Chemaly RF, Hill JA, Riches M, Auletta JJ. Infection after CD19 chimeric antigen receptor T cell therapy for large B cell lymphoma: Real-world analysis from CIBMTR. Blood Adv. 2025 May. Pubmedid: [40435511](https://www.ncbi.nlm.nih.gov/pubmed/40435511). 
    * Henning JE, Nishihori T, Freeman C, Lazarides A, Song J, Kuruvilla D, Feuerlein S, Costello JR. Whole-body MRI for a patient with progressive multiple myeloma. BJR Case Rep. 2025 May.11(3):uaaf028. Pubmedid: [40386466](https://www.ncbi.nlm.nih.gov/pubmed/40386466). Pmcid: PMC12085220. 
    * Sidana S, Ahmed N, Akhtar OS, Brazauskas R, Oloyede T, Bye M, Hansen DK, Ferreri CJ, Freeman CL, Afrough A, Anderson LD, Dhakal B, Dhanda DS, Gowda L, Hashmi H, Harrison MJ, Kitali A, Landau HJ, Mirza AS, Patwardhan P, Qazilbash MH, Usmani SZ, Patel KK, Nishihori T, Ganguly S, Pasquini MC. Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma. Blood. 2025 Jul.146(2):167-177. Pubmedid: [40198886](https://www.ncbi.nlm.nih.gov/pubmed/40198886). 
    * Jhaveri K, Thapa R, Ercan D, Saha A, Noble J, Singh P, Fahrmann J, Saini N, Wu R, Dennison JB, Hanash S, Jenq RR, Modi K, Figura N, Chavez J, Shah B, Nishihori T, Lazaryan A, Khimani F, Bachmeier C, Gage K, Mishra A, Perna F, Davila ML, Spiegel J, Rejeski K, Subklewe M, Locke FL, Freeman C, Parker N, Jain MD. Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma. Clin Cancer Res. 2025 Jul.31(13):2756-2766. Pubmedid: [40238583](https://www.ncbi.nlm.nih.gov/pubmed/40238583). Pmcid: PMC12213223. 
    * Shouval R, Strouse C, Kim S, Oloyede T, Ahmed S, Awan FT, Luan D, Bachanova V, Badar T, Bar M, Barba P, Beitinjaneh AM, Cashen A, Dholaria B, Elsawy M, Ganguly S, Geethakumari PR, Greenbaum U, Hashmi H, Hill LC, Jain MD, Jain T, Kebriaei P, Kittai AS, Locke FL, Lulla PD, Mead E, McGuirk JP, Mussetti A, Nishihori T, Olson AL, Pennisi M, Perales MA, Riedell PA, Saber W, Mirza AS, Magalhaes-Silverman M, Shpall EJ, Sorror M, Wudhikarn K, Turtle CJ, Moskop A, Pasquini MC. Cytokine Release Syndrome and Neurotoxicity Following CD19 CAR-T in B-Cell Lymphoma. Transplant Cell Ther. 2025 Jul.31(7):419-433. Pubmedid: [40288610](https://www.ncbi.nlm.nih.gov/pubmed/40288610). 
    * Sudalagunta PR, Canevarolo RR, Meads MB, Silva M, Zhao X, Cubitt CL, Sansil SS, DeAvila G, Alugubelli RR, Bishop RT, Tungesvik A, Zhang Q, Hampton O, Teer JK, Welsh EA, Yoder SJ, Shah BD, Hazlehurst L, Gatenby RA, Van Domelen DR, Chai Y, Wang F, DeCastro A, Bloomer AM, Siegel EM, Lynch CC, Sullivan DM, Alsina M, Nishihori T, Brayer J, Cleveland JL, Dalton W, Walker CJ, Landesman Y, Baz R, Silva AS, Shain KH. The Functional Transcriptomic Landscape Informs Therapeutic Strategies in Multiple Myeloma. Cancer Res. 2025 Jan.85(2):378-398. Pubmedid: [39476082](https://www.ncbi.nlm.nih.gov/pubmed/39476082). Pmcid: PMC11733535. 
    * Adoncecchi G, Kumar A, Mogili K, Faramand R, Liu H, Khimani F, Mishra A, Nieder M, Nishihori T, Hansen D, Jain M, Lazaryan A, Perez L, Pidala J, Locke F, Anasetti C, Bejanyan N, Elmariah H. Comparison of Outcomes of Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide in Older Versus Younger Patients. Cancers (Basel). 2025 Jan.17(2). Pubmedid: [39858092](https://www.ncbi.nlm.nih.gov/pubmed/39858092). Pmcid: PMC11763395. 
    * Wallis W, Gulbis AM, Wang T, Lee CJ, Sharma A, Williams KM, Nishihori T, Prestidge T, Gowda L, Byrne M, Krem MM, MacMillan ML, Kitko CL, Pidala J, Spellman SR, Lee SJ, Alousi AM. Incidence of bacterial blood stream infections in patients with acute GVHD. Bone Marrow Transplant. 2025 Jan.60(1):52-57. Pubmedid: [39420192](https://www.ncbi.nlm.nih.gov/pubmed/39420192). Pmcid: PMC11724748. 
    * Greenbaum U, Hashmi H, Elsawy M, Kim S, Moskop A, Oloyede T, Awan FT, Bachanova V, Badar T, Bar M, Barba P, Beitinjaneh AM, Cashen AF, Dholaria B, Farooq U, Foglesong J, Ganguly S, Hematti P, Hill LC, Jain MD, Jain T, Kebriaei P, Kittai AS, Locke FL, Lulla PD, McGuirk JP, Mead E, Mussetti A, Nishihori T, Olson AL, Pennisi M, Perales MA, Ramakrishnan Geethakumari P, Riedell PA, Saber W, Shouval R, Shpall EJ, Magalhaes-Silverman M, Strouse CS, Turtle CJ, Valluripalli A, Wudhikarn K, Pasquini MC, Ahmed S, Sorror ML. New Comorbidity Index Associated with Survival After Chimeric Antigen Receptor T Cell Therapy for Large B-Cell Lymphoma. Blood Adv. 2025 Aug. Pubmedid: [40811818](https://www.ncbi.nlm.nih.gov/pubmed/40811818). 
    * Freeman CL, Abraham-Miranda J, Menges M, Atkins RM, Noble J, Liu H, Corallo S, Cuadrado Delgado LA, Ribickas AJ, Savid-Frontera C, de Avila G, Castaneda Puglianini OA, Ochoa-Bayona J, Hansen DK, Alsina M, Baz R, Nishihori T, Shain KH, Locke FL. Enhanced CAR-T cell function and mitochondrial fitness from earlier unfractionated stem cell product in multiple myeloma. Mol Ther. 2025 Aug.33(8):3576-3589. Pubmedid: [40253586](https://www.ncbi.nlm.nih.gov/pubmed/40253586). Pmcid: PMC12461620. 
    * Palfi S, Peres LC, Koelmeyer H, Alsina M, Baz RC, Blue BJ, Corallo S, De Avila G, Freeman C, Gonzalez R, Grajales-Cruz A, Harvey K, Liu HD, Nishihori T, Oliveira GH, Oswald LB, Castaneda Puglianini O, Selvakumar S, Sharma AB, Wang E, Shain KH, Jain M, Locke FL, Alomar M, Hansen DK, Lee DH. Cardiovascular adverse events and outcomes after anti-BCMA CAR-T for relapsed and refractory multiple myeloma. Blood Cancer J. 2025 Apr.15(1):63. Pubmedid: [40229239](https://www.ncbi.nlm.nih.gov/pubmed/40229239). Pmcid: PMC11997198. 
    * Akhtar OS, Oloyede T, Brazauskas R, Afrough A, Hashmi H, Sidana S, Ahmed N, Bye M, Hansen DK, Ferreri CJ, Dhakal B, Dhanda DS, Harrison MJ, Kitali A, Landau HJ, Mirza AS, Patel J, Patwardhan P, Qazilbash MH, Patel KK, Nishihori T, Ganguly S, Gowda L, Anderson LD, Pasquini MC, Usmani SZ, Freeman CL. Outcomes of older adults and frail patients receiving idecabtagene vicleucel: a CIBMTR study. Blood Adv. 2025 Apr.9(7):1587-1592. Pubmedid: [39786391](https://www.ncbi.nlm.nih.gov/pubmed/39786391). Pmcid: PMC11986210. 
    * Freeman CL, Noble J, Menges M, Villanueva R, Nakashima JY, Figura NB, Tonseth RP, Idiaquez DW, Skelson L, Smith EC, Abraham-Miranda J, Corallo S, De Avila G, Castaneda Puglianini O, Liu HD, Alsina M, Nishihori T, Shain KH, Baz RC, Blue BJ, Grajales-Cruz A, Koomen JM, Atkins RM, Hansen DK, Siqueira Silva A, Kim J, Balagurunathan Y, Locke FL. Tumor burden quantified by soluble B-cell maturation antigen and metabolic tumor volume determines myeloma CAR-T outcomes. Blood. 2025 Apr.145(15):1645-1657. Pubmedid: [39652773](https://www.ncbi.nlm.nih.gov/pubmed/39652773). 
    * Renatino Canevarolo R, Sudalagunta PR, Meads MB, Silva M, Zhao X, Magaletti D, Alugubelli RR, DeAvila G, Persi E, Maura F, Bell ET, Bishop RT, Cubitt CL, Sansil SS, Zhang W, Teer JK, Teng M, Yoder SJ, Siegel EM, Shah BD, Nishihori T, Hazlehurst LA, Lynch CC, Landgren O, Hampton O, Gatenby RA, Sullivan DM, Brayer JB, Dalton WS, Cleveland JL, Alsina M, Baz R, Shain KH, Silva AS. Epigenetic Plasticity Drives Carcinogenesis and Multi-Therapy Resistance in Multiple Myeloma. Res Sq. 2025 Apr. Pubmedid: [40321765](https://www.ncbi.nlm.nih.gov/pubmed/40321765). Pmcid: PMC12048002. 
    * Zhang Y, Rose A, Khadka S, Cao B, Eatrides J, Saeed H, Shah BD, Chavez J, Bello C, Lazaryan A, Khimani F, Ibarz JP, Liu HD, Locke FL, Jain MD, Zhang L, Kharfan-Dabaja MA, Kim J, Ayala E, Nishihori T, Sokol L. Autologous Hematopoietic Cell Transplantation Consolidation for First Response is Associated With Longer Survival Among Patients With Nodal Peripheral T Cell Lymphoma. Transplant Cell Ther. 2024 Sep.30(9):887.e1-887.e9. Pubmedid: [38740140](https://www.ncbi.nlm.nih.gov/pubmed/38740140). 
    * Kahn J, Brazauskas R, Bo-Subait S, Buchbinder D, Hamilton BK, Schoemans H, Abraham AA, Agrawal V, Auletta JJ, Badawy SM, Beitinjaneh A, Bhatt NS, Broglie L, Diaz Perez MA, Farhadfar N, Freytes CO, Gale RP, Ganguly S, Hayashi RJ, Hematti P, Hildebrandt GC, Inamoto Y, Kamble RT, Koo J, Lazarus HM, Mayo SJ, Mehta PA, Myers KC, Nishihori T, Prestidge T, Rotz SJ, Savani BN, Schears RM, Sharma A, Stenger E, Ustun C, Williams KM, Vrooman LM, Satwani P, Phelan R. Late effects after allogeneic haematopoietic cell transplantation in children and adolescents with non-malignant disorders: a retrospective cohort study. Lancet Child Adolesc Health. 2024 Oct.8(10):740-750. Pubmedid: [39217999](https://www.ncbi.nlm.nih.gov/pubmed/39217999). Pmcid: PMC11588140. 
    * Elmariah H, Otoukesh S, Kumar A, Ali H, Arslan S, Dimaggio E, Gonzalez R, Shouse G, Pourhassan H, Nishihori T, Faramand R, Mishra A, Khimani F, Fernandez H, Lazaryan A, Nieder M, Perez L, Liu H, Nakamura R, Pidala J, Marcucci G, Forman SJ, Anasetti C, Bejanyan N, Al Malki MM. Lower Weight-Based Mycophenolate Mofetil Dosing is Associated with Superior Outcomes after Haploidentical Hematopoietic Cell Transplant with Post-transplant Cyclophosphamide. Transplant Cell Ther. 2024 Oct.30(10):1019.e1-1019.e9. Pubmedid: [39102983](https://www.ncbi.nlm.nih.gov/pubmed/39102983). 
    * Handley G, Yepes A, Eliassen E, Dominguez G, Pasikhova Y, Klinkova O, Baluch A, Febres-Aldana AJ, Alsina M, Elmariah H, Khimani F, Hansen DK, Freeman CL, Jain MD, Locke F, Lazaryan A, Liu HD, Mishra A, Mirza AS, Nishihori T, Ochoa L, Perez L, Pidala J, Puglianini OC, Nieder M, Perna F, Kim J, Bejanyan N, Faramand R. Outcomes of Haploidentical Stem Cell Transplant Recipients With HHV-6B Reactivation. Open Forum Infect Dis. 2024 Oct.11(10):ofae564. Pubmedid: [39411216](https://www.ncbi.nlm.nih.gov/pubmed/39411216). Pmcid: PMC11475747. 
    * Bhatt VR, Shostrom VK, Choe HK, Hamilton BK, Gundabolu K, Maness LJ, Kumar V, Mahato RI, Smith LM, Nishihori T, Lee SJ. A Multicenter Phase II Trial of Ruxolitinib for Treatment of Corticosteroid Refractory Sclerotic Chronic Graft-Versus-Host Disease. J Clin Oncol. 2024 Nov.42(33):3977-3985. Pubmedid: [39151112](https://www.ncbi.nlm.nih.gov/pubmed/39151112). Pmcid: PMC11568950. 
    * Pidala JA, Holtan SG, Walton K, Kim J, Cao B, Elmariah H, Mishra A, Bejanyan N, Nishihori T, Khimani F, Perez LE, Faramand RG, Davila ML, McSain S, Pleskow J, Baron J, Anasetti C, Moran Segura CM, Weisdorf DJ, Blazar BR, Miller JS, Bachanova V, El Jurdi N, Betts BC. JAK2/mTOR inhibition fails to prevent acute GVHD despite reduced Th1/Th17 cells: final phase 2 trial results. Blood. 2024 Nov.144(22):2295-2307. Pubmedid: [39046783](https://www.ncbi.nlm.nih.gov/pubmed/39046783). Pmcid: PMC11619790. 
    * Albanyan O, Elmariah H, Kalos D, Kim J, Faramand R, Sallman D, Mishra A, Sweet K, Perez L, Ochoa-Bayona J, Nieder M, Komrokji R, Lancet J, Fernandez H, Nishihori T, Pidala J, Anasetti C, Bejanyan N. Melphalan Dose in Combination With Fludarabine Affects Gastrointestinal Toxicity and Graft-Versus-Host Disease After Allogeneic Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndromes. Transplant Cell Ther. 2024 Nov.30(11):1090.e1-1090.e10. Pubmedid: [39147136](https://www.ncbi.nlm.nih.gov/pubmed/39147136). 
    * Faramand RG, Lee SB, Jain MD, Cao B, Wang X, Rejeski K, Subklewe M, Fahrmann JF, Saini NY, Hanash SM, Kang YP, Chang D, Rodriguez PC, Dean EA, Nishihori T, Shah BD, Lazaryan A, Chavez J, Khimani F, Pinilla-Ibarz JA, Dam M, Reid KM, Corallo SA, Menges M, Hidalgo Vargas M, Mandula JK, Holliday BA, Bachmeier CA, Speth K, Song Q, Mattie M, Locke FL, Davila ML. Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma. Blood Cancer Discov. 2024 Mar.5(2):106-113. Pubmedid: [38194367](https://www.ncbi.nlm.nih.gov/pubmed/38194367). Pmcid: PMC10905320. 
    * Akhtar OS, Modi K, Kim J, Skellson L, Smith E, Al-Jumayli MA, Extermann M, De Avila G, Parker N, Castaneda-Puglianini O, Grajales-Cruz A, Baz R, Blue B, Shain K, Alsina M, Liu H, Nishihori T, Jain MD, Locke FL, Hansen DK, Freeman CL. Simple Score of Albumin and CRP Predicts High-Grade Toxicity in Patients with Multiple Myeloma Receiving CAR-T Therapy. Transplant Cell Ther. 2024 Mar.30(3):283.e1-283.e10. Pubmedid: [38123069](https://www.ncbi.nlm.nih.gov/pubmed/38123069). 
    * Akhtar OS, Sheeba BA, Azad F, Alessi L, Hansen D, Alsina M, Baz R, Shain K, Grajales Cruz A, Castaneda Puglianini O, Liu H, Blue B, Nishihori T, Al Jumayli M, Extermann M, Locke FL, Mhaskar R, Freeman CL. Safety and efficacy of anti-BCMA CAR-T cell therapy in older adults with multiple myeloma: A systematic review and meta-analysis. Geriatr Oncol. 2024 Mar.15(2):101628. Pubmedid: [37723045](https://www.ncbi.nlm.nih.gov/pubmed/37723045). 
    * Caprice T, Fan W, Kim J, Faramand R, Mishra A, Perez L, Khimani F, Lazar-Yan A, Ochoa-Bayona JL, Liu H, Jain MD, Nieder M, Anasetti C, Nishihori T, Pidala JA, Bejanyan N, Elmariah H. Mismatched donor allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide achieves comparable outcomes between racially and ethnically diverse patient populations. Am J Hematol. 2024 Jun.99(6):1196-1200. Pubmedid: [38546371](https://www.ncbi.nlm.nih.gov/pubmed/38546371). 
    * Ionescu F, David JC, Ravichandran A, Sallman DA, Sweet K, Komrokji RS, Chan O, Kuykendall A, Padron E, Faramand R, Bejanyan N, Khimani F, Elmariah H, Pidala J, Mishra A, Perez L, Nishihori T, Lancet JE. Hypomethylating Agents and Venetoclax for Acute Myeloid Leukemia Relapsed After Hematopoietic Stem Cell Transplant. Clin Lymphoma Myeloma Leuk. 2024 Jun.24(6):400-406. Pubmedid: [38429222](https://www.ncbi.nlm.nih.gov/pubmed/38429222). 
    * Ho TT, Perkins JB, Gonzalez R, Hicks JK, Martinez RA, Duranceau K, North B, Kim J, Teer JK, Yao J, Yoder SJ, Nishihori T, Bejanyan N, Pidala J, Elmariah H. Association between CYP3A4, CYP3A5 and ABCB1 genotype and tacrolimus treatment outcomes among allogeneic HSCT patients. Pharmacogenomics. 2024 Jan.25(1):29-40. Pubmedid: [38189154](https://www.ncbi.nlm.nih.gov/pubmed/38189154). 
    * Peres LC, Oswald LB, Dillard CM, De Avila G, Nishihori T, Blue BJ, Freeman CL, Locke FL, Alsina M, Castaneda Puglianini OA, Shune L, Sborov DW, Wagner C, Dima D, Hashmi H, Davis JA, Kocoglu MH, Badros AZ, Atrash S, Simmons G, Kalariya N, Ferreri CJ, Anderson LD, Afrough A, Kaur G, Lin Y, Liu L, Nadeem O, Voorhees PM, Khouri J, McGuirk JP, Sidana S, Hansen DK, Patel KK. Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy. Blood Adv. 2024 Jan.8(1):251-259. Pubmedid: [37855718](https://www.ncbi.nlm.nih.gov/pubmed/37855718). 
    * Elmariah H, Otoukesh S, Kumar A, Ali H, Arslan S, Shouse G, Pourhassan H, Nishihori T, Faramand R, Mishra A, Khimani F, Fernandez H, Lazaryan A, Nieder M, Perez L, Liu H, Nakamura R, Pidala J, Marcucci G, Forman SJ, Anasetti C, Locke F, Bejanyan N, Al Malki MM. Sirolimus Is an Acceptable Alternative to Tacrolimus for Graft-versus-Host Disease Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplant Cell Ther. 2024 Feb.30(2):229.e1-229.e11. Pubmedid: [37952648](https://www.ncbi.nlm.nih.gov/pubmed/37952648). 
    * Zinter MS, Brazauskas R, Strom J, Chen S, Bo-Subait S, Sharma A, Beitinjaneh A, Dimitrova D, Guilcher G, Preussler JM, Myers KC, Bhatt NS, Ringden O, Hematti P, Hayashi RJ, Patel SS, De Oliveira S, Rotz SJ, Badawy SM, Nishihori T, Buchbinder DK, Hamilton BK, Savani BN, Schoemans HM, Sorror ML, Winestone LE, Duncan C, Phelan R, Dvorak CC. Intensive care risk and long-term outcomes in pediatric allogeneic hematopoietic cell transplant recipients. Blood Adv. 2024 Feb.8(4):1002-1017. Pubmedid: [38127268](https://www.ncbi.nlm.nih.gov/pubmed/38127268). Pmcid: PMC10879681. 
    * Hoogland AI, Barata A, Li X, Irizarry-Arroyo N, Jain MD, Welniak T, Rodriguez Y, Oswald LB, Gudenkauf LM, Chavez JC, Khimani F, Lazaryan A, Liu HD, Nishihori T, Pinilla-Ibarz J, Shah BD, Crowder SL, Parker NH, Carson TL, Vinci CE, Pidala JA, Logue J, Locke FL, Jim HSL. Prospective Assessment of Quality of Life and Patient-Reported Toxicities Over the First Year After Chimeric Antigen Receptor T-Cell Therapy. Transplant Cell Ther. 2024 Dec.30(12):1219.e1-1219.e11. Pubmedid: [39306278](https://www.ncbi.nlm.nih.gov/pubmed/39306278). Pmcid: PMC11635818. 
    * Jain T, Estrada-Merly N, Salas MQ, Kim S, DeVos JD, Chen M, Fang X, Kumar R, Andrade-Campos M, Elmariah H, Agrawal V, Aljurf M, Bacher U, Badar T, Badawy SM, Ballen KK, Beitinjaneh A, Bhatt VR, Bredeson CN, DeFilipp Z, Dholaria B, Farhadfar N, Farhan S, Gandhi A, Ganguly S, Gergis U, Grunwald MR, Hamad N, Hamilton BK, Inamoto Y, Iqbal M, Jamy O, Juckett M, Kharfan-Dabaja MA, Krem MM, Lad DP, Liesveld JL, Al Malki MM, Malone AK, Murthy HS, Ortí G, Patel SS, Pawarode A, Perales MA, van der Poel MWM, Ringden O, Rizzieri DA, Rovo A, Savani BN, Savoie ML, Seo S, Solh MM, Ustun C, Verdonck LF, Wingard JR, Wirk B, Bejanyan N, Jones RJ, Nishihori T, Oran B, Nakamura R, Scott BL, Saber W, Gupta V. Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study. Blood Adv. 2024 Aug.8(16):4281-4293. Pubmedid: [38916866](https://www.ncbi.nlm.nih.gov/pubmed/38916866). Pmcid: PMC11372592. 
    * Oswald LB, Gudenkauf LM, Li X, De Avila G, Peres LC, Kirtane K, Gonzalez BD, Hoogland AI, Nguyen O, Rodriguez Y, Baz RC, Shain KH, Alsina M, Locke FL, Freeman C, Castaneda Puglianini O, Nishihori T, Liu H, Blue B, Grajales-Cruz A, Jim HSL, Hansen DK. Patient-Reported Outcomes among Multiple Myeloma Patients Treated with Standard of Care Idecabtagene Vicleucel. Cancers (Basel). 2023 Sep.15(19). Pubmedid: [37835405](https://www.ncbi.nlm.nih.gov/pubmed/37835405). Pmcid: PMC10571575. 
    * Freeman CL, Atkins R, Varadarajan I, Menges M, Edelman J, Baz R, Brayer J, Castaneda Puglianini O, Ochoa-Bayona JL, Nishihori T, Shain KH, Shah B, Chen DT, Kelley L, Coppola D, Alsina M, Antonia S, Anasetti C, Locke FL. Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with Myeloma. Clin Cancer Res. 2023 Nov.29(22):4575-4585. Pubmedid: [37735756](https://www.ncbi.nlm.nih.gov/pubmed/37735756). 
    * Murthy HS, Zhang MJ, Chen K, Ahmed S, Deotare U, Ganguly S, Kansagra A, Michelis FV, Nishihori T, Patnaik MM, Abid MB, Aljurf M, Arai Y, Bacher U, Badar T, Badawy SM, Ballen K, Battiwalla M, Beitinjaneh A, Bejanyan N, Bhatt VR, Brown VI, Martino R, Cahn JY, Castillo P, Cerny J, Chhabra S, Copelan EA, Daly A, Dholaria B, Diaz MA, Freytes CO, Grunwald MR, Hashmi S, Hildebrandt GC, Jamy O, Joseph J, Kanakry CG, Khera N, Krem MM, Kuwatsuka Y, Lazarus HM, Lekakis LJ, Liu H, Modi D, Munshi P, Mussetti A, Palmisiano N, Patel SS, Rizzieri DA, Seo S, Shah MV, Sharma A, Solh MM, Solomon SR, Ulrickson ML, Ustun C, van der Poel MWM, Verdonck LF, Wagner JL, Wang TP, Wirk B, Zeidan AM, Litzow MR, Kebriaei P, Hourigan CS, Weisdorf DJ, Saber W, Kharfan-Dabaja MA. Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis. Blood Adv. 2023 Nov.7(22):7007-7016. Pubmedid: [37792849](https://www.ncbi.nlm.nih.gov/pubmed/37792849). Pmcid: PMC10690553. 
    * Taylor MR, Cole SW, Strom J, Brazauskas R, Baker KS, Phelan R, Buchbinder D, Hamilton B, Schoemans H, Shaw BE, Sharma A, Bhatt NS, Badawy SM, Winestone LE, Preussler JM, Mayo S, Jamani K, Nishihori T, Lee MA, Knight JM. Unfavorable transcriptome profiles and social disadvantage in hematopoietic cell transplantation: a CIBMTR analysis. Blood Adv. 2023 Nov.7(22):6830-6838. Pubmedid: [37773924](https://www.ncbi.nlm.nih.gov/pubmed/37773924). Pmcid: PMC10679811. 
    * Boyiadzis M, Zhang MJ, Chen K, Abdel-Azim H, Abid MB, Aljurf M, Bacher U, Badar T, Badawy SM, Battiwalla M, Bejanyan N, Bhatt VR, Brown VI, Castillo P, Cerny J, Copelan EA, Craddock C, Dholaria B, Perez MAD, Ebens CL, Gale RP, Ganguly S, Gowda L, Grunwald MR, Hashmi S, Hildebrandt GC, Iqbal M, Jamy O, Kharfan-Dabaja MA, Khera N, Lazarus HM, Lin R, Modi D, Nathan S, Nishihori T, Patel SS, Pawarode A, Sharma A, Solh M, Wagner JL, Wang T, Williams KM, Winestone LE, Wirk B, Hourigan CS, Litzow M, Kebriaei P, de Lima M, Page K, Weisdorf DJ. Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients. Leukemia. 2023 May.37(5):1006-1017. Pubmedid: [36310182](https://www.ncbi.nlm.nih.gov/pubmed/36310182). Pmcid: PMC10148918. 
    * Boyiadzis M, Zhang MJ, Chen K, Abdel-Azim H, Abid MB, Aljurf M, Bacher U, Badar T, Badawy SM, Battiwalla M, Bejanyan N, Bhatt VR, Brown VI, Castillo P, Cerny J, Copelan EA, Craddock C, Dholaria B, Perez MAD, Ebens CL, Gale RP, Ganguly S, Gowda L, Grunwald MR, Hashmi S, Hildebrandt GC, Iqbal M, Jamy O, Kharfan-Dabaja MA, Khera N, Lazarus HM, Lin R, Modi D, Nathan S, Nishihori T, Patel SS, Pawarode A, Saber W, Sharma A, Solh M, Wagner JL, Wang T, Williams KM, Winestone LE, Wirk B, Zeidan A, Hourigan CS, Litzow M, Kebriaei P, de Lima M, Page K, Weisdorf DJ. Correction to: Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113AML patients. Leukemia. 2023 May.37(5):1173. Pubmedid: [36949156](https://www.ncbi.nlm.nih.gov/pubmed/36949156). 
    * Dong N, Lopes-Garcia LR, Viñal D, Bachmeier C, Shah BD, Nishihori T, Khimani F, Davila ML, Lazaryan A, Pinilla-Ibarz J, Locke FL, Jain MD, Chavez JC. Outcomes of CD19-Directed Chimeric Antigen Receptor T Cell Therapy for Transformed Nonfollicular Lymphoma. Transplant Cell Ther. 2023 Jun.29(6):349.e1-349.e8. Pubmedid: [36878427](https://www.ncbi.nlm.nih.gov/pubmed/36878427). 
    * Bashir Q, Nishihori T, Pasquini MC, Martens MJ, Wu J, Alsina M, Anasetti C, Brunstein C, Dawson P, Efebera Y, Gasparetto C, Geller N, Giralt S, Hall AC, Koreth J, McCarthy P, Scott E, Stadtmauer EA, Vesole DH, Hari P. A Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 Trial. Transplant Cell Ther. 2023 Jun.29(6):358.e1-358.e7. Pubmedid: [35840087](https://www.ncbi.nlm.nih.gov/pubmed/35840087). 
    * Ragon BK, Shah MV, D'Souza A, Estrada-Merly N, Gowda L, George G, DeLima M, Hashmi S, Kharfan-Dabaja MA, Majhail NS, Banerjee R, Saad A, Hildebrandt GC, Mian H, Abid MB, Battiwalla M, Lekakis LJ, Patel SS, Murthy HS, Nieto Y, Strouse CS, Badawy SM, Al Hadidi SA, Dholaria B, Aljurf M, Vesole DH, Lee CH, Pawarode A, Gergis U, Miller KC, Holmberg LA, Afrough A, Solh MM, Munshi P, Nishihori T, Anderson LD, Wirk B, Kaur G, Qazilbash MH, Shah N, Kumar SK, Usmani SZ. Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis. Blood Adv. 2023 Jun.7(12):2746-2757. Pubmedid: [36827681](https://www.ncbi.nlm.nih.gov/pubmed/36827681). Pmcid: PMC10275699. 
    * Bumma N, Dhakal B, Fraser R, Estrada-Merly N, Anderson K, Freytes CO, Hildebrandt GC, Holmberg L, Krem MM, Lee C, Lekakis L, Lazarus HM, Mian H, Murthy HS, Nathan S, Nishihori T, Parrondo R, Patel SS, Solh M, Strouse C, Vesole DH, Kumar S, Qazilbash MH, Shah N, D'Souza A, Sidana S. Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma. Cancer. 2023 Jul.129(14):2179-2191. Pubmedid: [37021929](https://www.ncbi.nlm.nih.gov/pubmed/37021929). 
    * Murthy GSG, Kim S, Estrada-Merly N, Abid MB, Aljurf M, Assal A, Badar T, Badawy SM, Ballen K, Beitinjaneh A, Cerny J, Chhabra S, DeFilipp Z, Dholaria B, Perez MAD, Farhan S, Freytes CO, Gale RP, Ganguly S, Gupta V, Grunwald MR, Hamad N, Hildebrandt GC, Inamoto Y, Jain T, Jamy O, Juckett M, Kalaycio M, Krem MM, Lazarus HM, Litzow M, Munker R, Murthy HS, Nathan S, Nishihori T, Ortí G, Patel SS, Van der Poel M, Rizzieri DA, Savani BN, Seo S, Solh M, Verdonck LF, Wirk B, Yared JA, Nakamura R, Oran B, Scott B, Saber W. Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis. Haematologica. 2023 Jul.108(7):1900-1908. Pubmedid: [36779595](https://www.ncbi.nlm.nih.gov/pubmed/36779595). Pmcid: PMC10316233. 
    * Narayan R, Niroula A, Wang T, Kuxhausen M, He M, Meyer E, Chen YB, Bhatt VR, Beitinjaneh A, Nishihori T, Sharma A, Brown VI, Kamoun M, Diaz MA, Abid MB, Askar M, Kanakry CG, Gragert L, Bolon YT, Marsh SGE, Gadalla SM, Paczesny S, Spellman S, Lee SJ. HLA Class I Genotype Is Associated with Relapse Risk after Allogeneic Stem Cell Transplantation for NPM1-Mutated Acute Myeloid Leukemia. Transplant Cell Ther. 2023 Jul.29(7):452.e1-452.e11. Pubmedid: [36997024](https://www.ncbi.nlm.nih.gov/pubmed/36997024). Pmcid: PMC10330307. 
    * Mei M, Pillai R, Kim S, Estrada-Merly N, Afkhami M, Yang L, Meng Z, Abid MB, Aljurf M, Bacher U, Beitinjaneh A, Bredeson C, Cahn JY, Cerny J, Copelan E, Cutler C, DeFilipp Z, Diaz Perez MA, Farhadfar N, Freytes CO, Gadalla SM, Ganguly S, Gale RP, Gergis U, Grunwald MR, Hamilton BK, Hashmi S, Hildebrandt GC, Lazarus HM, Litzow M, Munker R, Murthy HS, Nathan S, Nishihori T, Patel SS, Rizzieri D, Seo S, Shah MV, Solh M, Verdonck LF, Vij R, Sobecks RM, Oran B, Scott BL, Saber W, Nakamura R. The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis. Haematologica. 2023 Jan.108(1):150-160. Pubmedid: [35443559](https://www.ncbi.nlm.nih.gov/pubmed/35443559). Pmcid: PMC9827167. 
    * Hashmi H, Darwin A, Nishihori T. Therapeutic Roles of Antibody Drug Conjugates (ADCs) in Relapsed/Refractory Lymphomas. Hematol Oncol Stem Cell Ther. 2023 Jan.16(1):21-34. Pubmedid: [36634275](https://www.ncbi.nlm.nih.gov/pubmed/36634275). 
    * Friend B, Broglie L, Logan BR, Chhabra S, Bupp C, Schiller G, Beitinjaneh A, Perez MAD, Guilcher GMT, Hashem H, Hildebrandt GC, Krem MM, Lazarus HM, Nishihori T, Nusrat R, Rotz SJ, Wirk B, Wieduwilt M, Pasquini M, Savani BN, Stadtmauer E, Sorror ML, Thakar MS. Adapting the HCT-CI Definitions for Children, Adolescents, and Young Adults with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther. 2023 Feb.29(2):123.e1-123.e10. Pubmedid: [36442769](https://www.ncbi.nlm.nih.gov/pubmed/36442769). Pmcid: PMC9911376. 
    * Lee DH, Kumar A, Mohammed T, Peres LC, Alsina M, Bachmeier CA, Blue B, Brayer J, Chandrasekhar S, Grajales-Cruz AF, De Avila G, Elmariah H, Faramand RG, Freeman CL, Jain MD, Khadka S, Khimani F, Liu H, Nishihori T, Oswald LB, Castaneda Puglianini OA, Shain KH, Smith E, Baz RC, Locke FL, Oliveira GH, Alomar M, Hansen DK. Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma. Blood Adv. 2023 Aug.7(16):4247-4257. Pubmedid: [37307173](https://www.ncbi.nlm.nih.gov/pubmed/37307173). Pmcid: PMC10424134. 
    * Dhakal B, Zhang MJ, Burns LJ, Tang X, Meyer C, Mau LW, Nooka AK, Stadtmauer E, Micallef IN, McGuirk J, Costa L, Juckett MB, Shah N, Champlin RE, Usmani SZ, Farag SS, Nishihori T, Roy V, Bodiford A, Barnes YJ, Drea EJ, Hari P, Hamadani M. Efficacy, safety, and cost of mobilization strategies in multiple myeloma: a prospective, observational study. Haematologica. 2023 Aug.108(8):2249-2254. Pubmedid: [36601982](https://www.ncbi.nlm.nih.gov/pubmed/36601982). Pmcid: PMC10388259. 
    * Tamari R, McLornan DP, Ahn KW, Estrada-Merly N, Hernandez-Boluda JC, Giralt SA, Palmer JM, Gale RP, DeFilipp Z, Marks D, van der Poel MWM, Verdonck LF, Battiwalla M, Díaz MA, Gupta V, Ali H, Litzow MR, Lazarus HM, Gergis U, Bashey A, Liesveld JL, Hashmi S, Pu JJ, Beitinjaneh A, Bredeson CN, Rizzieri DA, Savani BN, Abid MB, Ganguly S, Agrawal V, Ulrike V, Wirk B, Jain T, Cutler CS, Aljurf M, Kindwall-Keller T, Kharfan-Dabaja MA, Hildebrandt GC, Pawarode A, Solh MM, Yared JA, Grunwald MR, Nathan S, Nishihori T, Seo S, Scott BL, Nakamura R, Oran B, Czerw T, Yakoub-Agha I, Saber W. A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis. Blood Adv. 2023 Aug.7(15):3993-4002. Pubmedid: [37134306](https://www.ncbi.nlm.nih.gov/pubmed/37134306). Pmcid: PMC10410129. 
    * Lee DH, Chandrasekhar S, Jain MD, Mhaskar R, Reid K, Lee SB, Corallo S, Hidalgo-Vargas MJ, Kumar A, Chavez J, Shah B, Lazaryan A, Khimani F, Nishihori T, Bachmeier C, Faramand R, Fradley MG, Jeong D, Oliveira GH, Locke FL, Davila ML, Alomar M. Cardiac and inflammatory biomarker differences in adverse cardiac events after chimeric antigen receptor T-Cell therapy: an exploratory study. Cardiooncology. 2023 Apr.9(1):18. Pubmedid: [37005652](https://www.ncbi.nlm.nih.gov/pubmed/37005652). Pmcid: PMC10067156. 
    * Lee D, Jordan AI, Menges MA, Lazaryan A, Nishihori T, Gaballa SR, Shah BD, Pinilla-Ibarz J, Baluch A, Klinkova OV, Chavez JC, Jain MD, Locke FL. Pneumococcal Conjugate Vaccine Does Not Induce Humoral Response When Administrated Within the Six Months After CD19 CAR T-Cell Therapy. Transplant Cell Ther. 2023 Apr.29(4):277.e1-277.e9. Pubmedid: [35970303](https://www.ncbi.nlm.nih.gov/pubmed/35970303). 
    * Nishihori T, Hoffman JE, Huff A, Kapoor GS, Eleftheriadou I, Zajic S, Urbano A, Suchindran S, Chisamore MJ, D'Souza JW, Faitg T, Rapoport AP. Safety and efficacy of letetresgene autoleucel alone or with pembrolizumab for relapsed/refractory multiple myeloma. Blood Adv. 2023 Apr.7(7):1168-1177. Pubmedid: [36534160](https://www.ncbi.nlm.nih.gov/pubmed/36534160). Pmcid: PMC10111356. 
    * Saliba RM, Majid AA, Pidala J, Arora M, Spellman SR, Hemmer MT, Wang T, Abboud C, Ahmed S, Antin JH, Beitinjaneh A, Buchbinder D, Byrne M, Cahn JY, Choe H, Hanna R, Hematti P, Kamble RT, Kitko CL, Laughlin M, Lekakis L, MacMillan ML, Martino R, Mehta PA, Nishihori T, Patel SS, Perales MA, Rangarajan HG, Ringdén O, Rosenthal J, Savani BN, Schultz KR, Seo S, Teshima T, van der Poel M, Verdonck LF, Weisdorf D, Wirk B, Yared JA, Schriber J, Champlin R, Ciurea S. Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis. Transplant Cell Ther. 2022 Oct.28(10):681-693. Pubmedid: [35853610](https://www.ncbi.nlm.nih.gov/pubmed/35853610). 
    * Bhatt NS, Sharma A, St Martin A, Abid MB, Brown VI, Diaz Perez MA, Frangoul H, Gadalla SM, Herr MM, Krem MM, Lazarus HM, Martens MJ, Mehta PA, Nishihori T, Prestidge T, Pulsipher MA, Rangarajan HG, Williams KM, Winestone LE, Yin DE, Riches ML, Dandoy CE, Auletta JJ. Clinical Characteristics and Outcomes of COVID-19 in Pediatric and Early Adolescent and Young Adult Hematopoietic Stem Cell Transplant Recipients: A Cohort Study. Transplant Cell Ther. 2022 Oct.28(10):696.e1-696.e7. Pubmedid: [35798233](https://www.ncbi.nlm.nih.gov/pubmed/35798233). Pmcid: PMC9251957. 
    * Kharfan-Dabaja MA, Reljic T, Yassine F, Nishihori T, Kumar A, Tawk MM, Keller K, Ayala E, Savani B, Mohty M, Aljurf M, Saber W. Efficacy of a Second Allogeneic Hematopoietic Cell Transplant in Relapsed Acute Myeloid Leukemia: Results of a Systematic Review and Meta-Analysis. Transplant Cell Ther. 2022 Nov.28(11):767.e1-767.e11. Pubmedid: [35970301](https://www.ncbi.nlm.nih.gov/pubmed/35970301). 
    * Jimenez Jimenez AM, De Lima M, Komanduri KV, Wang TP, Zhang MJ, Chen K, Abdel-Azim H, Abid MB, Aljurf M, Alkhateeb H, Assal A, Bacher U, Baron F, Battiwalla M, Beitinjaneh A, Bejanyan N, Bhatt VR, Byrne M, Cahn JY, Cairo M, Castillo P, Copelan E, DeFilipp Z, Perez MAD, Elsawy M, Gale RP, George B, Grunwald MR, Hildebrandt GC, Hogan WJ, Kanakry CG, Kansagra A, Kharfan-Dabaja MA, Khera N, Krem MM, Lazaryan A, Maakaron J, Martino R, McGuirk J, Michelis FV, Milone G, Mishra A, Murthy HS, Mussetti A, Nathan S, Nishihori T, Olsson RF, Palmisiano N, Patel S, Saad A, Seo S, Sharma A, Solh M, Verdonck LF, Wirk B, Yared JA, Litzow M, Kebriaei P, Hourigan CS, Saber W, Weisdorf D. Correction to: An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis. Bone Marrow Transplant. 2022 May.57(5):852. Pubmedid: [35297406](https://www.ncbi.nlm.nih.gov/pubmed/35297406). 
    * Abou-Ismail MY, Fraser R, Allbee-Johnson M, Metheny L, Ravi G, Ahn KW, Bhatt NS, Lazarus HM, de Lima M, El Jurdy N, Hematti P, Beitinjaneh AM, Nishihori T, Badawy SM, Sharma A, Pasquini MC, Savani BN, Sorror ML, Stadtmauer EA, Chhabra S. Does recipient body mass index inform donor selection for allogeneic haematopoietic cell transplantation?. Brit J Haematol. 2022 May.197(3):326-338. Pubmedid: [35286719](https://www.ncbi.nlm.nih.gov/pubmed/35286719). Pmcid: PMC9675037. 
    * Guru Murthy GS, Kim S, Hu ZH, Estrada-Merly N, Abid MB, Aljurf M, Bacher U, Badawy SM, Beitinjaneh A, Bredeson C, Cahn JY, Cerny J, Diaz Perez MA, Farhadfar N, Gale RP, Ganguly S, Gergis U, Hildebrandt GC, Grunwald MR, Hashmi S, Hossain NM, Kalaycio M, Kamble RT, Kharfan-Dabaja MA, Hamilton BK, Lazarus HM, Liesveld J, Litzow M, Marks DI, Murthy HS, Nathan S, Nazha A, Nishihori T, Patel SS, Pawarode A, Rizzieri D, Savani B, Seo S, Solh M, Ustun C, van der Poel M, Verdonck LF, Vij R, Wirk B, Oran B, Nakamura R, Scott B, Saber W. Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors. JAMA Oncol. 2022 Mar.8(3):404-411. Pubmedid: [35024768](https://www.ncbi.nlm.nih.gov/pubmed/35024768). Pmcid: PMC8759031. 
    * Fuchs EJ, McCurdy SR, Solomon SR, Wang T, Herr MM, Modi D, Grunwald MR, Nishihori T, Kuxhausen M, Fingerson S, McKallor C, Bashey A, Kasamon YL, Bolon YT, Saad A, McGuirk JP, Paczesny S, Gadalla SM, Marsh SG, Shaw BE, Spellman SR, Lee SJ, Petersdorf EW. HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide. Blood. 2022 Mar.139(10):1452-1468. Pubmedid: [34724567](https://www.ncbi.nlm.nih.gov/pubmed/34724567). Pmcid: PMC8914182. 
    * Song J, Zhang H, Dong N, Zhang X, Hussaini M, Jain A, Moscinski L, Shain K, Baz R, Alsina M, Nishihori T, Zhang L. The Application of NextGen Sequencing in the Diagnosis of Myeloid Neoplasms in Myeloma Patients With Cytopenia. Clin Lymphoma Myeloma Leuk. 2022 Jun.22(6):e414-e426. Pubmedid: [34998786](https://www.ncbi.nlm.nih.gov/pubmed/34998786). 
    * Patel SS, Ahn KW, Khanal M, Bupp C, Allbee-Johnson M, Majhail NS, Hamilton BK, Rotz SJ, Hashem H, Beitinjaneh A, Lazarus HM, Krem MM, Prestidge T, Bhatt NS, Sharma A, Gadalla SM, Murthy HS, Broglie L, Nishihori T, Freytes CO, Hildebrandt GC, Gergis U, Seo S, Wirk B, Pasquini MC, Savani BN, Sorror ML, Stadtmauer EA, Chhabra S. Noninfectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther. 2022 Jun.28(6):310-320. Pubmedid: [35314376](https://www.ncbi.nlm.nih.gov/pubmed/35314376). Pmcid: PMC9197865. 
    * Peres LC, Colin-Leitzinger C, Teng M, Dutil J, Alugubelli RR, DeAvila G, Teer JK, Du D, Mo Q, Siegel EM, Hampton O, Alsina M, Brayer J, Blue B, Baz R, Siqueira Silva A, Nishihori T, Shain KH, Gillis N. Racial and ethnic differences in clonal hematopoiesis, tumor markers, and outcomes of patients with multiple myeloma. Blood Adv. 2022 Jun.6(12):3767-3778. Pubmedid: [35500227](https://www.ncbi.nlm.nih.gov/pubmed/35500227). Pmcid: PMC9631567. 
    * Perez A, Johnson G, Patel K, Arciola B, Wood A, Bachmeier CA, Chavez JC, Shah BD, Khimani F, Nishihori T, Lazaryan A, Davila ML, Mhaskar R, Locke FL, Gaballa S, Jain MD. Primary progression during frontline CIT associates with decreased efficacy of subsequent CD19 CAR T-cell therapy in LBCL. Blood Adv. 2022 Jul.6(13):3970-3973. Pubmedid: [35816359](https://www.ncbi.nlm.nih.gov/pubmed/35816359). Pmcid: PMC9278282. 
    * Kansagra A, Dispenzieri A, Fraser R, Estrada-Merly N, Sidana S, Nishihori T, Hansen DK, Anderson LD, Banerjee R, Bumma N, Dhakal B, Khouri J, Landau H, Lee CH, Mian H, Nathan S, Savani BN, Kumar SK, Qazilbash MH, Shah N, D'Souza A. Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma. Blood Adv. 2022 Jul.6(13):3991-3995. Pubmedid: [35507742](https://www.ncbi.nlm.nih.gov/pubmed/35507742). Pmcid: PMC9278304. 
    * Lazaryan A, Lee SJ, Arora M, Kim J, Betts BC, Khimani F, Nishihori T, Bejanyan N, Liu H, Kharfan-Dabaja MA, Locke FL, Gonzalez R, Jain MD, Davila ML, Perez LE, Mishra A, Perez Perez A, Balke K, Ayala E, Ochoa L, Castaneda Puglianini O, Faramand RG, Alsina M, Elmariah H, Nieder M, Fernandez H, Anasetti C, Pidala J. A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease. Blood Adv. 2022 Jan.6(1):259-269. Pubmedid: [34649279](https://www.ncbi.nlm.nih.gov/pubmed/34649279). Pmcid: PMC8753213. 
    * Pasvolsky O, Yeshurun M, Fraser R, Estrada-Merly N, Rozovski U, Shargian-Alon L, Assal A, Banerjee R, Bumma N, Gale RP, Hagen P, Holmberg L, Hossain NM, Lazarus HM, Lee C, Mian H, Miller KC, Nathan S, Nagler A, Nishihori T, Parrondo RD, Patel S, Schroeder MA, Usmani SZ, Wang T, Wirk B, Kumar S, Shah N, Qazilbash MH, D'Souza A. Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis. Bone Marrow Transplant. 2022 Jan.57(1):31-37. Pubmedid: [34608275](https://www.ncbi.nlm.nih.gov/pubmed/34608275). Pmcid: PMC8764606. 
    * Wieduwilt MJ, Metheny L, Zhang MJ, Wang HL, Estrada-Merly N, Marks DI, Al-Homsi AS, Muffly L, Chao NJ, Rizzieri D, Gale RP, Gadalla SM, Cairo MS, Mussetti A, Gore SD, Bhatt VR, Patel SS, Michelis FV, Inamoto Y, Badawy SM, Copelan E, Palmisiano N, Kharfan-Dabaja MA, Lazarus HM, Ganguly S, Bredeson CN, Diaz Perez MA, Cassaday R, Savani BN, Ballen KK, Martino R, Wirk B, Bacher U, Aljurf M, Bashey A, Murthy HS, Yared JA, Aldoss I, Farhadfar N, Liu H, Abdel-Azim H, Waller EK, Solh M, Seftel M, van der Poel MWM, Grunwald MR, Liesveld JL, Kamble RT, McGuirk JP, Munker R, Cahn JY, Lee JW, Freytes CO, Krem M, Winestone LE, Gergis U, Nathan S, Olsson RF, Verdonck LF, Sharma A, Ringden O, Friend BD, Cerny J, Choe HK, Chhabra S, Nishihori T, Seo S, George B, Baxter-Lowe LA, Hildebrandt GC, de Lima M, Litzow MR, Kebriaei P, Hourigan CS, Abid MB, Weisdorf DJ, Saber W. Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. Blood Adv. 2022 Jan.6(1):339-357. Pubmedid: [34547770](https://www.ncbi.nlm.nih.gov/pubmed/34547770). Pmcid: PMC8753217. 
    * Tan CR, Estrada-Merly N, Landau H, Lekakis L, Banerjee R, Mian H, Usmani SZ, Hanbali A, Lazarus HM, Kyle RA, Dholaria B, Bal S, Strouse C, Murthy HS, Wirk B, Nishihori T, Kumar S, Shah N, Qazilbash M, D'Souza A. A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patients. Bone Marrow Transplant. 2022 Feb.57(2):295-298. Pubmedid: [34802047](https://www.ncbi.nlm.nih.gov/pubmed/34802047). Pmcid: PMC8825695. 
    * Otoukesh S, Elmariah H, Yang D, Clark MC, Siraj M, Ali H, Mogili K, Arslan S, Nishihori T, Nakamura R, Pidala J, Marcucci G, Forman SJ, Anasetti C, Malki MMA, Bejanyan N. Cytokine Release Syndrome Following Peripheral Blood Stem Cell Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplant Cell Ther. 2022 Feb.28(2):111.e1-111.e8. Pubmedid: [34844022](https://www.ncbi.nlm.nih.gov/pubmed/34844022). 
    * Wood AC, Perez AP, Arciola B, Patel K, Johnson G, DiMaggio E, Bachmeier CA, Reid K, Carallo S, Vargas MH, Faramand R, Chavez JC, Shah B, Gaballa S, Khimani F, Elmariah H, Nishihori T, Lazaryan A, Freeman C, Davila ML, Locke FL, Mhaskar R, Bassil C, Jain MD. Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including Dialysis. Transplant Cell Ther. 2022 Dec.28(12):829.e1-829.e8. Pubmedid: [36174934](https://www.ncbi.nlm.nih.gov/pubmed/36174934). Pmcid: PMC9791940. 
    * Logue JM, Peres LC, Hashmi H, Colin-Leitzinger C, Shrewsbury AM, Hosoya H, Gonzalez R, Copponex C, Kottra KH, Hovanky V, Sahaf B, Patil S, Lazaryan A, Jain MD, Baluch A, Klinkova O, Bejanyan N, Faramand RG, Elmariah H, Khimani F, Davila ML, Mishra A, Blue B, Grajales-Cruz AF, Castaneda Puglianini O, Liu H, Nishihori T, Freeman CL, Brayer J, Shain KH, Baz R, Locke FL, Alsina M, Sidana S, Hansen DK. Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma. Blood Adv. 2022 Dec.6(24):6109-6119. Pubmedid: [35939783](https://www.ncbi.nlm.nih.gov/pubmed/35939783). Pmcid: PMC9768247. 
    * Feurstein SK, Trottier AM, Estrada-Merly N, Pozsgai MJ, McNeely KE, Drazer MW, Ruhle B, Sadera K, Koppayi AL, Scott BL, Oran B, Nishihori T, Agrawal V, Saad A, Lindsley RC, Nakamura R, Kim S, Hu ZH, Sobecks RM, Spellman SR, Saber W, Godley LA. Germ line predisposition variants occur in myelodysplastic syndrome patients of all ages. Blood. 2022 Dec.140(24):2533-2548. Pubmedid: [35969835](https://www.ncbi.nlm.nih.gov/pubmed/35969835). 
    * Zhang Y, Duncanson L, Brayer J, Reu F, Hansen D, Alsina M, Nishihori T, Ochoa-Bayona J, Liu H, Shain K, Thompson Z, Baz R, Blue B. Adding Cyclophosphamide to Bortezomib and Dexamethasone was not Associated With Improved Outcomes of Patients With Newly Diagnosed Light Chain Amyloidosis: A Retrospective Study. Clin Lymphoma Myeloma Leuk. 2022 Aug.22(8):e770-e776. Pubmedid: [35504808](https://www.ncbi.nlm.nih.gov/pubmed/35504808). 
    * Dholaria B, Radujkovic A, Estrada-Merly N, Sirait T, Kim S, Hernández-Boluda JC, Czerw T, Hayden PJ, Kansagra A, Ho VT, Nishihori T, Shaughnessy P, Scott B, Nakamura R, Oran B, Kharfan-Dabaja M, Savani BN, McLornan D, Yakoub-Agha I, Saber W. Outcomes of allogeneic haematopoietic cell transplantation for chronic neutrophilic leukaemia: A combined CIBMTR/CMWP of EBMT analysis. Brit J Haematol. 2022 Aug.198(4):785-789. Pubmedid: [35658101](https://www.ncbi.nlm.nih.gov/pubmed/35658101). Pmcid: PMC9750039. 
    * Mirza AS, Tandon A, Jenneman D, Cao S, Brimer T, Kumar A, Kidd M, Khimani F, Faramand R, Mishra A, Liu H, Nishihori T, Perez L, Lazaryan A, Bejanyan N, Nieder M, Pidala J, Elmariah H. Outcomes Following Intolerance to Tacrolimus/Sirolimus Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther. 2022 Apr.28(4):185.e1-185.e7. Pubmedid: [35017119](https://www.ncbi.nlm.nih.gov/pubmed/35017119). 
    * Murthy HS, Ahn KW, Estrada-Merly N, Alkhateeb HB, Bal S, Kharfan-Dabaja MA, Dholaria B, Foss F, Gowda L, Jagadeesh D, Sauter C, Abid MB, Aljurf M, Awan FT, Bacher U, Badawy SM, Battiwalla M, Bredeson C, Cerny J, Chhabra S, Deol A, Diaz MA, Farhadfar N, Freytes C, Gajewski J, Gandhi MJ, Ganguly S, Grunwald MR, Halter J, Hashmi S, Hildebrandt GC, Inamoto Y, Jimenez-Jimenez AM, Kalaycio M, Kamble R, Krem MM, Lazarus HM, Lazaryan A, Maakaron J, Munshi PN, Munker R, Nazha A, Nishihori T, OIuwole OO, Ortí G, Pan DC, Patel SS, Pawarode A, Rizzieri D, Saba NS, Savani B, Seo S, Ustun C, van der Poel M, Verdonck LF, Wagner JL, Wirk B, Oran B, Nakamura R, Scott B, Saber W. Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research. Transplant Cell Ther. 2022 Apr.28(4):187.e1-187.e10. Pubmedid: [35081472](https://www.ncbi.nlm.nih.gov/pubmed/35081472). Pmcid: PMC8977261. 
    * Hussaini MO, Srivastava J, Lee LW, Nishihori T, Shah BD, Alsina M, Pinilla-Ibarz J, Shain KH. Assessment of Clonotypic Rearrangements and Minimal Residual Disease in Lymphoid Malignancies. Arch Pathol Lab Med. 2022 Apr.146(4):485-493. Pubmedid: [34343238](https://www.ncbi.nlm.nih.gov/pubmed/34343238). 
    * Cortes A, Perez A, Bachmeier C, Mhaskar R, Chavez JC, Shah B, Nishihori T, Khimani F, Lazaryan A, Davila ML, Locke FL, Jain MD. Outcomes of CD19 Chimeric Antigen Receptor T Cell Therapy in Patients with Gastrointestinal Tract Involvement of Large B Cell Lymphoma. Transplant Cell Ther. 2021 Sep.27(9):768.e1-768.e6. Pubmedid: [34077811](https://www.ncbi.nlm.nih.gov/pubmed/34077811). Pmcid: PMC8403629. 
    * Percival ME, Wang HL, Zhang MJ, Saber W, de Lima M, Litzow M, Kebriaei P, Abdel-Azim H, Adekola K, Aljurf M, Bacher U, Badawy SM, Beitinjaneh A, Bejanyan N, Bhatt V, Byrne M, Cahn JY, Castillo P, Chao N, Chhabra S, Copelan E, Cutler C, DeFilipp Z, Dias A, Diaz MA, Estey E, Farhadfar N, Frangoul HA, Freytes CO, Gale RP, Ganguly S, Gowda L, Grunwald M, Hossain N, Kamble RT, Kanakry CG, Kansagra A, Kharfan-Dabaja MA, Krem M, Lazarus HM, Lee JW, Liesveld JL, Lin R, Liu H, McGuirk J, Munker R, Murthy HS, Nathan S, Nishihori T, Olsson RF, Palmisiano N, Passweg JR, Prestidge T, Ringdén O, Rizzieri DA, Rybka WB, Savoie ML, Schultz KR, Seo S, Sharma A, Solh M, Strair R, van der Poel M, Verdonck LF, Yared JA, Weisdorf D, Sandmaier BM. Correction to: Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2021 Sep.56(9):2319. Pubmedid: [34017072](https://www.ncbi.nlm.nih.gov/pubmed/34017072). Pmcid: PMC8450771. 
    * Percival ME, Wang HL, Zhang MJ, Saber W, de Lima M, Litzow M, Kebriaei P, Abdel-Azim H, Adekola K, Aljurf M, Bacher U, Badawy SM, Beitinjaneh A, Bejanyan N, Bhatt V, Byrne M, Cahn JY, Castillo P, Chao N, Chhabra S, Copelan E, Cutler C, DeFilipp Z, Dias A, Diaz MA, Estey E, Farhadfar N, Frangoul HA, Freytes CO, Gale RP, Ganguly S, Gowda L, Grunwald M, Hossain N, Kamble RT, Kanakry CG, Kansagra A, Kharfan-Dabaja MA, Krem M, Lazarus HM, Lee JW, Liesveld JL, Lin R, Liu H, McGuirk J, Munker R, Murthy HS, Nathan S, Nishihori T, Olsson RF, Palmisiano N, Passweg JR, Prestidge T, Ringdén O, Rizzieri DA, Rybka WB, Savoie ML, Schultz KR, Seo S, Sharma A, Solh M, Strair R, van der Poel M, Verdonck LF, Yared JA, Weisdorf D, Sandmaier BM. Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2021 Sep.56(9):2108-2117. Pubmedid: [33864019](https://www.ncbi.nlm.nih.gov/pubmed/33864019). Pmcid: PMC8425595. 
    * Merryman RW, Castagna L, Giordano L, Ho VT, Corradini P, Guidetti A, Casadei B, Bond DA, Jaglowski S, Spinner MA, Arai S, Lowsky R, Shah GL, Perales MA, De Colella JMS, Blaise D, Herrera AF, Shouse G, Spilleboudt C, Ansell SM, Nieto Y, Badar T, Hamadani M, Feldman TA, Dahncke L, Singh AK, McGuirk JP, Nishihori T, Chavez J, Serritella AV, Kline J, Mohty M, Dulery R, Stamatoulas A, Houot R, Manson G, Moles-Moreau MP, Orvain C, Bouabdallah K, Modi D, Ramchandren R, Lekakis L, Beitinjaneh A, Frigault MJ, Chen YB, Lynch RC, Smith SD, Rao U, Byrne M, Romancik JT, Cohen JB, Nathan S, Phillips T, Joyce RM, Rahimian M, Bashey A, Ballard HJ, Svoboda J, Torri V, Sollini M, De Philippis C, Magagnoli M, Santoro A, Armand P, Zinzani PL, Carlo-Stella C. Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. Leukemia. 2021 Sep.35(9):2672-2683. Pubmedid: [33658659](https://www.ncbi.nlm.nih.gov/pubmed/33658659). 
    * Khimani F, Ranspach P, Elmariah H, Kim J, Whiting J, Nishihori T, Locke FL, Perez Perez A, Dean E, Mishra A, Perez L, Lazaryan A, Jain MD, Nieder M, Liu H, Faramand R, Hansen D, Alsina M, Ochoa L, Davila M, Anasetti C, Pidala J, Bejanyan N. Increased Infections and Delayed CD4+ T Cell but Faster B Cell Immune Reconstitution after Post-Transplantation Cyclophosphamide Compared to Conventional GVHD Prophylaxis in Allogeneic Transplantation. Transplant Cell Ther. 2021 Nov.27(11):940-948. Pubmedid: [34329754](https://www.ncbi.nlm.nih.gov/pubmed/34329754). 
    * Metheny L, Callander NS, Hall AC, Zhang MJ, Bo-Subait K, Wang HL, Agrawal V, Al-Homsi AS, Assal A, Bacher U, Beitinjaneh A, Bejanyan N, Bhatt VR, Bredeson C, Byrne M, Cairo M, Cerny J, DeFilipp Z, Perez MAD, Freytes CO, Ganguly S, Grunwald MR, Hashmi S, Hildebrandt GC, Inamoto Y, Kanakry CG, Kharfan-Dabaja MA, Lazarus HM, Lee JW, Nathan S, Nishihori T, Olsson RF, Ringdén O, Rizzieri D, Savani BN, Savoie ML, Seo S, van der Poel M, Verdonck LF, Wagner JL, Yared JA, Hourigan CS, Kebriaei P, Litzow M, Sandmaier BM, Saber W, Weisdorf D, de Lima M. Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults. Transplant Cell Ther. 2021 Nov.27(11):923.e1-923.e12. Pubmedid: [34428556](https://www.ncbi.nlm.nih.gov/pubmed/34428556). Pmcid: PMC9064046. 
    * Oran B, Ahn KW, Fretham C, Beitinjaneh A, Bashey A, Pawarode A, Wirk B, Scott BL, Savani BN, Bredeson C, Weisdorf D, Marks DI, Rizzieri D, Copelan E, Hildebrandt GC, Hale GA, Murthy HS, Lazarus HM, Cerny J, Liesveld JL, Yared JA, Yves-Cahn J, Szer J, Verdonck LF, Aljurf M, van der Poel M, Litzow M, Kalaycio M, Grunwald MR, Diaz MA, Sabloff M, Kharfan-Dabaja MA, Majhail NS, Farhadfar N, Reshef R, Olsson RF, Gale RP, Nakamura R, Seo S, Chhabra S, Hashmi S, Farhan S, Ganguly S, Nathan S, Nishihori T, Jain T, Agrawal V, Bacher U, Popat U, Saber W. Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes. Transplant Cell Ther. 2021 Nov.27(11):921.e1-921.e10. Pubmedid: [34403791](https://www.ncbi.nlm.nih.gov/pubmed/34403791). Pmcid: PMC9562611. 
    * Riedell PA, Hamadani M, Ahn KW, Litovich C, Murthy GSG, Locke FL, Brunstein CG, Merryman RW, Stiff PJ, Pawarode A, Nishihori T, Kharfan-Dabaja MA, Herrera AF, Sauter CS, Smith SM. Outcomes and Utilization Trends of Front-Line Autologous Hematopoietic Cell Transplantation for Mantle Cell Lymphoma. Transplant Cell Ther. 2021 Nov.27(11):911.e1-911.e7. Pubmedid: [34450333](https://www.ncbi.nlm.nih.gov/pubmed/34450333). Pmcid: PMC8556305. 
    * Pidala J, Walton K, Elmariah H, Kim J, Mishra A, Bejanyan N, Nishihori T, Khimani F, Perez L, Faramand RG, Davila ML, Nieder ML, Sagatys EM, Holtan SG, Lawrence NJ, Lawrence HR, Blazar BR, Anasetti C, Sebti SM, Betts BC. Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results. Clin Cancer Res. 2021 May.27(10):2712-2722. Pubmedid: [33753457](https://www.ncbi.nlm.nih.gov/pubmed/33753457). Pmcid: PMC8127396. 
    * Jain MD, Zhao H, Wang X, Atkins R, Menges M, Reid K, Spitler K, Faramand R, Bachmeier CA, Dean EA, Cao B, Chavez JC, Shah BD, Lazaryan A, Nishihori T, Hussaini MO, Gonzalez RJ, Mullinax JE, Rodriguez P, Conejo-Garcia J, Anasetti C, Davila ML, Locke FL. Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. Blood. 2021 May.137(19):2621-2633. Pubmedid: [33512407](https://www.ncbi.nlm.nih.gov/pubmed/33512407). Pmcid: PMC8120145. 
    * Farhadfar N, Dias A, Wang T, Fretham C, Chhabra S, Murthy HS, Broglie L, D'Souza A, Gadalla SM, Gale RP, Hashmi S, Al-Homsi AS, Hildebrandt GC, Hematti P, Rizzieri D, Chee L, Lazarus HM, Bredeson C, Jaimes EA, Beitinjaneh A, Bashey A, Prestidge T, Krem MM, Marks DI, Benoit S, Yared JA, Nishihori T, Olsson RF, Freytes CO, Stadtmauer E, Savani BN, Sorror ML, Ganguly S, Wingard JR, Pasquini M. Impact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther. 2021 May.27(5):410-422. Pubmedid: [33775617](https://www.ncbi.nlm.nih.gov/pubmed/33775617). Pmcid: PMC8168834. 
    * Hoogland AI, Jayani RV, Collier A, Irizarry-Arroyo N, Rodriguez Y, Jain MD, Booth-Jones M, Hyland KA, James BW, Barata A, Bachmeier CA, Chavez JC, Khimani F, Krivenko GS, Lazaryan A, Liu HD, Nishihori T, Pinilla-Ibarz J, Shah BD, Abidi M, Locke FL, Jim HSL. Acute patient-reported outcomes in B-cell malignancies treated with axicabtagene ciloleucel. Cancer Med. 2021 Mar.10(6):1936-1943. Pubmedid: [33641257](https://www.ncbi.nlm.nih.gov/pubmed/33641257). Pmcid: PMC7957158. 
    * Bejanyan N, Pidala JA, Wang X, Thapa R, Nishihori T, Elmariah H, Lazaryan A, Khimani F, Davila ML, Mishra A, Faramand R, Jain MD, Ochoa L, Perez LE, Liu H, Alsina M, Kharfan-Dabaja MA, Fernandez H, Nieder ML, Locke FL, Anasetti C, Ayala E. A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation. Blood Adv. 2021 Mar.5(5):1154-1163. Pubmedid: [33635333](https://www.ncbi.nlm.nih.gov/pubmed/33635333). Pmcid: PMC7948297. 
    * Hansen DK, Kim J, Thompson Z, Hussaini M, Nishihori T, Ahmad A, Elmariah H, Faramand R, Mishra A, Davila ML, Khimani F, Lazaryan A, Sallman D, Liu H, Perez LE, Fernandez H, Nieder ML, Lancet JE, Pidala JA, Anasetti C, Bejanyan N. ELN 2017 Genetic Risk Stratification Predicts Survival of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation. Transplant Cell Ther. 2021 Mar.27(3):256.e1-256.e7. Pubmedid: [33781526](https://www.ncbi.nlm.nih.gov/pubmed/33781526). Pmcid: PMC8711732. 
    * Merryman RW, Redd RA, Nishihori T, Chavez J, Nieto Y, Darrah JM, Rao U, Byrne MT, Bond DA, Maddocks KJ, Spinner MA, Advani RH, Ballard HJ, Svoboda J, Singh AK, McGuirk JP, Modi D, Ramchandren R, Romancik J, Cohen JB, Frigault MJ, Chen YB, Serritella AV, Kline J, Ansell S, Nathan S, Rahimian M, Joyce RM, Shah M, David KA, Park S, Beaven AW, Habib A, Bachanova V, Nakhoda S, Khan N, Lynch RC, Smith SD, Ho VT, LaCasce A, Armand P, Herrera AF. Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma. Blood Adv. 2021 Mar.5(6):1648-1659. Pubmedid: [33710337](https://www.ncbi.nlm.nih.gov/pubmed/33710337). Pmcid: PMC7993097. 
    * Mirza AS, Kumar A, Hashmi H, Garcia F, Logothetis CN, Darwin A, Faramand R, Reid K, Bachmeier C, Chavez JC, Shah B, Pinilla-Ibarz J, Khimani F, Lazaryan A, Liu H, Davila ML, Nishihori T, Locke FL, Jain MD. Incidence and Management of Effusions Before and After CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Large B Cell Lymphoma. Transplant Cell Ther. 2021 Mar.27(3):242.e1-242.e6. Pubmedid: [33781520](https://www.ncbi.nlm.nih.gov/pubmed/33781520). 
    * Koomen DC, Meads MB, Magaletti DM, Guingab-Cagmat JD, Oliveira PS, Fang B, Liu M, Welsh EA, Meke LE, Jiang Z, Hampton OA, Tungesvik A, De Avila G, Alugubelli RR, Nishihori T, Silva AS, Eschrich SA, Garrett TJ, Koomen JM, Shain KH. Metabolic Changes Are Associated with Melphalan Resistance in Multiple Myeloma. J Proteome Res. 2021 Jun.20(6):3134-3149. Pubmedid: [34014671](https://www.ncbi.nlm.nih.gov/pubmed/34014671). 
    * Dhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, Kanate AS, Assal A, Hanbali A, Bashey A, Pawarode A, Freytes CO, Lee C, Vesole D, Cornell RF, Hildebrandt GC, Murthy HS, Lazarus HM, Cerny J, Yared JA, Schriber J, Berdeja J, Stockerl-Goldstein K, Meehan K, Holmberg L, Solh M, Diaz MA, Kharfan-Dabaja MA, Farhadfar N, Bashir Q, Munker R, Olsson RF, Gale RP, Bayer RL, Seo S, Chhabra S, Hashmi S, Badawy SM, Nishihori T, Gonsalves W, Nieto Y, Efebera Y, Kumar S, Shah N, Qazilbash M, Hari P, D'Souza A. Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Leukemia. 2021 Jun.35(6):1828. Pubmedid: [33782538](https://www.ncbi.nlm.nih.gov/pubmed/33782538). Pmcid: PMC8188513. 
    * Goldsmith SR, Abid MB, Auletta JJ, Bashey A, Beitinjaneh A, Castillo P, Chemaly RF, Chen M, Ciurea SO, Dandoy CE, Angel Diaz M, Fuchs EJ, Ganguly S, Kanakry CG, Kanakry JA, Kim S, Komanduri K, Krem M, Lazarus HM, Liu H, Ljungman P, Maziarz RT, Mulroney C, Nathan S, Nishihori T, Page KM, Perales MA, Taplitz RA, Romee R, Riches M. Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis. Blood. 2021 Jun.137(23):3291-3305. Pubmedid: [33657221](https://www.ncbi.nlm.nih.gov/pubmed/33657221). Pmcid: PMC8351903. 
    * Khimani F, Dutta M, Faramand R, Nishihori T, Perez AP, Dean E, Nieder M, Perez L, Mishra A, Elmariah H, Davila M, Ochoa L, Alsina M, Lazaryan A, Bejanyan N, Hansen D, Jain M, Locke F, Liu H, Pidala J, Shah B, Mhaskar R. Impact of Total Body Irradiation-Based Myeloablative Conditioning Regimens in Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Systematic Review and Meta-Analysis. Transplant Cell Ther. 2021 Jul.27(7):620.e1-620.e9. Pubmedid: [33798768](https://www.ncbi.nlm.nih.gov/pubmed/33798768). 
    * Mulroney CM, Bilal Abid M, Bashey A, Chemaly RF, Ciurea SO, Chen M, Dandoy CE, Diaz Perez MA, Friend BD, Fuchs E, Ganguly S, Goldsmith SR, Kanakry CG, Kim S, Komanduri KV, Krem MM, Lazarus HM, Ljungman P, Maziarz R, Nishihori T, Patel SS, Perales MA, Romee R, Singh AK, Reid Wingard J, Yared J, Riches M, Taplitz R. Incidence and impact of community respiratory viral infections in post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis and haploidentical stem cell transplantation. Brit J Haematol. 2021 Jul.194(1):145-157. Pubmedid: [34124796](https://www.ncbi.nlm.nih.gov/pubmed/34124796). Pmcid: PMC8853845. 
    * Dhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, Kanate AS, Assal A, Hanbali A, Bashey A, Pawarode A, Freytes CO, Lee C, Vesole D, Cornell RF, Hildebrandt GC, Murthy HS, Lazarus HM, Cerny J, Yared JA, Schriber J, Berdeja J, Stockerl-Goldstein K, Meehan K, Holmberg L, Solh M, Diaz MA, Kharfan-Dabaja MA, Farhadfar N, Bashir Q, Munker R, Olsson RF, Gale RP, Bayer RL, Seo S, Chhabra S, Hashmi S, Badawy SM, Nishihori T, Gonsalves W, Nieto Y, Efebera Y, Kumar S, Shah N, Qazilbash M, Hari P, D'Souza A. Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Leukemia. 2021 Jul.35(7):2141. Pubmedid: [34091601](https://www.ncbi.nlm.nih.gov/pubmed/34091601). 
    * Elmariah H, Naqvi SMH, Kim J, Nishihori T, Mishra A, Perez L, Faramand R, Lazaryan A, Liu HD, Khimani F, Nieder M, Anasetti C, Pidala J, Bejanyan N. Impact of infused CD34+ stem cell dosing for allogeneic peripheral blood stem cell transplantation with post-transplant cyclophosphamide. Bone Marrow Transplant. 2021 Jul.56(7):1683-1690. Pubmedid: [33658647](https://www.ncbi.nlm.nih.gov/pubmed/33658647). 
    * Bejanyan N, Zhang M, Bo-Subait K, Brunstein C, Wang H, Warlick ED, Giralt S, Nishihori T, Martino R, Passweg J, Dias A, Copelan E, Hale G, Gale RP, Solh M, Kharfan-Dabaja MA, Diaz MA, Ganguly S, Gore S, Verdonck LF, Hossain NM, Kekre N, Savani B, Byrne M, Kanakry C, Cairo MS, Ciurea S, Schouten HC, Bredeson C, Munker R, Lazarus H, Cahn JY, van Der Poel M, Rizzieri D, Yared JA, Freytes C, Cerny J, Aljurf M, Palmisiano ND, Pawarode A, Bacher VU, Grunwald MR, Nathan S, Wirk B, Hildebrandt GC, Seo S, Olsson RF, George B, de Lima M, Hourigan CS, Sandmaier B, Litzow M, Kebriaei P, Saber W, Weisdorf D. Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Ma. Transplant Cell Ther. 2021 Jan.27(1):68.e1-68.e9. Pubmedid: [33010430](https://www.ncbi.nlm.nih.gov/pubmed/33010430). Pmcid: PMC8015679. 
    * Camacho-Bydume C, Wang T, Sees JA, Fernandez-Viña M, Abid MB, Askar M, Beitinjaneh A, Brown V, Castillo P, Chharbra S, Gadalla SM, Hsu JM, Kamoun M, Lazaryan A, Nishihori T, Page K, Schetelig J, Fleischhauer K, Marsh SGE, Paczesny S, Spellman SR, Lee SJ, Hsu KC. Specific Class I HLA Supertypes but Not HLA Zygosity or Expression Are Associated with Outcomes following HLA-Matched Allogeneic Hematopoietic Cell Transplant: HLA Supertypes Impact Allogeneic HCT Outcomes. Transplant Cell Ther. 2021 Feb.27(2):142.e1-142.e11. Pubmedid: [33053450](https://www.ncbi.nlm.nih.gov/pubmed/33053450). Pmcid: PMC8015676. 
    * Grunwald MR, Zhang MJ, Elmariah H, Johnson MH, St Martin A, Bashey A, Battiwalla M, Bredeson CN, Copelan E, Cutler CS, George BR, Gupta V, Kanakry C, Mehta RS, Milano F, Mussetti A, Nakamura R, Nishihori T, Saber W, Solh M, Weisdorf DJ, Eapen M. Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors. Blood Adv. 2021 Feb.5(4):975-983. Pubmedid: [33576783](https://www.ncbi.nlm.nih.gov/pubmed/33576783). Pmcid: PMC7903230. 
    * Elgarten CW, Li Y, Getz KD, Hemmer M, Huang YV, Hall M, Wang T, Kitko CL, Jagasia MH, Nishihori T, Murthy HS, Hashem H, Cairo MS, Sharma A, Hashmi SK, Askar M, Beitinjaneh A, Kelly MS, Auletta JJ, Badawy SM, Mavers M, Aplenc R, MacMillan ML, Spellman SR, Arora M, Fisher BT. Broad-Spectrum Antibiotics and Risk of Graft-versus-Host Disease in Pediatric Patients Undergoing Transplantation for Acute Leukemia: Association of Carbapenem Use with the Risk of Acute Graft-versus-Host Disease. Transplant Cell Ther. 2021 Feb.27(2):177.e1-177.e8. Pubmedid: [33718896](https://www.ncbi.nlm.nih.gov/pubmed/33718896). Pmcid: PMC7946150. 
    * Mishra A, Pidala J, Thapa R, Betts BC, Fernandez H, Locke FL, Nishihori T, Perez L, Wang X, Anasetti C, Jim H. Objective and subjective physical function in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2021 Dec.56(12):2897-2903. Pubmedid: [34381169](https://www.ncbi.nlm.nih.gov/pubmed/34381169). 
    * Jimenez Jimenez AM, De Lima M, Komanduri KV, Wang TP, Zhang MJ, Chen K, Abdel-Azim H, Abid MB, Aljurf M, Alkhateeb H, Assal A, Bacher U, Baron F, Battiwalla M, Beitinjaneh A, Bejanyan N, Bhatt VR, Byrne M, Cahn JY, Cairo M, Castillo P, Copelan E, DeFilipp Z, Perez MAD, Elsawy M, Gale RP, George B, Grunwald MR, Hildebrandt GC, Hogan WJ, Kanakry CG, Kansagra A, Kharfan-Dabaja MA, Khera N, Krem MM, Lazaryan A, Maakaron J, Martino R, McGuirk J, Michelis FV, Milone G, Mishra A, Murthy HS, Mussetti A, Nathan S, Nishihori T, Olsson RF, Palmisiano N, Patel S, Saad A, Seo S, Sharma A, Solh M, Verdonck LF, Wirk B, Yared JA, Litzow M, Kebriaei P, Hourigan CS, Saber W, Weisdorf D. An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis. Bone Marrow Transplant. 2021 Dec.56(12):3068-3077. Pubmedid: [34584240](https://www.ncbi.nlm.nih.gov/pubmed/34584240). Pmcid: PMC8758206. 
    * Figura NB, Robinson TJ, Sim AJ, Wang X, Cao B, Chavez JC, Shah BD, Khimani F, Lazaryan A, Davila M, Bachmeier C, Nishihori T, Liu HD, Kim S, Locke FL, Jain MD. Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell Therapy. Int J Radiat Oncol Biol Phys. 2021 Dec.111(5):1145-1154. Pubmedid: [34242714](https://www.ncbi.nlm.nih.gov/pubmed/34242714). Pmcid: PMC9791939. 
    * Kharfan-Dabaja MA, Kumar A, Ayala E, Aljurf M, Nishihori T, Marsh R, Burroughs LM, Majhail N, Al-Homsi AS, Al-Kadhimi ZS, Bar M, Bertaina A, Boelens JJ, Champlin R, Chaudhury S, DeFilipp Z, Dholaria B, El-Jawahri A, Fanning S, Fraint E, Gergis U, Giralt S, Hamilton BK, Hashmi SK, Horn B, Inamoto Y, Jacobsohn DA, Jain T, Johnston L, Kanate AS, Kansagra A, Kassim A, Kean LS, Kitko CL, Knight-Perry J, Kurtzberg J, Liu H, MacMillan ML, Mahmoudjafari Z, Mielcarek M, Mohty M, Nagler A, Nemecek E, Olson TS, Oran B, Perales MA, Prockop SE, Pulsipher MA, Pusic I, Riches ML, Rodriguez C, Romee R, Rondon G, Saad A, Shah N, Shaw PJ, Shenoy S, Sierra J, Talano J, Verneris MR, Veys P, Wagner JE, Savani BN, Hamadani M, Carpenter PA. Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular The. Transplant Cell Ther. 2021 Aug.27(8):642-649. Pubmedid: [34304802](https://www.ncbi.nlm.nih.gov/pubmed/34304802). 
    * Lazaryan A, Dolan M, Zhang MJ, Wang HL, Kharfan-Dabaja MA, Marks DI, Bejanyan N, Copelan E, Majhail NS, Waller EK, Chao N, Prestidge T, Nishihori T, Kebriaei P, Inamoto Y, Hamilton B, Hashmi SK, Kamble RT, Bacher U, Hildebrandt GC, Stiff PJ, McGuirk J, Aldoss I, Beitinjaneh AM, Muffly L, Vij R, Olsson RF, Byrne M, Schultz KR, Aljurf M, Seftel M, Savoie ML, Savani BN, Verdonck LF, Cairo MS, Hossain N, Bhatt VR, Frangoul HA, Abdel-Azim H, Al Malki M, Munker R, Rizzieri D, Khera N, Nakamura R, Ringdén O, Van der Poel M, Murthy HS, Liu H, Mori S, De Oliveira S, Bolaños-Meade J, Elsawy M, Barba P, Nathan S, George B, Pawarode A, Grunwald M, Agrawal V, Wang Y, Assal A, Caro PC, Kuwatsuka Y, Seo S, Ustun C, Politikos I, Lazarus HM, Saber W, Sandmaier BM, De Lima M, Litzow M, Bachanova V, Weisdorf D. Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and. Haematologica. 2021 Aug.106(8):2295-2296. Pubmedid: [34333962](https://www.ncbi.nlm.nih.gov/pubmed/34333962). Pmcid: PMC8327734. 
    * Bhatt NS, Brazauskas R, Salit RB, Syrjala K, Bo-Subait S, Tecca H, Badawy SM, Baker KS, Beitinjaneh A, Bejanyan N, Byrne M, Dias A, Farhadfar N, Freytes CO, Ganguly S, Hashmi S, Hayashi RJ, Hong S, Inamoto Y, Jamani K, Kasow KA, Khera N, Krem MM, Lazarus HM, Lee CJ, Lee S, Majhail NS, Malone AK, Marks DI, Mau LW, Mayo SJ, Muffly LS, Nathan S, Nishihori T, Page KM, Preussler J, Rangarajan HG, Rotz SJ, Salooja N, Savani BN, Schears R, Schechter-Finkelstein T, Schiller G, Shah AJ, Sharma A, Wang T, Wirk B, Battiwalla M, Schoemans H, Hamilton B, Buchbinder D, Phelan R, Shaw B. Return to Work Among Young Adult Survivors of Allogeneic Hematopoietic Cell Transplantation in the United States. Transplant Cell Ther. 2021 Aug.27(8):679.e1-679.e8. Pubmedid: [33895402](https://www.ncbi.nlm.nih.gov/pubmed/33895402). Pmcid: PMC8425287. 
    * Logue JM, Zucchetti E, Bachmeier CA, Krivenko GS, Larson V, Ninh D, Grillo G, Cao B, Kim J, Chavez JC, Baluch A, Khimani F, Lazaryan A, Nishihori T, Liu HD, Pinilla-Ibarz J, Shah BD, Faramand R, Coghill AE, Davila ML, Dholaria BR, Jain MD, Locke FL. Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma. Haematologica. 2021 Apr.106(4):978-986. Pubmedid: [32327504](https://www.ncbi.nlm.nih.gov/pubmed/32327504). Pmcid: PMC8017820. 
    * Faramand R, Jain M, Staedtke V, Kotani H, Bai R, Reid K, Lee SB, Spitler K, Wang X, Cao B, Pinilla J, Lazaryan A, Khimani F, Shah B, Chavez JC, Nishihori T, Mishra A, Mullinax J, Gonzalez R, Hussaini M, Dam M, Brandjes BD, Bachmeier CA, Anasetti C, Locke FL, Davila ML. Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel. Clin Cancer Res. 2020 Sep.26(18):4823-4831. Pubmedid: [32669372](https://www.ncbi.nlm.nih.gov/pubmed/32669372). Pmcid: PMC7501265. 
    * Hashmi H, Mirza AS, Darwin A, Logothetis C, Garcia F, Kommalapati A, Mhaskar RS, Bachmeier C, Chavez JC, Shah B, Pinilla-Ibarz J, Khimani F, Lazaryan A, Liu H, Davila ML, Locke FL, Nishihori T, Jain MD. Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma. Blood Adv. 2020 Sep.4(17):4086-4090. Pubmedid: [32877523](https://www.ncbi.nlm.nih.gov/pubmed/32877523). Pmcid: PMC7479945. 
    * Hashmi H, Nishihori T. Role of hematopoietic cell transplantation in relapsed acute promyelocytic leukemia. Clin Transplant. 2020 Sep.34(9):e14009. Pubmedid: [32526047](https://www.ncbi.nlm.nih.gov/pubmed/32526047). 
    * Gupta V, Kim S, Hu ZH, Liu Y, Aljurf M, Bacher U, Beitinjaneh A, Cahn JY, Cerny J, Copelan E, Gadalla SM, Gale RP, Ganguly S, George B, Gerds AT, Gergis U, Hamilton BK, Hashmi S, Hildebrandt GC, Kamble RT, Kindwall-Keller T, Lazarus HM, Liesveld JL, Litzow M, Maziarz RT, Nishihori T, Olsson RF, Rizzieri D, Savani BN, Seo S, Solh M, Szer J, Verdonck LF, Wirk B, Woolfrey A, Yared JA, Alyea EP, Popat UR, Sobecks RM, Scott BL, Nakamura R, Saber W. Comparison of outcomes of HCT in blast phase of BCR-ABL1- MPN with de novo AML and with AML following MDS. Blood Adv. 2020 Oct.4(19):4748-4757. Pubmedid: [33007075](https://www.ncbi.nlm.nih.gov/pubmed/33007075). Pmcid: PMC7556156. 
    * Nazha A, Hu ZH, Wang T, Lindsley RC, Abdel-Azim H, Aljurf M, Bacher U, Bashey A, Cahn JY, Cerny J, Copelan E, DeFilipp Z, Diaz MA, Farhadfar N, Gadalla SM, Gale RP, George B, Gergis U, Grunwald MR, Hamilton B, Hashmi S, Hildebrandt GC, Inamoto Y, Kalaycio M, Kamble RT, Kharfan-Dabaja MA, Lazarus HM, Liesveld JL, Litzow MR, Majhail NS, Murthy HS, Nathan S, Nishihori T, Pawarode A, Rizzieri D, Sabloff M, Savani BN, Schachter L, Schouten HC, Seo S, Shah NN, Solh M, Valcárcel D, Vij R, Warlick E, Wirk B, Wood WA, Yared JA, Alyea E, Popat U, Sobecks RM, Scott BL, Nakamura R, Saber W. A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes. Biol Blood Marrow Tr. 2020 Nov.26(11):2139-2146. Pubmedid: [32781289](https://www.ncbi.nlm.nih.gov/pubmed/32781289). Pmcid: PMC7609542. 
    * Lazaryan A, Dolan M, Zhang MJ, Wang HL, Kharfan-Dabaja MA, Marks DI, Bejanyan N, Copelan E, Majhail NS, Waller EK, Chao N, Prestidge T, Nishihori T, Kebriaei P, Inamoto Y, Hamilton B, Hashmi SK, Kamble RT, Bacher U, Hildebrandt GC, Stiff PJ, McGuirk J, Aldoss I, Beitinjaneh AM, Muffly L, Vij R, Olsson RF, Byrne M, Schultz KR, Aljurf M, Seftel M, Savoie ML, Savani BN, Verdonck LF, Cairo MS, Hossain N, Bhatt VR, Frangoul HA, Abdel-Azim H, Al Malki M, Munker R, Rizzieri D, Khera N, Nakamura R, Ringdén O, van der Poel M, Murthy HS, Liu H, Mori S, De Oliveira S, Bolaños-Meade J, Elsawy M, Barba P, Nathan S, George B, Pawarode A, Grunwald M, Agrawal V, Wang Y, Assal A, Castillo Caro P, Kuwatsuka Y, Seo S, Ustun C, Politikos I, Lazarus HM, Saber W, Sandmaier BM, De Lima M, Litzow M, Bachanova V, Weisdorf D. Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and. Haematologica. 2020 May.105(5):1329-1338. Pubmedid: [31558669](https://www.ncbi.nlm.nih.gov/pubmed/31558669). Pmcid: PMC7193485. 
    * Jagadeesh D, Majhail NS, He Y, Ahn KW, Litovich C, Ahmed S, Aljurf M, Bacher U, Badawy SM, Bejanyan N, Cairo M, Cerny J, Epperla N, Farhadfar N, Freytes CO, Gale RP, Haverkos B, Hossain N, Inwards D, Kamble RT, Kenkre VP, Lazarus HM, Lazaryan A, Lekakis L, Mei M, Murthy HS, Mussetti A, Nathan S, Nishihori T, Olsson RF, Ramakrishnan Geethakumari P, Savani BN, Yared JA, Fenske TS, Kharfan-Dabaja MA, Sureda A, Hamadani M. Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation. Cancer. 2020 May.126(10):2279-2287. Pubmedid: [32049359](https://www.ncbi.nlm.nih.gov/pubmed/32049359). Pmcid: PMC7190439. 
    * Kahn JM, Brazauskas R, Tecca HR, Bo-Subait S, Buchbinder D, Battiwala M, Flowers MED, Savani BN, Phelan R, Broglie L, Abraham AA, Keating AK, Daly A, Wirk B, George B, Alter BP, Ustun C, Freytes CO, Beitinjaneh AM, Duncan C, Copelan E, Hildebrandt GC, Murthy HS, Lazarus HM, Auletta JJ, Myers KC, Williams KM, Page KM, Vrooman LM, Norkin M, Byrne M, Diaz MA, Kamani N, Bhatt NS, Rezvani A, Farhadfar N, Mehta PA, Hematti P, Shaw PJ, Kamble RT, Schears R, Olsson RF, Hayashi RJ, Gale RP, Mayo SJ, Chhabra S, Rotz SJ, Badawy SM, Ganguly S, Pavletic S, Nishihori T, Prestidge T, Agrawal V, Hogan WJ, Inamoto Y, Shaw BE, Satwani P. Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases. Blood Adv. 2020 May.4(9):2084-2094. Pubmedid: [32396620](https://www.ncbi.nlm.nih.gov/pubmed/32396620). Pmcid: PMC7218429. 
    * Gowin K, Ballen K, Ahn KW, Hu ZH, Ali H, Arcasoy MO, Devlin R, Coakley M, Gerds AT, Green M, Gupta V, Hobbs G, Jain T, Kandarpa M, Komrokji R, Kuykendall AT, Luber K, Masarova L, Michaelis LC, Patches S, Pariser AC, Rampal R, Stein B, Talpaz M, Verstovsek S, Wadleigh M, Agrawal V, Aljurf M, Angel Diaz M, Avalos BR, Bacher U, Bashey A, Beitinjaneh AM, Cerny J, Chhabra S, Copelan E, Cutler CS, DeFilipp Z, Gadalla SM, Ganguly S, Grunwald MR, Hashmi SK, Kharfan-Dabaja MA, Kindwall-Keller T, Kröger N, Lazarus HM, Liesveld JL, Litzow MR, Marks DI, Nathan S, Nishihori T, Olsson RF, Pawarode A, Rowe JM, Savani BN, Savoie ML, Seo S, Solh M, Tamari R, Verdonck LF, Yared JA, Alyea E, Popat U, Sobecks R, Scott BL, Nakamura R, Mesa R, Saber W. Survival following allogeneic transplant in patients with myelofibrosis. Blood Adv. 2020 May.4(9):1965-1973. Pubmedid: [32384540](https://www.ncbi.nlm.nih.gov/pubmed/32384540). Pmcid: PMC7218417. 
    * DeFilipp Z, Ancheta R, Liu Y, Hu ZH, Gale RP, Snyder D, Schouten HC, Kalaycio M, Hildebrandt GC, Ustun C, Daly A, Ganguly S, Inamoto Y, Litzow M, Szer J, Savoie ML, Hossain N, Kharfan-Dabaja MA, Hamadani M, Reshef R, Bajel A, Schultz KR, Gadalla S, Gerds A, Liesveld J, Juckett MB, Kamble R, Hashmi S, Abdel-Azim H, Solh M, Bacher U, Lazarus H, Olsson R, Cahn JY, Grunwald MR, Savani BN, Yared J, Rowe JM, Cerny J, Chaudhri NA, Aljurf M, Beitinjaneh A, Seo S, Nishihori T, Hsu JW, Ramanathan M, Alyea E, Popat U, Sobecks R, Saber W. Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study. Biol Blood Marrow Tr. 2020 Mar.26(3):472-479. Pubmedid: [31669399](https://www.ncbi.nlm.nih.gov/pubmed/31669399). Pmcid: PMC7358778. 
    * Epperla N, Li A, Logan B, Fretham C, Chhabra S, Aljurf M, Chee L, Copelan E, Freytes CO, Hematti P, Lazarus HM, Litzow M, Nishihori T, Olsson RF, Prestidge T, Saber W, Wirk B, Yared JA, Loren A, Pasquini M. Incidence, Risk Factors for and Outcomes of Transplant-Associated Thrombotic Microangiopathy. Brit J Haematol. 2020 Jun.189(6):1171-1181. Pubmedid: [32124435](https://www.ncbi.nlm.nih.gov/pubmed/32124435). Pmcid: PMC7726817. 
    * Mehta RS, Holtan SG, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel DR, Alousi AM, Pidala J, Abdel-Azim H, Agrawal V, Ahmed I, Al-Homsi AS, Aljurf M, Antin JH, Askar M, Auletta JJ, Bhatt VR, Chee L, Chhabra S, Daly A, DeFilipp Z, Gajewski J, Gale RP, Gergis U, Hematti P, Hildebrandt GC, Hogan WJ, Inamoto Y, Martino R, Majhail NS, Marks DI, Nishihori T, Olsson RF, Pawarode A, Diaz MA, Prestidge T, Rangarajan HG, Ringden O, Saad A, Savani BN, Schoemans H, Seo S, Schultz KR, Solh M, Spitzer T, Storek J, Teshima T, Verdonck LF, Wirk B, Yared JA, Cahn JY, Weisdorf DJ. Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. J Clin Oncol. 2020 Jun.38(18):2062-2076. Pubmedid: [32364845](https://www.ncbi.nlm.nih.gov/pubmed/32364845). Pmcid: PMC7302955. 
    * Schmidt S, Liu Y, Hu ZH, Williams KM, Lazarus HM, Vij R, Kharfan-Dabaja MA, Ortí G, Wiernik PH, Weisdorf D, Kamble RT, Herzig R, Wirk B, Cerny J, Bacher U, Chaudhri NA, Nathan S, Farhadfar N, Aljurf M, Gergis U, Szer J, Seo S, Hsu JW, Olsson RF, Maharaj D, George B, Hildebrandt GC, Agrawal V, Nishihori T, Abdel-Azim H, Alyea E, Popat U, Sobecks R, Scott BL, Chakrabarty JH, Saber W. The Role of Donor Lymphocyte Infusion (DLI) in Post-Hematopoietic Cell Transplant (HCT) Relapse for Chronic Myeloid Leukemia (CML) in the Tyrosine Kinase Inhibitor (TKI) Era. Biol Blood Marrow Tr. 2020 Jun.26(6):1137-1143. Pubmedid: [32062061](https://www.ncbi.nlm.nih.gov/pubmed/32062061). Pmcid: PMC7367282. 
    * Dean EA, Mhaskar RS, Lu H, Mousa MS, Krivenko GS, Lazaryan A, Bachmeier CA, Chavez JC, Nishihori T, Davila ML, Khimani F, Liu HD, Pinilla-Ibarz J, Shah BD, Jain MD, Balagurunathan Y, Locke FL. High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020 Jul.4(14):3268-3276. Pubmedid: [32702097](https://www.ncbi.nlm.nih.gov/pubmed/32702097). Pmcid: PMC7391155. 
    * DiMaggio E, Zhou JM, Caddell R, Tombleson R, Perkins J, Anasetti C, Khimani F, Pidala J, Nishihori T, Perez L, Betts B, Fernandez HF, Mishra A. Reduced-intensity fludarabine/melphalan confers similar survival to busulfan/fludarabine myeloablative regimens for patients with acute myeloid leukemia and myelodysplasia. Leuk Lymphoma. 2020 Jul.61(7):1678-1687. Pubmedid: [32133897](https://www.ncbi.nlm.nih.gov/pubmed/32133897). Pmcid: PMC7771324. 
    * Zhou Z, Nath R, Cerny J, Wang HL, Zhang MJ, Abdel-Azim H, Agrawal V, Ahmed G, Al-Homsi AS, Aljurf M, Alkhateeb HB, Assal A, Bacher U, Bajel A, Bashir Q, Battiwalla M, Bhatt VR, Byrne M, Cahn JY, Cairo M, Choe H, Copelan E, Cutler C, Damlaj MB, DeFilipp Z, De Lima M, Diaz MA, Farhadfar N, Foran J, Freytes CO, Gerds AT, Gergis U, Grunwald MR, Gul Z, Hamadani M, Hashmi S, Hertzberg M, Hildebrandt GC, Hossain N, Inamoto Y, Isola L, Jain T, Kamble RT, Khan MW, Kharfan-Dabaja MA, Kebriaei P, Kekre N, Khera N, Lazarus HM, Liesveld JL, Litzow M, Liu H, Marks DI, Martino R, Mathews V, Mishra A, Murthy HS, Nagler A, Nakamura R, Nathan S, Nishihori T, Olin R, Olsson RF, Palmisiano N, Patel SS, Patnaik MM, Pawarode A, Perales MA, Politikos I, Popat U, Rizzieri D, Sandmaier BM, Savani BN, Seo S, Shah NN, Uy GL, Valcárcel D, Verdonck LF, Waller EK, Wang Y, Weisdorf D, Wirk B, Wong E, Yared JA, Saber W. Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. Blood Adv. 2020 Jul.4(13):3180-3190. Pubmedid: [32663298](https://www.ncbi.nlm.nih.gov/pubmed/32663298). Pmcid: PMC7362362. 
    * Ghosh N, Ahmed S, Ahn KW, Khanal M, Litovich C, Aljurf M, Bacher VU, Bredeson C, Epperla N, Farhadfar N, Freytes CO, Ganguly S, Haverkos B, Inwards D, Kamble RT, Lazarus HM, Lekakis L, Murthy HS, Nishihori T, Ramakrishnan P, Rizzieri DA, Yared JA, Kharfan-Dabaja MA, Sureda A, Hamadani M. Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant. JAMA Oncol. 2020 Jul.6(7):1011-1018. Pubmedid: [32496525](https://www.ncbi.nlm.nih.gov/pubmed/32496525). Pmcid: PMC7273311. 
    * Frairia C, Nicolosi M, Shapiro J, Kim J, Betts BC, Fernandez HF, Locke FL, Mishra A, Nishihori T, Ochoa-Bayona JL, Perez L, Pidala J, Anasetti C. Sole Upfront Therapy with Beclomethasone and Budesonide for Upper Gastrointestinal Acute Graft-versus-Host Disease. Biol Blood Marrow Tr. 2020 Jul.26(7):1303-1311. Pubmedid: [32361010](https://www.ncbi.nlm.nih.gov/pubmed/32361010). Pmcid: PMC7771266. 
    * Badar T, Hari P, Dávila O, Fraser R, Wirk B, Dhakal B, Freytes CO, Rodriguez Valdes C, Lee C, Vesole DH, Malek E, Hildebrandt GC, Landau H, Murthy HS, Lazarus HM, Berdeja JG, Meehan KR, Solh M, Diaz MA, Kharfan-Dabaja MA, Callander NS, Farhadfar N, Bashir Q, Kamble RT, Vij R, Munker R, Kyle RA, Chhabra S, Hashmi S, Ganguly S, Jagannath S, Nishihori T, Nieto Y, Kumar S, Shah N, D'Souza A. African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States. Cancer. 2020 Jan.127(1):82-92. Pubmedid: [32966625](https://www.ncbi.nlm.nih.gov/pubmed/32966625). Pmcid: PMC7736245. 
    * Dandoy CE, Kim S, Chen M, Ahn KW, Ardura MI, Brown V, Chhabra S, Diaz MA, Dvorak C, Farhadfar N, Flagg A, Ganguly S, Hale GA, Hashmi SK, Hematti P, Martino R, Nishihori T, Nusrat R, Olsson RF, Rotz SJ, Sung AD, Perales MA, Lindemans CA, Komanduri KV, Riches ML. Incidence, Risk Factors, and Outcomes of Patients Who Develop Mucosal Barrier Injury-Laboratory Confirmed Bloodstream Infections in the First 100 Days After Allogeneic Hematopoietic Stem Cell Transplant. JAMA Netw Open. 2020 Jan.3(1):e1918668. Pubmedid: [31913492](https://www.ncbi.nlm.nih.gov/pubmed/31913492). Pmcid: PMC6991246. 
    * Nishihori T, Baz R. Selective inhibitors of nuclear export (SINEs) in myeloma: breakthrough or bust?. Expert Opin Drug Saf. 2020 Feb.19(2):113-115. Pubmedid: [31910353](https://www.ncbi.nlm.nih.gov/pubmed/31910353). 
    * Turner JG, Cui Y, Bauer AA, Dawson JL, Gomez JA, Kim J, Cubitt CL, Nishihori T, Dalton WS, Sullivan DM. Melphalan and Exportin 1 Inhibitors Exert Synergistic Antitumor Effects in Preclinical Models of Human Multiple Myeloma. Cancer Res. 2020 Dec.80(23):5344-5354. Pubmedid: [33023948](https://www.ncbi.nlm.nih.gov/pubmed/33023948). Pmcid: PMC7718436. 
    * Hu B, Lin X, Lee HC, Huang X, Tidwell RSS, Ahn KW, Hu ZH, Jabbour E, Verstovsek S, Ravandi F, Garcia-Manero G, Kharfan-Dabaja MA, Hossain NM, Marks DI, Kamble RT, Inamoto Y, Kindwall-Keller T, Saad A, Litzow MR, Savani BN, Hale GA, Bacher U, Gerds AT, Liesveld JL, Ustun C, Olsson RF, Daly A, Grunwald MR, Solh M, DeFilipp Z, Aljurf M, Wirk B, Akpek G, Nishihori T, Cerny J, Seo S, Hsu JW, Champlin R, de Lima M, Alyea E, Popat U, Sobecks R, Scott BL, Kantarjian H, Cortes J, Saber W. Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients. Leuk Lymphoma. 2020 Dec.61(12):2811-2820. Pubmedid: [32662346](https://www.ncbi.nlm.nih.gov/pubmed/32662346). Pmcid: PMC8424781. 
    * Munshi PN, Vesole D, Jurczyszyn A, Zaucha JM, St Martin A, Davila O, Agrawal V, Badawy SM, Battiwalla M, Chhabra S, Copelan E, Kharfan-Dabaja MA, Farhadfar N, Ganguly S, Hashmi S, Krem MM, Lazarus HM, Malek E, Meehan K, Murthy HS, Nishihori T, Olin RL, Olsson RF, Schriber J, Seo S, Shah G, Solh M, Tay J, Kumar S, Qazilbash MH, Shah N, Hari PN, D'Souza A. Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma. Cancer. 2020 Dec.126(23):5077-5087. Pubmedid: [32965680](https://www.ncbi.nlm.nih.gov/pubmed/32965680). Pmcid: PMC8063213. 
    * Dhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, Kanate AS, Assal A, Hanbali A, Bashey A, Pawarode A, Freytes CO, Lee C, Vesole D, Cornell RF, Hildebrandt GC, Murthy HS, Lazarus HM, Cerny J, Yared JA, Schriber J, Berdeja J, Stockerl-Goldstein K, Meehan K, Holmberg L, Solh M, Diaz MA, Kharfan-Dabaja MA, Farhadfar N, Bashir Q, Munker R, Olsson RF, Gale RP, Bayer RL, Seo S, Chhabra S, Hashmi S, Badawy SM, Nishihori T, Gonsalves W, Nieto Y, Efebera Y, Kumar S, Shah N, Qazilbash M, Hari P, D'Souza A. Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Leukemia. 2020 Dec.34(12):3338-3347. Pubmedid: [32313109](https://www.ncbi.nlm.nih.gov/pubmed/32313109). Pmcid: PMC7572530. 
    * Im A, Rashidi A, Wang T, Hemmer M, MacMillan ML, Pidala J, Jagasia M, Pavletic S, Majhail NS, Weisdorf D, Abdel-Azim H, Agrawal V, Al-Homsi AS, Aljurf M, Askar M, Auletta JJ, Bashey A, Beitinjaneh A, Bhatt VR, Byrne M, Cahn JY, Cairo M, Castillo P, Cerny J, Chhabra S, Choe H, Ciurea S, Daly A, Perez MAD, Farhadfar N, Gadalla SM, Gale R, Ganguly S, Gergis U, Hanna R, Hematti P, Herzig R, Hildebrandt GC, Lad DP, Lee C, Lehmann L, Lekakis L, Kamble RT, Kharfan-Dabaja MA, Khandelwal P, Martino R, Murthy HS, Nishihori T, O'Brien TA, Olsson RF, Patel SS, Perales MA, Prestidge T, Qayed M, Romee R, Schoemans H, Seo S, Sharma A, Solh M, Strair R, Teshima T, Urbano-Ispizua A, Van der Poel M, Vij R, Wagner JL, William B, Wirk B, Yared JA, Spellman SR, Arora M, Hamilton BK. Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. Biol Blood Marrow Tr. 2020 Aug.26(8):1459-1468. Pubmedid: [32434056](https://www.ncbi.nlm.nih.gov/pubmed/32434056). Pmcid: PMC7391266. 
    * Atallah E, Logan B, Chen M, Cutler C, Deeg J, Jacoby M, Champlin R, Nishihori T, Confer D, Gajewski J, Farnia S, Greenberg P, Warlick E, Weisdorf D, Saber W, Horowitz MM, Rizzo JD. Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome: The Medicare Coverage With Evidence Development Study. JAMA Oncol. 2020 Apr.6(4):486-493. Pubmedid: [31830234](https://www.ncbi.nlm.nih.gov/pubmed/31830234). Pmcid: PMC6990739. 
    * Saad A, Lamb L, Wang T, Hemmer MT, Spellman S, Couriel D, Alousi A, Pidala J, Abdel-Azim H, Agrawal V, Aljurf M, Beitinjaneh AM, Bhatt VR, Buchbinder D, Byrne M, Cahn JY, Cairo M, Castillo P, Chhabra S, Diaz MA, Farhan S, Floisand Y, Frangoul HA, Gadalla SM, Gajewski J, Gale RP, Gandhi M, Gergis U, Hamilton BK, Hematti P, Hildebrandt GC, Kamble RT, Kanate AS, Khandelwal P, Lazaryn A, MacMillan M, Marks DI, Martino R, Mehta PA, Nishihori T, Olsson RF, Patel SS, Qayed M, Rangarajan HG, Reshef R, Ringden O, Savani BN, Schouten HC, Schultz KR, Seo S, Shaffer BC, Solh M, Teshima T, Urbano-Ispizua A, Verdonck LF, Vij R, Waller EK, William B, Wirk B, Yared JA, Yu LC, Arora M, Hashmi S. Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation. Biol Blood Marrow Tr. 2019 Sep.25(9):1875-1883. Pubmedid: [31085303](https://www.ncbi.nlm.nih.gov/pubmed/31085303). Pmcid: PMC7071947. 
    * Ustun C, Kim S, Chen M, Beitinjaneh AM, Brown VI, Dahi PB, Daly A, Diaz MA, Freytes CO, Ganguly S, Hashmi S, Hildebrandt GC, Lazarus HM, Nishihori T, Olsson RF, Page KM, Papanicolaou G, Saad A, Seo S, William BM, Wingard JR, Wirk B, Yared JA, Perales MA, Auletta JJ, Komanduri KV, Lindemans CA, Riches ML. Increased overall and bacterial infections following myeloablative allogeneic HCT for patients with AML in CR1. Blood Adv. 2019 Sep.3(17):2525-2536. Pubmedid: [31471322](https://www.ncbi.nlm.nih.gov/pubmed/31471322). Pmcid: PMC6737406. 
    * Hamilton BK, Liu Y, Hemmer MT, Majhail N, Ringden O, Kim D, Costa L, Stuart R, Alousi A, Pidala JA, Couriel DR, Aljurf M, Antin JH, Bredeson C, Cahn JY, Cairo M, Choi SW, Dandoy C, Gale RP, Gergis U, Hematti P, Inamoto Y, Kamble RT, MacMillan M, Marks DI, Nemecek E, Nishihori T, Saad A, Savani BN, Schriber J, Seo S, Socié G, Teshima T, Verdonck LF, Waller EK, Wirk M, Spellman SR, Arora M, Chhabra S. Inferior Outcomes with Cyclosporine and Mycophenolate Mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Tr. 2019 Sep.25(9):1744-1755. Pubmedid: [31158502](https://www.ncbi.nlm.nih.gov/pubmed/31158502). Pmcid: PMC7039394. 
    * Hashmi H, Bachmeier C, Chavez JC, Song J, Hussaini M, Krivenko G, Nishihori T, Kotani H, Davila ML, Locke FL, Jain MD. Haemophagocytic lymphohistiocytosis has variable time to onset following CD19 chimeric antigen receptor T cell therapy. Brit J Haematol. 2019 Oct.187(2):e35-e38. Pubmedid: [31410842](https://www.ncbi.nlm.nih.gov/pubmed/31410842). 
    * Mehta RS, Holtan SG, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel DR, Alousi AM, Pidala J, Abdel-Azim H, Ahmed I, Aljurf M, Askar M, Auletta JJ, Bhatt V, Bredeson C, Chhabra S, Gadalla S, Gajewski J, Gale RP, Gergis U, Hematti P, Hildebrandt GC, Inamoto Y, Kitko C, Khandelwal P, MacMillan ML, Majhail N, Marks DI, Mehta P, Nishihori T, Olsson RF, Pawarode A, Diaz MA, Prestidge T, Qayed M, Rangarajan H, Ringden O, Saad A, Savani BN, Seo S, Shah A, Shah N, Schultz KR, Solh M, Spitzer T, Szer J, Teshima T, Verdonck LF, Williams KM, Wirk B, Wagner J, Yared JA, Weisdorf DJ. GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia. Blood Adv. 2019 May.3(9):1441-1449. Pubmedid: [31053571](https://www.ncbi.nlm.nih.gov/pubmed/31053571). Pmcid: PMC6517657. 
    * Brunstein CG, Pasquini MC, Kim S, Fei M, Adekola K, Ahmed I, Aljurf M, Agrawal V, Auletta JJ, Battiwalla M, Bejanyan N, Bubalo J, Cerny J, Chee L, Ciurea SO, Freytes C, Gadalla SM, Gale RP, Ganguly S, Hashmi SK, Hematti P, Hildebrandt G, Holmberg LA, Lahoud OB, Landau H, Lazarus HM, de Lima M, Mathews V, Maziarz R, Nishihori T, Norkin M, Olsson R, Reshef R, Rotz S, Savani B, Schouten HC, Seo S, Wirk BM, Yared J, Mineishi S, Rogosheske J, Perales MA. Effect of Conditioning Regimen Dose Reduction in Obese Patients Undergoing Autologous Hematopoietic Cell Transplantation. Biol Blood Marrow Tr. 2019 Mar.25(3):480-487. Pubmedid: [30423481](https://www.ncbi.nlm.nih.gov/pubmed/30423481). Pmcid: PMC6445718. 
    * Kilari D, D'Souza A, Fraser R, Qayed M, Davila O, Agrawal V, Diaz MA, Chhabra S, Cerny J, Copelan E, Farhadfar N, Freytes CO, Gale RP, Ganguly S, Hildebrandt GC, Holmberg L, Kamble RT, Kapoor P, Lazarus H, Lee C, Murthy HS, Naik S, Nishihori T, Saad A, Savani BN, Seo S, Warwick A, Wirk B, Yared JA, Nieto Y, Hari P. Autologous Hematopoietic Stem Cell Transplantation for Male Germ Cell Tumors: Improved Outcomes Over 3 Decades. Biol Blood Marrow Tr. 2019 Jun.25(6):1099-1106. Pubmedid: [30794931](https://www.ncbi.nlm.nih.gov/pubmed/30794931). Pmcid: PMC6559839. 
    * Dholaria BR, Kumar A, Azzuqua AG, Nishihori T, Kharfan-Dabaja MA, Tun HW, Ayala E. Autologous Stem Cell Transplantation in Central Nervous System Lymphoma: A Multicenter Retrospective Series and a Review of the Literature. Clin Lymphoma Myeloma Leuk. 2019 Jun.19(6):e273-e280. Pubmedid: [30914301](https://www.ncbi.nlm.nih.gov/pubmed/30914301). 
    * Rashidi A, Hamadani M, Zhang MJ, Wang HL, Abdel-Azim H, Aljurf M, Assal A, Bajel A, Bashey A, Battiwalla M, Beitinjaneh AM, Bejanyan N, Bhatt VR, Bolaños-Meade J, Byrne M, Cahn JY, Cairo M, Ciurea S, Copelan E, Cutler C, Daly A, Diaz MA, Farhadfar N, Gale RP, Ganguly S, Grunwald MR, Hahn T, Hashmi S, Hildebrandt GC, Holland HK, Hossain N, Kanakry CG, Kharfan-Dabaja MA, Khera N, Koc Y, Lazarus HM, Lee JW, Maertens J, Martino R, McGuirk J, Munker R, Murthy HS, Nakamura R, Nathan S, Nishihori T, Palmisiano N, Patel S, Pidala J, Olin R, Olsson RF, Oran B, Ringden O, Rizzieri D, Rowe J, Savoie ML, Schultz KR, Seo S, Shaffer BC, Singh A, Solh M, Stockerl-Goldstein K, Verdonck LF, Wagner J, Waller EK, De Lima M, Sandmaier BM, Litzow M, Weisdorf D, Romee R, Saber W. Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. Blood Adv. 2019 Jun.3(12):1826-1836. Pubmedid: [31201170](https://www.ncbi.nlm.nih.gov/pubmed/31201170). Pmcid: PMC6595262. 
    * Epperla N, Ahn KW, Litovich C, Ahmed S, Battiwalla M, Cohen JB, Dahi P, Farhadfar N, Farooq U, Freytes CO, Ghosh N, Haverkos B, Herrera A, Hertzberg M, Hildebrandt G, Inwards D, Kharfan-Dabaja MA, Khimani F, Lazarus H, Lazaryan A, Lekakis L, Murthy H, Nathan S, Nishihori T, Pawarode A, Prestidge T, Ramakrishnan P, Rezvani AR, Romee R, Shah NN, Sureda A, Fenske TS, Hamadani M. Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis. J Hematol Oncol. 2019 Jan.12(1):6. Pubmedid: [30630534](https://www.ncbi.nlm.nih.gov/pubmed/30630534). Pmcid: PMC6329157. 
    * Chhabra S, Liu Y, Hemmer MT, Costa L, Pidala JA, Couriel DR, Alousi AM, Majhail NS, Stuart RK, Kim D, Ringden O, Urbano-Ispizua A, Saad A, Savani BN, Cooper B, Marks DI, Socie G, Schouten HC, Schoemans H, Abdel-Azim H, Yared J, Cahn JY, Wagner J, Antin JH, Verdonck LF, Lehmann L, Aljurf MD, MacMillan ML, Litzow MR, Solh MM, Qayed M, Hematti P, Kamble RT, Vij R, Hayashi RJ, Gale RP, Martino R, Seo S, Hashmi SK, Nishihori T, Teshima T, Gergis U, Inamoto Y, Spellman SR, Arora M, Hamilton BK. Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation. Biol Blood Marrow Tr. 2019 Jan.25(1):73-85. Pubmedid: [30153491](https://www.ncbi.nlm.nih.gov/pubmed/30153491). Pmcid: PMC6355336. 
    * Yeshurun M, Weisdorf D, Rowe JM, Tallman MS, Zhang MJ, Wang HL, Saber W, de Lima M, Sandmaier BM, Uy G, Kamble RT, Cairo MS, Cooper BW, Cahn JY, Ganguly S, Camitta B, Verdonck LF, Dandoy C, Diaz MA, Savani BN, George B, Liesveld J, McGuirk J, Byrne M, Grunwald MR, Drobyski WR, Pulsipher MA, Abdel-Azim H, Prestidge T, Wieduwilt MJ, Martino R, Norkin M, Beitinjaneh A, Seo S, Nishihori T, Wirk B, Frangoul H, Bashey A, Mori S, Marks DI, Bachanova V. The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia. Blood Adv. 2019 Feb.3(4):670-680. Pubmedid: [30808685](https://www.ncbi.nlm.nih.gov/pubmed/30808685). Pmcid: PMC6391668. 
    * Sabloff M, Chhabra S, Wang T, Fretham C, Kekre N, Abraham A, Adekola K, Auletta JJ, Barker C, Beitinjaneh AM, Bredeson C, Cahn JY, Diaz MA, Freytes C, Gale RP, Ganguly S, Gergis U, Guinan E, Hamilton B, Hashmi S, Hematti P, Hildebrandt G, Holmberg L, Hong S, Lazarus HM, Martino R, Muffly L, Nishihori T, Perales MA, Yared J, Mineishi S, Stadtmauer EA, Pasquini MC, Loren AW. Comparison of High Doses of Total Body Irradiation in Myeloablative Conditioning before Hematopoietic Cell Transplantation. Biol Blood Marrow Tr. 2019 Dec.25(12):2398-2407. Pubmedid: [31473319](https://www.ncbi.nlm.nih.gov/pubmed/31473319). Pmcid: PMC7304318. 
    * Ustun C, Young JH, Papanicolaou GA, Kim S, Ahn KW, Chen M, Abdel-Azim H, Aljurf M, Beitinjaneh A, Brown V, Cerny J, Chhabra S, Kharfan-Dabaja MA, Dahi PB, Daly A, Dandoy CE, Dvorak CC, Freytes CO, Hashmi S, Lazarus H, Ljungman P, Nishihori T, Page K, Pingali SRK, Saad A, Savani BN, Weisdorf D, Williams K, Wirk B, Auletta JJ, Lindemans CA, Komanduri K, Riches M. Bacterial blood stream infections (BSIs), particularly post-engraftment BSIs, are associated with increased mortality after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2019 Aug.54(8):1254-1265. Pubmedid: [30546070](https://www.ncbi.nlm.nih.gov/pubmed/30546070). Pmcid: PMC6565512. 
    * Kim HT, Ahn KW, Hu ZH, Davids MS, Volpe VO, Antin JH, Sorror ML, Shadman M, Press O, Pidala J, Hogan W, Negrin R, Devine S, Uberti J, Agura E, Nash R, Mehta J, McGuirk J, Forman S, Langston A, Giralt SA, Perales MA, Battiwalla M, Hale GA, Gale RP, Marks DI, Hamadani M, Ganguly S, Bacher U, Lazarus H, Reshef R, Hildebrandt GC, Inamoto Y, Cahn JY, Solh M, Kharfan-Dabaja MA, Ghosh N, Saad A, Aljurf M, Schouten HC, Hill BT, Pawarode A, Kindwall-Keller T, Saba N, Copelan EA, Nathan S, Beitinjaneh A, Savani BN, Cerny J, Grunwald MR, Yared J, Wirk BM, Nishihori T, Chhabra S, Olsson RF, Bashey A, Gergis U, Popat U, Sobecks R, Alyea E, Saber W, Brown JR. Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. Clin Cancer Res. 2019 Aug.25(16):5143-5155. Pubmedid: [31253630](https://www.ncbi.nlm.nih.gov/pubmed/31253630). Pmcid: PMC6697588. 
    * Abidi MZ, Hari P, Chen M, Kim S, Battiwala M, Dahi PB, Diaz MA, Gale RP, Ganguly S, Gergis U, Green J, Hildebrandt G, Hill JA, Komanduri K, Lazarus H, Marks D, Nishihori T, Olsson R, Seo S, Ustun C, Yared J, Yin D, Wingard J, Wirk BM, Auletta J, Lindemans C, Riches M. Virus detection in the cerebrospinal fluid of hematopoietic stem cell transplant recipients is associated with poor patient outcomes: a CIBMTR contemporary longitudinal study. Bone Marrow Transplant. 2019 Aug.54(8):1354-1360. Pubmedid: [30696997](https://www.ncbi.nlm.nih.gov/pubmed/30696997). Pmcid: PMC7001099. 
    * Gopalakrishnan S, D'Souza A, Scott E, Fraser R, Davila O, Shah N, Gale RP, Kamble R, Diaz MA, Lazarus HM, Savani BN, Hildebrandt GC, Solh M, Freytes CO, Lee C, Kyle RA, Usmani SZ, Ganguly S, Assal A, Berdeja J, Kanate AS, Dhakal B, Meehan K, Kindwall-Keller T, Saad A, Locke F, Seo S, Nishihori T, Gergis U, Gasparetto C, Mark T, Nieto Y, Kumar S, Hari P. Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months after autologous transplantation for newly diagnosed multiple myeloma. biol blood marrow tr. 2019 apr.254:683-688. pubmedid:>[30579965](https://www.ncbi.nlm.nih.gov/pubmed/30579965). Pmcid: PMC6453717. 
    * Kharfan-Dabaja MA, Labopin M, Polge E, Nishihori T, Bazarbachi A, Finke J, Stadler M, Ehninger G, Lioure B, Schaap N, Afanasyev B, Yeshurun M, Isaksson C, Maertens J, Chalandon Y, Schmid C, Nagler A, Mohty M. Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse. JAMA Oncol. 2018 Sep.4(9):1245-1253. Pubmedid: [30003233](https://www.ncbi.nlm.nih.gov/pubmed/30003233). Pmcid: PMC6143013. 
    * Nikiforow S, Wang T, Hemmer M, Spellman S, Akpek G, Antin JH, Choi SW, Inamoto Y, Khoury HJ, MacMillan M, Marks DI, Meehan K, Nakasone H, Nishihori T, Olsson R, Paczesny S, Przepiorka D, Reddy V, Reshef R, Schoemans H, Waller N, Weisdorf D, Wirk B, Horowitz M, Alousi A, Couriel D, Pidala J, Arora M, Cutler C. Upper gastrointestinal acute graft-versus-host disease adds minimal prognostic value in isolation or with other graft-versus-host disease symptoms as currently diagnosed and treated. Haematologica. 2018 Oct.103(10):1708-1719. Pubmedid: [30076185](https://www.ncbi.nlm.nih.gov/pubmed/30076185). Pmcid: PMC6165812. 
    * Buchbinder D, Kelly DL, Duarte RF, Auletta JJ, Bhatt N, Byrne M, DeFilipp Z, Gabriel M, Mahindra A, Norkin M, Schoemans H, Shah AJ, Ahmed I, Atsuta Y, Basak GW, Beattie S, Bhella S, Bredeson C, Bunin N, Dalal J, Daly A, Gajewski J, Gale RP, Galvin J, Hamadani M, Hayashi RJ, Adekola K, Law J, Lee CJ, Liesveld J, Malone AK, Nagler A, Naik S, Nishihori T, Parsons SK, Scherwath A, Schofield HL, Soiffer R, Szer J, Twist I, Warwick AB, Wirk BM, Yi J, Battiwalla M, Flowers MDE, Savani B, Shaw BE. Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT. Bone Marrow Transplant. 2018 May.53(5):535-555. Pubmedid: [29343837](https://www.ncbi.nlm.nih.gov/pubmed/29343837). Pmcid: PMC5985976. 
    * Kharfan-Dabaja MA, Sheets K, Kumar A, Murthy HS, Nishihori T, Tsalatsanis A, Mina A, Mathews J, Ayala E, Chavez J, Perez LE, Betts BC, Anasetti C, Pidala J. Hypoalbuminaemia segregates different prognostic subgroups within the refined standard risk acute graft-versus-host disease score. Brit J Haematol. 2018 Mar.180(6):854-862. Pubmedid: [29345306](https://www.ncbi.nlm.nih.gov/pubmed/29345306). 
    * Pidala J, Beato F, Kim J, Betts B, Jim H, Sagatys E, Levine JE, Ferrara JL, Ozbek U, Ayala E, Davila M, Fernandez HF, Field T, Kharfan-Dabaja MA, Khaira D, Khimani F, Locke FL, Mishra A, Nieder M, Nishihori T, Perez L, Riches M, Anasetti C. IL-12/IL-23p40 neutralization blocks Th1/Th17 response after allogeneic hematopoietic cell transplantation. Haematologica. 2018 Mar.103(3):531-539. Pubmedid: [29242294](https://www.ncbi.nlm.nih.gov/pubmed/29242294). Pmcid: PMC5830373. 
    * Htut M, D'Souza A, Krishnan A, Bruno B, Zhang MJ, Fei M, Diaz MA, Copelan E, Ganguly S, Hamadani M, Kharfan-Dabaja M, Lazarus H, Lee C, Meehan K, Nishihori T, Saad A, Seo S, Ramanathan M, Usmani SZ, Gasparetto C, Mark TM, Nieto Y, Hari P. Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival. Biol Blood Marrow Tr. 2018 Mar.24(3):478-485. Pubmedid: [29079457](https://www.ncbi.nlm.nih.gov/pubmed/29079457). Pmcid: PMC5826888. 
    * Qayed M, Wang T, Hemmer MT, Spellman S, Arora M, Couriel D, Alousi A, Pidala J, Abdel-Azim H, Aljuf M, Ayas M, Bitan M, Cairo M, Choi SW, Dandoy C, Delgado D, Gale RP, Hale G, Frangoul H, Kamble RT, Kharfan-Dabaja M, Lehman L, Levine J, MacMillan M, Marks DI, Nishihori T, Olsson RF, Hematti P, Ringden O, Saad A, Satwani P, Savani BN, Schultz KR, Seo S, Shenoy S, Waller EK, Yu L, Horowitz MM, Horan J. Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis. Biol Blood Marrow Tr. 2018 Mar.24(3):521-528. Pubmedid: [29155316](https://www.ncbi.nlm.nih.gov/pubmed/29155316). Pmcid: PMC5826854. 
    * Nelson AM, Jim HSL, Small BJ, Nishihori T, Gonzalez BD, Cessna JM, Hyland KA, Rumble ME, Jacobsen PB. Sleep disruption among cancer patients following autologous hematopoietic cell transplantation. Bone Marrow Transplant. 2018 Mar.53(3):307-314. Pubmedid: [29269811](https://www.ncbi.nlm.nih.gov/pubmed/29269811). Pmcid: PMC5851802. 
    * Hill BT, Ahn KW, Hu ZH, Aljurf M, Beitinjaneh A, Cahn JY, Cerny J, Kharfan-Dabaja MA, Ganguly S, Ghosh N, Grunwald MR, Inamoto Y, Kindwall-Keller T, Nishihori T, Olsson RF, Saad A, Seftel M, Seo S, Szer J, Tallman M, Ustun C, Wiernik PH, Maziarz RT, Kalaycio M, Alyea E, Popat U, Sobecks R, Saber W. Assessment of Impact of HLA Type on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia. Biol Blood Marrow Tr. 2018 Mar.24(3):581-586. Pubmedid: [29032274](https://www.ncbi.nlm.nih.gov/pubmed/29032274). Pmcid: PMC5944847. 
    * Harris AC, Boelens JJ, Ahn KW, Fei M, Abraham A, Artz A, Dvorak C, Frangoul H, Freytes C, Gale RP, Hong S, Lazarus HM, Loren A, Mineishi S, Nishihori T, O'Brien T, Williams K, Pasquini MC, Levine JE. Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabine. Blood Adv. 2018 Jun.2(11):1198-1206. Pubmedid: [29844205](https://www.ncbi.nlm.nih.gov/pubmed/29844205). Pmcid: PMC5998928. 
    * Ayala E, LaFave D, Nishihori T, Kharfan-Dabaja MA. Haploidentical transplantation as a promising therapy for relapsed hemophagocytic lymphohistiocytosis in an older adult patient. Hematol Oncol Stem Cell Ther. 2018 Jun.11(2):96-98. Pubmedid: [27352259](https://www.ncbi.nlm.nih.gov/pubmed/27352259). 
    * Smith SM, Godfrey J, Ahn KW, DiGilio A, Ahmed S, Agrawal V, Bachanova V, Bacher U, Bashey A, Bolaños-Meade J, Cairo M, Chen A, Chhabra S, Copelan E, Dahi PB, Aljurf M, Farooq U, Ganguly S, Hertzberg M, Holmberg L, Inwards D, Kanate AS, Karmali R, Kenkre VP, Kharfan-Dabaja MA, Klein A, Lazarus HM, Mei M, Mussetti A, Nishihori T, Ramakrishnan Geethakumari P, Saad A, Savani BN, Schouten HC, Shah N, Urbano-Ispizua A, Vij R, Vose J, Sureda A, Hamadani M. Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure. Cancer. 2018 Jun.124(12):2541-2551. Pubmedid: [29645093](https://www.ncbi.nlm.nih.gov/pubmed/29645093). Pmcid: PMC5990449. 
    * Turcotte LM, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel D, Alousi A, Pidala J, Abdel-Azim H, Ahmed I, Beitinjaneh A, Buchbinder D, Byrne M, Callander N, Chao N, Choi SW, DeFilipp Z, Gadalla SM, Gale RP, Gergis U, Hashmi S, Hematti P, Holmberg L, Inamoto Y, Kamble RT, Lehmann L, MacMillan MA, McIver Z, Nishihori T, Norkin M, O'Brien T, Olsson RF, Reshef R, Saad A, Savani BN, Schouten HC, Seo S, Solh M, Verdonck L, Vij R, Wirk B, Yared J, Horowitz MM, Knight JM, Verneris MR. Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantation. Bone Marrow Transplant. 2018 Jul.53(7):932-937. Pubmedid: [29382954](https://www.ncbi.nlm.nih.gov/pubmed/29382954). Pmcid: PMC6041147. 
    * Kharfan-Dabaja MA, Kumar A, Stingo FE, Khimani F, Hussaini M, Ayala E, Nishihori T, Shah B, Locke FL, Pinilla-Ibarz J, Chavez JC. Allogeneic Hematopoietic Cell Transplantation for Richter Syndrome: A Single-Center Experience. Clin Lymphoma Myeloma Leuk. 2018 Jan.18(1):e35-e39. Pubmedid: [29126867](https://www.ncbi.nlm.nih.gov/pubmed/29126867). Pmcid: PMC6716154. 
    * Murthy HS, Sheets K, Kumar A, Nishihori T, Mina A, Chavez JC, Ayala E, Field T, Mathews J, Locke F, Perez L, Betts BC, Khimani F, Miladinovic B, Tsalatsanis A, Ochoa-Bayona JL, Alsina M, Fernandez H, Pidala J, Anasetti C, Kharfan-Dabaja MA. Hypoalbuminemia at Day +90 Is Associated with Inferior Nonrelapse Mortality and Overall Survival in Allogeneic Hematopoietic Cell Transplantation Recipients: A Confirmatory Study. Biol Blood Marrow Tr. 2018 Feb.24(2):400-405. Pubmedid: [29032266](https://www.ncbi.nlm.nih.gov/pubmed/29032266). 
    * Kelly DL, Buchbinder D, Duarte RF, Auletta JJ, Bhatt N, Byrne M, Gabriel M, Mahindra A, Norkin M, Schoemans H, Shah AJ, Ahmed I, Atsuta Y, Basak GW, Beattie S, Bhella S, Bredeson C, Bunin N, Dalal J, Daly A, Gajewski J, Gale RP, Galvin J, Hamadani M, Hayashi RJ, Adekola K, Law J, Lee CJ, Liesveld J, Malone AK, Nagler A, Naik S, Nishihori T, Parsons SK, Scherwath A, Schofield HL, Soiffer R, Szer J, Twist I, Warwick A, Wirk BM, Yi J, Battiwalla M, Flowers ME, Savani B, Shaw BE. Neurocognitive Dysfunction in Hematopoietic Cell Transplant Recipients: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Complications and Quality of Life Wo. Biol Blood Marrow Tr. 2018 Feb.24(2):228-241. Pubmedid: [28939455](https://www.ncbi.nlm.nih.gov/pubmed/28939455). Pmcid: PMC5768142. 
    * Scott EC, Hari P, Kumar S, Fraser R, Davila O, Shah N, Gale RP, Diaz MA, Agrawal V, Cornell RF, Ganguly S, Akpek G, Freytes C, Hashmi S, Malek E, Kamble RT, Lazarus H, Solh M, Usmani SZ, Kanate AS, Saad A, Chhabra S, Gergis U, Cerny J, Kyle RA, Lee C, Kindwall-Keller T, Assal A, Hildebrandt GC, Holmberg L, Maziarz RT, Nishihori T, Seo S, Kumar S, Mark T, D'Souza A. Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups. Biol Blood Marrow Tr. 2018 Dec.24(12):2443-2449. Pubmedid: [30142419](https://www.ncbi.nlm.nih.gov/pubmed/30142419). Pmcid: PMC6293469. 
    * Dholaria BR, Ayala E, Sokol L, Nishihori T, Chavez JC, Hussaini M, Kumar A, Kharfan-Dabaja MA. Allogeneic hematopoietic cell transplantation in T-cell prolymphocytic leukemia: A single-center experience. Leuk Res. 2018 Apr.67:1-5. Pubmedid: [29407180](https://www.ncbi.nlm.nih.gov/pubmed/29407180). 
    * Kumar SK, Dispenzieri A, Fraser R, Mingwei F, Akpek G, Cornell R, Kharfan-Dabaja M, Freytes C, Hashmi S, Hildebrandt G, Holmberg L, Kyle R, Lazarus H, Lee C, Mikhael J, Nishihori T, Tay J, Usmani S, Vesole D, Vij R, Wirk B, Krishnan A, Gasparetto C, Mark T, Nieto Y, Hari P, D'Souza A. Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time. Leukemia. 2018 Apr.32(4):986-995. Pubmedid: [29263438](https://www.ncbi.nlm.nih.gov/pubmed/29263438). Pmcid: PMC5871538. 
    * Shah NN, Ahn KW, Litovich C, Fenske TS, Ahmed S, Battiwalla M, Bejanyan N, Dahi PB, Bolaños-Meade J, Chen AI, Ciurea SO, Bachanova V, DeFilipp Z, Epperla N, Farhadfar N, Herrera AF, Haverkos BM, Holmberg L, Hossain NM, Kharfan-Dabaja MA, Kenkre VP, Lazarus HM, Murthy HS, Nishihori T, Rezvani AR, D'Souza A, Savani BN, Ulrickson ML, Waller EK, Sureda A, Smith SM, Hamadani M. Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis. Blood Adv. 2018 Apr.2(8):933-940. Pubmedid: [29685953](https://www.ncbi.nlm.nih.gov/pubmed/29685953). Pmcid: PMC5916010. 
    * Rafei H, Kharfan-Dabaja MA, Nishihori T. A Critical Appraisal of Extracorporeal Photopheresis as a Treatment Modality for Acute and Chronic Graft-Versus-Host Disease. Biomedicines. 2017 Oct.5(4). Pubmedid: [29019937](https://www.ncbi.nlm.nih.gov/pubmed/29019937). Pmcid: PMC5744084. 
    * Kharfan-Dabaja MA, Komrokji RS, Zhang Q, Kumar A, Tsalatsanis A, Perkins J, Nishihori T, Field T, Al Ali N, Mishra A, Sallman D, Salem KZ, Zhang L, Moscinski L, Fernandez HF, Lancet J, List A, Anasetti C, Padron E. TP53 and IDH2 Somatic Mutations Are Associated With Inferior Overall Survival After Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk. 2017 Nov.17(11):753-758. Pubmedid: [28687222](https://www.ncbi.nlm.nih.gov/pubmed/28687222). Pmcid: PMC5675815. 
    * Betts BC, Pidala J, Kim J, Mishra A, Nishihori T, Perez L, Ochoa-Bayona JL, Khimani F, Walton K, Bookout R, Nieder M, Khaira DK, Davila M, Alsina M, Field T, Ayala E, Locke FL, Riches M, Kharfan-Dabaja M, Fernandez H, Anasetti C. IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation. Haematologica. 2017 May.102(5):948-957. Pubmedid: [28104702](https://www.ncbi.nlm.nih.gov/pubmed/28104702). Pmcid: PMC5477614. 
    * Liu HD, Ahn KW, Hu ZH, Hamadani M, Nishihori T, Wirk B, Beitinjaneh A, Rizzieri D, Grunwald MR, Sabloff M, Olsson RF, Bajel A, Bredeson C, Daly A, Inamoto Y, Majhail N, Saad A, Gupta V, Gerds A, Malone A, Tallman M, Reshef R, Marks DI, Copelan E, Gergis U, Savoie ML, Ustun C, Litzow MR, Cahn JY, Kindwall-Keller T, Akpek G, Savani BN, Aljurf M, Rowe JM, Wiernik PH, Hsu JW, Cortes J, Kalaycio M, Maziarz R, Sobecks R, Popat U, Alyea E, Saber W. Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia. Biol Blood Marrow Tr. 2017 May.23(5):767-775. Pubmedid: [28115276](https://www.ncbi.nlm.nih.gov/pubmed/28115276). Pmcid: PMC5590102. 
    * Khoury HJ, Wang T, Hemmer MT, Couriel D, Alousi A, Cutler C, Aljurf M, Antin JH, Ayas M, Battiwalla M, Cahn JY, Cairo M, Chen YB, Gale RP, Hashmi S, Hayashi RJ, Jagasia M, Juckett M, Kamble RT, Kharfan-Dabaja M, Litzow M, Majhail N, Miller A, Nishihori T, Qayed M, Schoemans H, Schouten HC, Socié G, Storek J, Verdonck L, Vij R, Wood WA, Yu L, Martino R, Carabasi M, Dandoy C, Gergis U, Hematti P, Solh M, Jamani K, Lehmann L, Savani B, Schultz KR, Wirk BM, Spellman S, Arora M, Pidala J. Improved survival after acute graft--host disease diagnosis in the modern era. Haematologica. 2017 May.102(5):958-966. Pubmedid: [28302712](https://www.ncbi.nlm.nih.gov/pubmed/28302712). Pmcid: PMC5477615. 
    * Chen YB, Wang T, Hemmer MT, Brady C, Couriel DR, Alousi A, Pidala J, Urbano-Ispizua A, Choi SW, Nishihori T, Teshima T, Inamoto Y, Wirk B, Marks DI, Abdel-Azim H, Lehmann L, Yu L, Bitan M, Cairo MS, Qayed M, Salit R, Gale RP, Martino R, Jaglowski S, Bajel A, Savani B, Frangoul H, Lewis ID, Storek J, Askar M, Kharfan-Dabaja MA, Aljurf M, Ringden O, Reshef R, Olsson RF, Hashmi S, Seo S, Spitzer TR, MacMillan ML, Lazaryan A, Spellman SR, Arora M, Cutler CS. GvHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes. Bone Marrow Transplant. 2017 Mar.52(3):400-408. Pubmedid: [27941764](https://www.ncbi.nlm.nih.gov/pubmed/27941764). Pmcid: PMC5332289. 
    * Rollison DE, Komrokji R, Lee JH, Hampras S, Fulp W, Fisher K, Baz R, Nishihori T, Xu Q, Olesnyckyj M, Kenvin L, Knight R, Sullivan D, Alsina M, Dalton W, Shain KH. Subsequent primary malignancies among multiple myeloma patients treated with or without lenalidomide. Leuk Lymphoma. 2017 Mar.58(3):560-568. Pubmedid: [27424609](https://www.ncbi.nlm.nih.gov/pubmed/27424609). Pmcid: PMC7771364. 
    * Gerds AT, Woo Ahn K, Hu ZH, Abdel-Azim H, Akpek G, Aljurf M, Ballen KK, Beitinjaneh A, Bacher U, Cahn JY, Chhabra S, Cutler C, Daly A, DeFilipp Z, Gale RP, Gergis U, Grunwald MR, Hale GA, Hamilton BK, Jagasia M, Kamble RT, Kindwall-Keller T, Nishihori T, Olsson RF, Ramanathan M, Saad AA, Solh M, Ustun C, Valcárcel D, Warlick E, Wirk BM, Kalaycio M, Alyea E, Popat U, Sobecks R, Saber W. Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes. Biol Blood Marrow Tr. 2017 Jun.23(6):971-979. Pubmedid: [28288952](https://www.ncbi.nlm.nih.gov/pubmed/28288952). Pmcid: PMC5474679. 
    * Michelis FV, Gupta V, Zhang MJ, Wang HL, Aljurf M, Bacher U, Beitinjaneh A, Chen YB, DeFilipp Z, Gale RP, Kebriaei P, Kharfan-Dabaja M, Lazarus HM, Nishihori T, Olsson RF, Oran B, Rashidi A, Rizzieri DA, Tallman MS, de Lima M, Khoury HJ, Sandmaier BM, Weisdorf D, Saber W. Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis. Cancer. 2017 Jun.123(11):2035-2042. Pubmedid: [28117898](https://www.ncbi.nlm.nih.gov/pubmed/28117898). Pmcid: PMC5445018. 
    * Khimani F, Kim J, Chen L, Dean E, Rizk V, Betts B, Nishihori T, Locke F, Mishra A, Perez L, Ayala E, Kharfan-Dabaja M, Nieder M, Fernandez H, Anasetti C, Pidala J. Predictors of overall survival among patients treated with sirolimus/tacrolimus vs methotrexate/tacrolimus for GvHD prevention. Bone Marrow Transplant. 2017 Jul.52(7):1003-1009. Pubmedid: [28368376](https://www.ncbi.nlm.nih.gov/pubmed/28368376). Pmcid: PMC7771296. 
    * Nassereddine S, Nishihori T, Padron E, Mahfouz R, Bazarbachi A, Komrokji RS, Kharfan-Dabaja MA. Integrating Genomics in Myelodysplastic Syndrome to Predict Outcomes After Allogeneic Hematopoietic Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2017 Jan.17(1):7-13. Pubmedid: [27771290](https://www.ncbi.nlm.nih.gov/pubmed/27771290). 
    * Rosko A, Wang HL, de Lima M, Sandmaier B, Khoury HJ, Artz A, Brammer J, Bredeson C, Farag S, Kharfan-Dabaja M, Lazarus HM, Marks DI, Martino Bufarull R, McGuirk J, Mohty M, Nishihori T, Nivison-Smith I, Rashidi A, Ringden O, Seftel M, Weisdorf D, Bachanova V, Saber W. Reduced intensity conditioned allograft yields favorable survival for older adults with B-cell acute lymphoblastic leukemia. Am J Hematol. 2017 Jan.92(1):42-49. Pubmedid: [27712033](https://www.ncbi.nlm.nih.gov/pubmed/27712033). Pmcid: PMC5167625. 
    * Cornell RF, Bachanova V, D'Souza A, Woo-Ahn K, Martens M, Huang J, Al-Homsi AS, Chhabra S, Copelan E, Diaz MA, Freytes CO, Gale RP, Ganguly S, Hamadani M, Hildebrandt G, Kamble RT, Kharfan-Dabaja M, Kindwall-Keller T, Lazarus HM, Marks DI, Nishihori T, Olsson RF, Saad A, Usmani S, Vesole DH, Yared J, Mark T, Nieto Y, Hari P. Allogeneic Transplantation for Relapsed Waldenström Macroglobulinemia and Lymphoplasmacytic Lymphoma. Biol Blood Marrow Tr. 2017 Jan.23(1):60-66. Pubmedid: [27789362](https://www.ncbi.nlm.nih.gov/pubmed/27789362). Pmcid: PMC5182098. 
    * Cornell RF, D'Souza A, Kassim AA, Costa LJ, Innis-Shelton RD, Zhang MJ, Huang J, Abidi M, Aiello J, Akpek G, Bashey A, Bashir Q, Cerny J, Comenzo R, Diaz MA, Freytes C, Gale RP, Ganguly S, Hamadani M, Hashmi S, Holmberg L, Hossain N, Kamble RT, Kharfan-Dabaja M, Kindwall-Keller T, Kyle R, Kumar S, Lazarus H, Lee C, Maiolino A, Marks DI, Meehan K, Mikhael J, Nath R, Nishihori T, Olsson RF, Ramanathan M, Saad A, Seo S, Usmani S, Vesole D, Vij R, Vogl D, Wirk BM, Yared J, Krishnan A, Mark T, Nieto Y, Hari P. Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma. Biol Blood Marrow Tr. 2017 Feb.23(2):269-277. Pubmedid: [27864161](https://www.ncbi.nlm.nih.gov/pubmed/27864161). Pmcid: PMC5346183. 
    * Nishihori T, Shain K. Insights on Genomic and Molecular Alterations in Multiple Myeloma and Their Incorporation towards Risk-Adapted Treatment Strategy: Concise Clinical Review. Int J Genomics. 2017 Dec.2017:6934183. Pubmedid: [29250532](https://www.ncbi.nlm.nih.gov/pubmed/29250532). Pmcid: PMC5698810. 
    * Kharfan-Dabaja MA, Al Malki MM, Deotare U, Raj RV, El-Jurdi N, Majhail N, Cherry MA, Bashir Q, Darrah J, Nishihori T, Sibai H, Hamadani M, de Lima M, Gerds AT, Selby G, Qazilbash MH, Forman SJ, Ayala E, Lipton JH, Hari PN, Muzzafar T, Zhang L, Olteanu H, Perkins J, Sokol L, Kumar A, Ahmed S. Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study. Brit J Haematol. 2017 Dec.179(5):781-789. Pubmedid: [28980314](https://www.ncbi.nlm.nih.gov/pubmed/28980314). 
    * Mahindra A, Hari P, Fraser R, Fei M, Huang J, Berdeja J, Callander N, Costa L, Diaz MA, Freytes C, Gale RP, Girnius S, Holmberg L, Kharfan-Dabaja M, Kumar S, Kyle R, Lazarus H, Lee C, Maiolino A, Moreb J, Nishihori T, Pawarode A, Saad A, Savani BN, Schriber J, William B, Wirk BM, Krishnan A, Nieto Y, D'Souza A. Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis. Bone Marrow Transplant. 2017 Dec.52(12):1616-1622. Pubmedid: [28920949](https://www.ncbi.nlm.nih.gov/pubmed/28920949). Pmcid: PMC5859934. 
    * Muffly L, Pasquini MC, Martens M, Brazauskas R, Zhu X, Adekola K, Aljurf M, Ballen KK, Bajel A, Baron F, Battiwalla M, Beitinjaneh A, Cahn JY, Carabasi M, Chen YB, Chhabra S, Ciurea S, Copelan E, D'Souza A, Edwards J, Foran J, Freytes CO, Fung HC, Gale RP, Giralt S, Hashmi SK, Hildebrandt GC, Ho V, Jakubowski A, Lazarus H, Luskin MR, Martino R, Maziarz R, McCarthy P, Nishihori T, Olin R, Olsson RF, Pawarode A, Peres E, Rezvani AR, Rizzieri D, Savani BN, Schouten HC, Sabloff M, Seftel M, Seo S, Sorror ML, Szer J, Wirk BM, Wood WA, Artz A. Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. Blood. 2017 Aug.130(9):1156-1164. Pubmedid: [28674027](https://www.ncbi.nlm.nih.gov/pubmed/28674027). Pmcid: PMC5580273. 
    * Schriber JR, Hari PN, Ahn KW, Fei M, Costa LJ, Kharfan-Dabaja MA, Angel-Diaz M, Gale RP, Ganguly S, Girnius SK, Hashmi S, Pawarode A, Vesole DH, Wiernik PH, Wirk BM, Marks DI, Nishihori T, Olsson RF, Usmani SZ, Mark TM, Nieto YL, D'Souza A. Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report. Cancer. 2017 Aug.123(16):3141-3149. Pubmedid: [28472539](https://www.ncbi.nlm.nih.gov/pubmed/28472539). Pmcid: PMC5544566. 
    * Deol A, Sengsayadeth S, Ahn KW, Wang HL, Aljurf M, Antin JH, Battiwalla M, Bornhauser M, Cahn JY, Camitta B, Chen YB, Cutler CS, Gale RP, Ganguly S, Hamadani M, Inamoto Y, Jagasia M, Kamble R, Koreth J, Lazarus HM, Liesveld J, Litzow MR, Marks DI, Nishihori T, Olsson RF, Reshef R, Rowe JM, Saad AA, Sabloff M, Schouten HC, Shea TC, Soiffer RJ, Uy GL, Waller EK, Wiernik PH, Wirk B, Woolfrey AE, Bunjes D, Devine S, de Lima M, Sandmaier BM, Weisdorf D, Khoury HJ, Saber W. Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. Cancer. 2016 Oct.122(19):3005-3014. Pubmedid: [27315441](https://www.ncbi.nlm.nih.gov/pubmed/27315441). Pmcid: PMC5030151. 
    * Lazaryan A, Wang T, Spellman SR, Wang HL, Pidala J, Nishihori T, Askar M, Olsson R, Oudshoorn M, Abdel-Azim H, Yong A, Gandhi M, Dandoy C, Savani B, Hale G, Page K, Bitan M, Reshef R, Drobyski W, Marsh SG, Schultz K, Müller CR, Fernandez-Viña MA, Verneris MR, Horowitz MM, Arora M, Weisdorf DJ, Lee SJ. Human leukocyte antigen supertype matching after myeloablative hematopoietic cell transplantation with 7/8 matched unrelated donor allografts: a report from the Center for International Blood and Marrow Transplant Research. Haematologica. 2016 Oct.101(10):1267-1274. Pubmedid: [27247320](https://www.ncbi.nlm.nih.gov/pubmed/27247320). Pmcid: PMC5046657. 
    * Scott EC, Hari P, Sharma M, Le-Rademacher J, Huang J, Vogl D, Abidi M, Beitinjaneh A, Fung H, Ganguly S, Hildebrandt G, Holmberg L, Kalaycio M, Kumar S, Kyle R, Lazarus H, Lee C, Maziarz RT, Meehan K, Mikhael J, Nishihori T, Ramanathan M, Usmani S, Tay J, Vesole D, Wirk B, Yared J, Savani BN, Gasparetto C, Krishnan A, Mark T, Nieto Y, D'Souza A. Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis. Biol Blood Marrow Tr. 2016 Oct.22(10):1893-1899. Pubmedid: [27496215](https://www.ncbi.nlm.nih.gov/pubmed/27496215). Pmcid: PMC5090978. 
    * Kharfan-Dabaja MA, Reljic T, El-Asmar J, Nishihori T, Ayala E, Hamadani M, Kumar A. Reduced-intensity or myeloablative allogeneic hematopoietic cell transplantation for mantle cell lymphoma: a systematic review. Future Oncol. 2016 Nov.12(22):2631-2642. Pubmedid: [27381652](https://www.ncbi.nlm.nih.gov/pubmed/27381652). 
    * El-Asmar J, Reljic T, Ayala E, Hamadani M, Nishihori T, Kumar A, Kharfan-Dabaja MA. Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Peripheral T Cell Lymphomas as Front-Line Consolidation or in the Relapsed/Refractory Setting: A Systematic Review/Meta-Analysis. Biol Blood Marrow Tr. 2016 May.22(5):802-814. Pubmedid: [26713431](https://www.ncbi.nlm.nih.gov/pubmed/26713431). 
    * Salem KZ, Nishihori T, Kharfan-Dabaja MA, Horna P, Alsina M. Primary plasmacytoma involving mediastinal lymph nodes: A diagnostic mimicry of primary mediastinal lymphoma. Hematol Oncol Stem Cell Ther. 2016 Mar.9(1):26-29. Pubmedid: [26169239](https://www.ncbi.nlm.nih.gov/pubmed/26169239). 
    * Seftel MD, Neuberg D, Zhang MJ, Wang HL, Ballen KK, Bergeron J, Couban S, Freytes CO, Hamadani M, Kharfan-Dabaja MA, Lazarus HM, Nishihori T, Paulson K, Saber W, Sallan SE, Soiffer R, Tallman MS, Woolfrey AE, DeAngelo DJ, Weisdorf DJ. Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remission. Am J Hematol. 2016 Mar.91(3):322-329. Pubmedid: [26701142](https://www.ncbi.nlm.nih.gov/pubmed/26701142). Pmcid: PMC4764423. 
    * Shaffer BC, Ahn KW, Hu ZH, Nishihori T, Malone AK, Valcárcel D, Grunwald MR, Bacher U, Hamilton B, Kharfan-Dabaja MA, Saad A, Cutler C, Warlick E, Reshef R, Wirk BM, Sabloff M, Fasan O, Gerds A, Marks D, Olsson R, Wood WA, Costa LJ, Miller AM, Cortes J, Daly A, Kindwall-Keller TL, Kamble R, Rizzieri DA, Cahn JY, Gale RP, William B, Litzow M, Wiernik PH, Liesveld J, Savani BN, Vij R, Ustun C, Copelan E, Popat U, Kalaycio M, Maziarz R, Alyea E, Sobecks R, Pavletic S, Tallman M, Saber W. Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. J Clin Oncol. 2016 Jun.34(16):1864-1871. Pubmedid: [27044940](https://www.ncbi.nlm.nih.gov/pubmed/27044940). Pmcid: PMC4966345. 
    * Nishihori T, Shaheen M, El-Asmar J, Aljurf M, Kharfan-Dabaja MA. Therapeutic strategies for cytomegalovirus in allogeneic hematopoietic cell transplantation. Immunotherapy. 2016 Jun.7(10):1059-1071. Pubmedid: [26507225](https://www.ncbi.nlm.nih.gov/pubmed/26507225). 
    * Chaudhury S, Sparapani R, Hu ZH, Nishihori T, Abdel-Azim H, Malone A, Olsson R, Hamadani M, Daly A, Bacher U, Wirk BM, Kamble RT, Gale RP, Wood WA, Hale G, Wiernik PH, Hashmi SK, Mark D, Ustun C, Munker R, Savani BN, Alyea E, Popat U, Sobecks R, Kalaycio M, Maziarz R, Hijiya N, Saber W. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis. Biol Blood Marrow Tr. 2016 Jun.22(6):1056-1064. Pubmedid: [26964698](https://www.ncbi.nlm.nih.gov/pubmed/26964698). Pmcid: PMC4877686. 
    * Kharfan-Dabaja MA, Nishihori T, Bazarbachi A. Allo-HCT regimens with low toxicity needed in older patients with acute myeloid leukaemia. Lancet Oncol. 2016 Jan.17(1):e1. Pubmedid: [26758754](https://www.ncbi.nlm.nih.gov/pubmed/26758754). 
    * Locke FL, Menges M, Nishihori T, Nwoga C, Alsina M, Anasetti C. Boosting humoral and cellular immunity to pneumococcus by vaccination before and just after autologous transplant for myeloma. Bone Marrow Transplant. 2016 Feb.51(2):291-294. Pubmedid: [26457911](https://www.ncbi.nlm.nih.gov/pubmed/26457911). Pmcid: PMC5726387. 
    * Pasquini MC, Zhang MJ, Medeiros BC, Armand P, Hu ZH, Nishihori T, Aljurf MD, Akpek G, Cahn JY, Cairo MS, Cerny J, Copelan EA, Deol A, Freytes CO, Gale RP, Ganguly S, George B, Gupta V, Hale GA, Kamble RT, Klumpp TR, Lazarus HM, Luger SM, Liesveld JL, Litzow MR, Marks DI, Martino R, Norkin M, Olsson RF, Oran B, Pawarode A, Pulsipher MA, Ramanathan M, Reshef R, Saad AA, Saber W, Savani BN, Schouten HC, Ringdén O, Tallman MS, Uy GL, Wood WA, Wirk B, Pérez WS, Batiwalla M, Weisdorf DJ. Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. Biol Blood Marrow Tr. 2016 Feb.22(2):248-257. Pubmedid: [26327629](https://www.ncbi.nlm.nih.gov/pubmed/26327629). Pmcid: PMC4716890. 
    * Khimani F, Jeong DK, Miladinovic B, Nishihori T, Ayala E, Locke F, Mishra A, Chavez J, Shah B, Gage K, Kharfan-Dabaja MA. Nonfluorodeoxyglucose-Avid Persistent Splenomegaly at Time of Transplantation Delays Neutrophil and Platelets Engraftment without Affecting Survival in Patients with Lymphomas Undergoing Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Tr. 2016 Dec.22(12):2201-2207. Pubmedid: [27660169](https://www.ncbi.nlm.nih.gov/pubmed/27660169). 
    * Nishihori T, Al-Kadhimi Z, Hamadani M, Kharfan-Dabaja MA. Antithymocyte globulin in allogeneic hematopoietic cell transplantation: benefits and limitations. Immunotherapy. 2016 Dec.8(4):435-447. Pubmedid: [26973125](https://www.ncbi.nlm.nih.gov/pubmed/26973125). 
    * Nishihori T, Song J, Shain KH. Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment. Curr Hematol Malig Rep. 2016 Apr.11(2):118-126. Pubmedid: [26898557](https://www.ncbi.nlm.nih.gov/pubmed/26898557). Pmcid: PMC4819726. 
    * Tees MT, Betts B, Hillgruber R, Ayala E, Field T, Kharfan-Dabaja MA, Locke F, Mishra A, Nishihori T, Ochoa-Bayona JL, Perez L, Pidala J, Anasetti C, Fernandez H, Riches ML. New sources for argument: do HLA-C and HLA disparity in adult double umbilical cord blood transplants predict outcomes?. Bone Marrow Transplant. 2016 09.51(9):1256-1258. Pubmedid: [27088383](https://www.ncbi.nlm.nih.gov/pubmed/27088383). 
    * Nishihori T, El-Asmar J, Shah B, Hussaini M, Komrokji R, List A, Anasetti C, Kharfan-Dabaja MA. Donor-derived constitutional chromosomal abnormalities after allogeneic hematopoietic cell transplantation: a single-center experience and a review of the literature. Bone Marrow Transplant. 2015 Oct.50(10):1388-1392. Pubmedid: [26191951](https://www.ncbi.nlm.nih.gov/pubmed/26191951). 
    * Griffin PT, Ho VQ, Fulp W, Nishihori T, Shain KH, Alsina M, Baz RC. A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma. Cancer. 2015 Oct.121(20):3622-3630. Pubmedid: [26149422](https://www.ncbi.nlm.nih.gov/pubmed/26149422). 
    * Inamoto Y, Flowers ME, Wang T, Urbano-Ispizua A, Hemmer MT, Cutler CS, Couriel DR, Alousi AM, Antin JH, Gale RP, Gupta V, Hamilton BK, Kharfan-Dabaja MA, Marks DI, Ringdén OT, Socié G, Solh MM, Akpek G, Cairo MS, Chao NJ, Hayashi RJ, Nishihori T, Reshef R, Saad A, Shah A, Teshima T, Tallman MS, Wirk B, Spellman SR, Arora M, Martin PJ. Tacrolimus versus Cyclosporine after Hematopoietic Cell Transplantation for Acquired Aplastic Anemia. Biol Blood Marrow Tr. 2015 Oct.21(10):1776-1782. Pubmedid: [26033280](https://www.ncbi.nlm.nih.gov/pubmed/26033280). Pmcid: PMC4568149. 
    * Urbano-Ispizua A, Pavletic SZ, Flowers ME, Klein JP, Zhang MJ, Carreras J, Montoto S, Perales MA, Aljurf MD, Akpek G, Bredeson CN, Costa LJ, Dandoy C, Freytes CO, Fung HC, Gale RP, Gibson J, Hamadani M, Hayashi RJ, Inamoto Y, Inwards DJ, Lazarus HM, Maloney DG, Martino R, Munker R, Nishihori T, Olsson RF, Rizzieri DA, Reshef R, Saad A, Savani BN, Schouten HC, Smith SM, Socié G, Wirk B, Yu LC, Saber W. The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen. Biol Blood Marrow Tr. 2015 Oct.21(10):1746-1753. Pubmedid: [25981509](https://www.ncbi.nlm.nih.gov/pubmed/25981509). Pmcid: PMC4568162. 
    * Nishihori T, Baz R, Shain K, Kim J, Ochoa-Bayona JL, Yue B, Sullivan D, Dalton W, Alsina M. An open-label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed myeloma. Eur J Haematol. 2015 Nov.95(5):426-435. Pubmedid: [25600676](https://www.ncbi.nlm.nih.gov/pubmed/25600676). Pmcid: PMC4508238. 
    * Nelson R, Shapiro JF, Perkins JB, Kim J, Nishihori T, Pidala J, Ayala E, Locke FL, Field T, Mishra A, Riches M, Betts B, Perez L, Yue B, Ochoa-Bayona JL, Alsina M, Fernandez H, Anasetti C, Kharfan-Dabaja MA. Sirolimus, tacrolimus and antithymocyte globulin as GVHD prophylaxis in HLA-mismatched unrelated donor hematopoietic cell transplantation: a single institution experience. Bone Marrow Transplant. 2015 Nov.50(11):1487-1489. Pubmedid: [26301969](https://www.ncbi.nlm.nih.gov/pubmed/26301969). Pmcid: PMC4863975. 
    * D'Souza A, Dispenzieri A, Wirk B, Zhang MJ, Huang J, Gertz MA, Kyle RA, Kumar S, Comenzo RL, Peter Gale R, Lazarus HM, Savani BN, Cornell RF, Weiss BM, Vogl DT, Freytes CO, Scott EC, Landau HJ, Moreb JS, Costa LJ, Ramanathan M, Callander NS, Kamble RT, Olsson RF, Ganguly S, Nishihori T, Kindwall-Keller TL, Wood WA, Mark TM, Hari P. Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study. J Clin Oncol. 2015 Nov.33(32):3741-3749. Pubmedid: [26371138](https://www.ncbi.nlm.nih.gov/pubmed/26371138). Pmcid: PMC4737858. 
    * Satwani P, Ahn KW, Carreras J, Abdel-Azim H, Cairo MS, Cashen A, Chen AI, Cohen JB, Costa LJ, Dandoy C, Fenske TS, Freytes CO, Ganguly S, Gale RP, Ghosh N, Hertzberg MS, Hayashi RJ, Kamble RT, Kanate AS, Keating A, Kharfan-Dabaja MA, Lazarus HM, Marks DI, Nishihori T, Olsson RF, Prestidge TD, Rolon JM, Savani BN, Vose JM, Wood WA, Inwards DJ, Bachanova V, Smith SM, Maloney DG, Sureda A, Hamadani M. A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma. Bone Marrow Transplant. 2015 Nov.50(11):1416-1423. Pubmedid: [26237164](https://www.ncbi.nlm.nih.gov/pubmed/26237164). Pmcid: PMC4633349. 
    * Kharfan-Dabaja MA, Nishihori T. Vaccine therapy for cytomegalovirus in the setting of allogeneic hematopoietic cell transplantation. Expert Rev Vaccines. 2015 Mar.14(3):341-350. Pubmedid: [25468066](https://www.ncbi.nlm.nih.gov/pubmed/25468066). 
    * Ayala E, Figueroa J, Perkins J, Kim J, Yue B, Riches M, Nishihori T, Locke F, Anasetti C, Kharfan-Dabaja MA. Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2015 Jun.15(6):335-340. Pubmedid: [25659459](https://www.ncbi.nlm.nih.gov/pubmed/25659459). 
    * Pidala J, Kim J, Betts BC, Alsina M, Ayala E, Fernandez HF, Field T, Kharfan-Dabaja MA, Locke FL, Mishra A, Nishihori T, Ochoa-Bayona L, Perez L, Riches M, Anasetti C. Ofatumumab in combination with glucocorticoids for primary therapy of chronic graft-versus-host disease: phase I trial results. Biol Blood Marrow Tr. 2015 Jun.21(6):1074-1082. Pubmedid: [25805300](https://www.ncbi.nlm.nih.gov/pubmed/25805300). Pmcid: PMC5757506. 
    * Pidala J, Kim J, Alsina M, Ayala E, Betts BC, Fernandez HF, Field T, Jim H, Kharfan-Dabaja MA, Locke FL, Mishra A, Nishihori T, Ochoa-Bayona L, Perez L, Riches M, Anasetti C. Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease. Haematologica. 2015 Jul.100(7):970-977. Pubmedid: [25840599](https://www.ncbi.nlm.nih.gov/pubmed/25840599). Pmcid: PMC4486232. 
    * Nishihori T, Komrokji R, Shain K, Anasetti C. Allogeneic hematopoietic cell transplantation for concurrent multiple myeloma and myelodysplastic syndrome. Bone Marrow Transplant. 2015 Feb.50(2):296-297. Pubmedid: [25330222](https://www.ncbi.nlm.nih.gov/pubmed/25330222). 
    * Uy GL, Costa LJ, Hari PN, Zhang MJ, Huang JX, Anderson KC, Bredeson CN, Callander NS, Cornell RF, Perez MA, Dispenzieri A, Freytes CO, Gale RP, Garfall A, Gertz MA, Gibson J, Hamadani M, Lazarus HM, Kalaycio ME, Kamble RT, Kharfan-Dabaja MA, Krishnan AY, Kumar SK, Kyle RA, Landau HJ, Lee CH, Maiolino A, Marks DI, Mark TM, Munker R, Nishihori T, Olsson RF, Ramanathan M, Rodriguez TE, Saad AA, Savani BN, Schiller GJ, Schouten HC, Schriber JR, Scott E, Seo S, Sharma M, Ganguly S, Stadtmauer EA, Tay J, To LB, Vesole DH, Vogl DT, Wagner JL, Wirk B, Wood WA, D'Souza A. Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation. Bone Marrow Transplant. 2015 Dec.50(12):1513-1518. Pubmedid: [26301967](https://www.ncbi.nlm.nih.gov/pubmed/26301967). Pmcid: PMC4548821. 
    * Goyal SD, Zhang MJ, Wang HL, Akpek G, Copelan EA, Freytes C, Gale RP, Hamadani M, Inamoto Y, Kamble RT, Lazarus HM, Marks DI, Nishihori T, Olsson RF, Reshef R, Ritchie DS, Saber W, Savani BN, Seber A, Shea TC, Tallman MS, Wirk B, Bunjes DW, Devine SM, de Lima M, Weisdorf DJ, Uy GL. Allogeneic hematopoietic cell transplant for AML: no impact of pre-transplant extramedullary disease on outcome. Bone Marrow Transplant. 2015 Aug.50(8):1057-1062. Pubmedid: [25915806](https://www.ncbi.nlm.nih.gov/pubmed/25915806). Pmcid: PMC4527880. 
    * Pidala J, Lee SJ, Ahn KW, Spellman S, Wang HL, Aljurf M, Askar M, Dehn J, Fernandez Viña M, Gratwohl A, Gupta V, Hanna R, Horowitz MM, Hurley CK, Inamoto Y, Kassim AA, Nishihori T, Mueller C, Oudshoorn M, Petersdorf EW, Prasad V, Robinson J, Saber W, Schultz KR, Shaw B, Storek J, Wood WA, Woolfrey AE, Anasetti C. Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation. Blood. 2014 Oct.124(16):2596-2606. Pubmedid: [25161269](https://www.ncbi.nlm.nih.gov/pubmed/25161269). Pmcid: PMC4199961. 
    * Abu-Dalle I, Reljic T, Nishihori T, Antar A, Bazarbachi A, Djulbegovic B, Kumar A, Kharfan-Dabaja MA. Extracorporeal photopheresis in steroid-refractory acute or chronic graft-versus-host disease: results of a systematic review of prospective studies. Biol Blood Marrow Tr. 2014 Nov.20(11):1677-1686. Pubmedid: [24867779](https://www.ncbi.nlm.nih.gov/pubmed/24867779). 
    * Sharma M, Zhang MJ, Zhong X, Abidi MH, Akpek G, Bacher U, Callander NS, Dispenzieri A, Freytes CO, Fung HC, Gale RP, Gasparetto C, Gibson J, Holmberg LA, Kindwall-Keller TL, Klumpp TR, Krishnan AY, Landau HJ, Lazarus HM, Lonial S, Maiolino A, Marks DI, Mehta P, Mikhael JR, Nishihori T, Olsson R, Ramanathan M, Roy V, Savani BN, Schouten HC, Scott E, Tay J, To LB, Vesole DH, Vogl DT, Hari P. Older patients with myeloma derive similar benefit from autologous transplantation. Biol Blood Marrow Tr. 2014 Nov.20(11):1796-1803. Pubmedid: [25046833](https://www.ncbi.nlm.nih.gov/pubmed/25046833). Pmcid: PMC4194262. 
    * Hamadani M, Hari PN, Zhang Y, Carreras J, Akpek G, Aljurf MD, Ayala E, Bachanova V, Chen AI, Chen YB, Costa LJ, Fenske TS, Freytes CO, Ganguly S, Hertzberg MS, Holmberg LA, Inwards DJ, Kamble RT, Kanfer EJ, Lazarus HM, Marks DI, Nishihori T, Olsson R, Reddy NM, Rizzieri DA, Savani BN, Solh M, Vose JM, Wirk B, Maloney DG, Smith SM, Montoto S, Saber W. Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation. Biol Blood Marrow Tr. 2014 Nov.20(11):1729-1736. Pubmedid: [25008330](https://www.ncbi.nlm.nih.gov/pubmed/25008330). Pmcid: PMC4194275. 
    * Saad A, Mahindra A, Zhang MJ, Zhong X, Costa LJ, Dispenzieri A, Drobyski WR, Freytes CO, Gale RP, Gasparetto CJ, Holmberg LA, Kamble RT, Krishnan AY, Kyle RA, Marks D, Nishihori T, Pasquini MC, Ramanathan M, Lonial S, Savani BN, Saber W, Sharma M, Sorror ML, Wirk BM, Hari PN. Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma. Biol Blood Marrow Tr. 2014 Mar.20(3):402-408.e1. Pubmedid: [24342394](https://www.ncbi.nlm.nih.gov/pubmed/24342394). Pmcid: PMC3961011. 
    * Nishihori T, Perkins J, Mishra A, Komrokji R, Kim J, Kharfan-Dabaja MA, Perez L, Lancet J, Fernandez H, List A, Anasetti C, Field T. Pretransplantation 5-azacitidine in high-risk myelodysplastic syndrome. Biol Blood Marrow Tr. 2014 Jun.20(6):776-780. Pubmedid: [24534108](https://www.ncbi.nlm.nih.gov/pubmed/24534108). 
    * Parmar SR, Bookout R, Shapiro JF, Tombleson R, Perkins J, Kim J, Yue B, Tomblyn M, Alsina M, Nishihori T. Comparison of 1-day vs 2-day dosing of high-dose melphalan followed by autologous hematopoietic cell transplantation in patients with multiple myeloma. Bone Marrow Transplant. 2014 Jun.49(6):761-766. Pubmedid: [24662419](https://www.ncbi.nlm.nih.gov/pubmed/24662419). 
    * Baz RC, Shain KH, Hussein MA, Lee JH, Sullivan DM, Finleyoliver E, Nardelli LA, Nodzon LA, Zhao X, Ochoa-Bayona JL, Nishihori T, Dalton WS, Alsina M. Phase II study of pegylated liposomal doxorubicin, low-dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myeloma. Am J Hematol. 2014 Jan.89(1):62-67. Pubmedid: [24030918](https://www.ncbi.nlm.nih.gov/pubmed/24030918). Pmcid: PMC4522918. 
    * Kunter G, Perkins JB, Pidala J, Nishihori T, Kharfan-Dabaja MA, Field T, Fernandez H, Perez L, Locke F, Ayala E, Tomblyn M, Ochoa-Bayona JL, Betts B, Nieder M, Anasetti C. Pharmacokinetically-targeted BU and fludarabine as conditioning before allogeneic hematopoietic cell transplantation for adults with ALL in first remission. Bone Marrow Transplant. 2014 Jan.49(1):11-16. Pubmedid: [23995098](https://www.ncbi.nlm.nih.gov/pubmed/23995098). 
    * Nishihori T, Hassoun Y, Zhang L, Shain K, Alsina M, Kharfan-Dabaja MA. High-dose melphalan produces favorable response in a patient with multiple myeloma and coexisting essential thrombocythemia with JAK2 mutation. Bone Marrow Transplant. 2014 Jan.49(1):148-149. Pubmedid: [23933759](https://www.ncbi.nlm.nih.gov/pubmed/23933759). 
    * Nishihori T, Ochoa-Bayona JL, Kim J, Pidala J, Shain K, Baz R, Sullivan D, Jim HS, Anasetti C, Alsina M. Allogeneic hematopoietic cell transplantation for consolidation of VGPR or CR for newly diagnosed multiple myeloma. Bone Marrow Transplant. 2013 Sep.48(9):1179-1184. Pubmedid: [23542223](https://www.ncbi.nlm.nih.gov/pubmed/23542223). Pmcid: PMC4500071. 
    * Baz R, Miladinovic B, Patel A, Ho VQ, Shain KH, Alsina M, Nishihori T, Ochoa-Bayona JL, Sullivan DM, Dalton WS, Djulbegovic B. Sequence of novel agents in multiple myeloma: an instrumental variable analysis. Leuk Res. 2013 Sep.37(9):1077-1082. Pubmedid: [23809054](https://www.ncbi.nlm.nih.gov/pubmed/23809054). 
    * Locke FL, Nishihori T, Alsina M, Kharfan-Dabaja MA. Immunotherapy strategies for multiple myeloma: the present and the future. Immunotherapy. 2013 Sep.5(9):1005-1020. Pubmedid: [23998734](https://www.ncbi.nlm.nih.gov/pubmed/23998734). Pmcid: PMC4905571. 
    * Kharfan-Dabaja MA, Nishihori T, Otrock ZK, Haidar N, Mohty M, Hamadani M. Monoclonal antibodies in conditioning regimens for hematopoietic cell transplantation. Biol Blood Marrow Tr. 2013 Sep.19(9):1288-1300. Pubmedid: [23618718](https://www.ncbi.nlm.nih.gov/pubmed/23618718). 
    * Costa LJ, Zhang MJ, Zhong X, Dispenzieri A, Lonial S, Krishnan A, Freytes C, Vesole D, Gale RP, Anderson K, Wirk B, Savani B, Waller EK, Schouten H, Lazarus H, Meehan K, Sharma M, Kamble R, Vij R, Kumar S, Nishihori T, Kindwall-Keller T, Saber W, Hari PN. Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma. Biol Blood Marrow Tr. 2013 Nov.19(11):1615-1624. Pubmedid: [23939198](https://www.ncbi.nlm.nih.gov/pubmed/23939198). Pmcid: PMC3952066. 
    * Michaelis LC, Saad A, Zhong X, Le-Rademacher J, Freytes CO, Marks DI, Lazarus HM, Bird JM, Holmberg L, Kamble RT, Kumar S, Lill M, Meehan KR, Saber W, Schriber J, Tay J, Vogl DT, Wirk B, Savani BN, Gale RP, Vesole DH, Schiller GJ, Abidi M, Anderson KC, Nishihori T, Kalaycio ME, Vose JM, Moreb JS, Drobyski W, Munker R, Roy V, Ghobadi A, Holland HK, Nath R, To LB, Maiolino A, Kassim AA, Giralt SA, Landau H, Schouten HC, Maziarz RT, Michael J, Kindwall-Keller T, Stiff PJ, Gibson J, Lonial S, Krishnan A, Dispenzieri A, Hari P. Salvage second hematopoietic cell transplantation in myeloma. Biol Blood Marrow Tr. 2013 May.19(5):760-766. Pubmedid: [23298856](https://www.ncbi.nlm.nih.gov/pubmed/23298856). Pmcid: PMC3816739. 
    * Pidala J, Kim J, Schell M, Lee SJ, Hillgruber R, Nye V, Ayala E, Alsina M, Betts B, Bookout R, Fernandez HF, Field T, Locke FL, Nishihori T, Ochoa JL, Perez L, Perkins J, Shapiro J, Tate C, Tomblyn M, Anasetti C. Race/ethnicity affects the probability of finding an HLA-A, -B, -C and -DRB1 allele-matched unrelated donor and likelihood of subsequent transplant utilization. Bone Marrow Transplant. 2013 Mar.48(3):346-350. Pubmedid: [22863723](https://www.ncbi.nlm.nih.gov/pubmed/22863723). Pmcid: PMC4500122. 
    * Kharfan-Dabaja MA, Anasetti C, Fernandez HF, Perkins J, Ochoa-Bayona JL, Pidala J, Perez LE, Ayala E, Field T, Alsina M, Nishihori T, Locke F, Pinilla-Ibarz J, Tomblyn M. Phase II study of CD4+-guided pentostatin lymphodepletion and pharmacokinetically targeted busulfan as conditioning for hematopoietic cell allografting. Biol Blood Marrow Tr. 2013 Jul.19(7):1087-1093. Pubmedid: [23632090](https://www.ncbi.nlm.nih.gov/pubmed/23632090). Pmcid: PMC4667782. 
    * Kharfan-Dabaja MA, Lazarus HM, Nishihori T, Mahfouz RA, Hamadani M. Diagnostic and therapeutic advances in blastic plasmacytoid dendritic cell neoplasm: a focus on hematopoietic cell transplantation. Biol Blood Marrow Tr. 2013 Jul.19(7):1006-1012. Pubmedid: [23396213](https://www.ncbi.nlm.nih.gov/pubmed/23396213). 
    * Kharfan-Dabaja MA, Hamadani M, Reljic T, Nishihori T, Bensinger W, Djulbegovic B, Kumar A. Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. J Hematol Oncol. 2013 Jan.6:2. Pubmedid: [23289975](https://www.ncbi.nlm.nih.gov/pubmed/23289975). Pmcid: PMC3548722. 
    * Nishihori T, Abu Kar SM, Baz R, Alsina M, Harousseau JL, Kharfan-Dabaja MA. Therapeutic advances in the treatment of primary plasma cell leukemia: a focus on hematopoietic cell transplantation. Biol Blood Marrow Tr. 2013 Aug.19(8):1144-1151. Pubmedid: [23416092](https://www.ncbi.nlm.nih.gov/pubmed/23416092). 
    * Nishihori T, Alekshun TJ, Shain K, Sullivan DM, Baz R, Perez L, Pidala J, Kharfan-Dabaja MA, Ochoa-Bayona JL, Fernandez HF, Yarde DN, Oliveira V, Fulp W, Han G, Kim J, Chen DT, Raychaudhuri J, Dalton W, Anasetti C, Alsina M. Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma. Brit J Haematol. 2012 Jun.157(5):553-563. Pubmedid: [22449149](https://www.ncbi.nlm.nih.gov/pubmed/22449149). Pmcid: PMC4030553. 
    * Pidala J, Kim J, Jim H, Kharfan-Dabaja MA, Nishihori T, Fernandez HF, Tomblyn M, Perez L, Perkins J, Xu M, Janssen WE, Veerapathran A, Betts BC, Locke FL, Ayala E, Field T, Ochoa L, Alsina M, Anasetti C. A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation. Haematologica. 2012 Dec.97(12):1882-1889. Pubmedid: [22689677](https://www.ncbi.nlm.nih.gov/pubmed/22689677). Pmcid: PMC3590095. 
    * Pidala J, Tomblyn M, Nishihori T, Field T, Ayala E, Perkins J, Fernandez H, Locke F, Perez L, Ochoa JL, Alsina M, Anasetti C. Sirolimus demonstrates activity in the primary therapy of acute graft-versus-host disease without systemic glucocorticoids. Haematologica. 2011 Sep.96(9):1351-1356. Pubmedid: [21565902](https://www.ncbi.nlm.nih.gov/pubmed/21565902). Pmcid: PMC3166106. 
    * Nishihori T, Alsina M. Advances in the autologous and allogeneic transplantation strategies for multiple myeloma. Cancer Control. 2011 Oct.18(4):258-267. Pubmedid: [21976244](https://www.ncbi.nlm.nih.gov/pubmed/21976244). 
    * Pidala J, Kim J, Anasetti C, Nishihori T, Betts B, Field T, Perkins J. The global severity of chronic graft-versus-host disease, determined by National Institutes of Health consensus criteria, is associated with overall survival and non-relapse mortality. Haematologica. 2011 Nov.96(11):1678-1684. Pubmedid: [21791465](https://www.ncbi.nlm.nih.gov/pubmed/21791465). Pmcid: PMC3208686. 
    * Nishihori T, Fernandez HF, Coppola D, Ochoa-Bayona JL, Lancet JE, Komrokji RS, Kharfan-Dabaja MA. Hepatobiliary manifestations of acute myeloid leukemia. Leuk Res. 2011 Jun.35(6):e81-e83. Pubmedid: [21232795](https://www.ncbi.nlm.nih.gov/pubmed/21232795). 
    * Pidala J, Roman-Diaz J, Kim J, Nishihori T, Perkins J, Tate C, Ochoa-Bayona JL, Field T, Fernandez HF, Tomblyn M, Ayala E, Anasetti C, Kharfan-Dabaja MA. Targeted IV busulfan and fludarabine followed by post-allogeneic hematopoietic cell transplantation rituximab demonstrate encouraging activity in CD20+ lymphoid malignancies without increased risk of infectious complications. Int J Hematol. 2011 Feb.93(2):206-212. Pubmedid: [21246311](https://www.ncbi.nlm.nih.gov/pubmed/21246311). Pmcid: PMC5718616. 
    * Pidala J, Kim J, Kharfan-Dabaja MA, Nishihori T, Field T, Perkins J, Perez L, Fernandez H, Anasetti C. Dysglycemia following glucocorticoid therapy for acute graft-versus-host disease adversely affects transplantation outcomes. Biol Blood Marrow Tr. 2011 Feb.17(2):239-248. Pubmedid: [20637884](https://www.ncbi.nlm.nih.gov/pubmed/20637884). Pmcid: PMC5726258. 
    * Lebovic D, Zhang L, Alsina M, Nishihori T, Shain KH, Sullivan D, Ochoa-Bayona JL, Kharfan-Dabaja MA, Baz R. Clinical outcomes of patients with plasma cell leukemia in the era of novel therapies and hematopoietic stem cell transplantation strategies: a single-institution experience. Clin Lymphoma Myeloma Leuk. 2011 Dec.11(6):507-511. Pubmedid: [21813352](https://www.ncbi.nlm.nih.gov/pubmed/21813352). 
    * Pidala J, Tomblyn M, Nishihori T, Ayala E, Field T, Fernandez H, Perez L, Locke F, Alsina M, Ochoa JL, Perkins J, Tate C, Shapiro J, Conwell M, Bookout R, Anasetti C. ATG prevents severe acute graft-versus-host disease in mismatched unrelated donor hematopoietic cell transplantation. Biol Blood Marrow Tr. 2011 Aug.17(8):1237-1244. Pubmedid: [21215811](https://www.ncbi.nlm.nih.gov/pubmed/21215811). Pmcid: PMC5735843. 
    * Nishihori T, Kharfan-Dabaja MA, Ochoa-Bayona JL, Bazarbachi A, Pasquini M, Alsina M. Role of reduced intensity conditioning in allogeneic hematopoietic cell transplantation for patients with multiple myeloma. Hematol Oncol Stem Cell Ther. 2011.4(1):1-9. Pubmedid: [21460601](https://www.ncbi.nlm.nih.gov/pubmed/21460601). 
    * Pidala J, Kim J, Anasetti C, Kharfan-Dabaja MA, Nishihori T, Field T, Perkins J, Perez L, Fernandez HF. Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia. J Hematol Oncol. 2010 Oct.3:36. Pubmedid: [20925957](https://www.ncbi.nlm.nih.gov/pubmed/20925957). Pmcid: PMC2958877. 
    * Pidala J, Kim J, Roman-Diaz J, Shapiro J, Nishihori T, Bookout R, Anasetti C, Kharfan-Dabaja MA. Pentostatin as rescue therapy for glucocorticoid-refractory acute and chronic graft-versus-host disease. Ann Transplant. 2010 Oct.15(4):21-29. Pubmedid: [21183872](https://www.ncbi.nlm.nih.gov/pubmed/21183872). 
    * Nishihori T, Perkins J, Kim J, Field T, Pidala J, Roman-Diaz J, Komrokji RS, Fernandez HF, Anasetti C, Kharfan-Dabaja MA. Allogeneic hematopoietic cell transplantation for myelofibrosis: a 10-year experience at single institution. Am J Hematol. 2010 Nov.85(11):904-907. Pubmedid: [20890908](https://www.ncbi.nlm.nih.gov/pubmed/20890908). 
    * Nishihori T, Strazzabosco M, Saif MW. Incidence and management of colorectal cancer in liver transplant recipients. Clin Colorectal Cancer. 2008 Jul.7(4):260-266. Pubmedid: [18650194](https://www.ncbi.nlm.nih.gov/pubmed/18650194). Pmcid: PMC3755274. 
    * Nishihori T, Choi J, DiGiovanna MP, Thomson JG, Kohler PC, McGurn J, Chung GG. Carpal tunnel syndrome associated with the use of aromatase inhibitors in breast cancer. Clin Breast Cancer. 2008 Aug.8(4):362-365. Pubmedid: [18757265](https://www.ncbi.nlm.nih.gov/pubmed/18757265). 
    * Nishihori T, Abdo-Matkiwsky M, Fleishman SB, Blum RH. Severe action tremor related to interferon-alpha 2b therapy for malignant melanoma. Am J Clin Oncol. 2005 Oct.28(5):526. Pubmedid: [16199995](https://www.ncbi.nlm.nih.gov/pubmed/16199995). 
    * Nishihori T, Shirato H, Aoyama H, Onimaru R, Komae T, Ishii N, Ikeda J, Miyasaka K, Sawamura Y, Iwasaki Y. Three-dimensional conformal radiotherapy for astrocytic tumors involving the eloquent area in children and young adults. J Neurooncol. 2002 Nov.60(2):177-183. Pubmedid: [12635666](https://www.ncbi.nlm.nih.gov/pubmed/12635666). 
  * ## Grants
    * Title: A Phase II Randomized Controlled Trial Comparing GVHD-Reduction Strategies for Allogeneic Peripheral Blood Transplantation (PBSCT) for Patients with Acute Leukemia  
Award Number: P015P01CA018029-47  
Sponsor: National Cancer Institute (NCI)  
Nishihori, T. (PD/PI)


## Find a Researcher Search
Program Select Cancer Biology and Evolution Program Cancer Epidemiology Program Molecular Medicine Program Health Outcomes & Behavior Program Immuno-Oncology Non-Programmatically Aligned
Department Select BioEngineering Biostatistics and Bioinformatics Cancer Epidemiology Metabolism and Physiology Drug Discovery Health Outcomes & Behavior Immunology Integrated Mathematical Oncology Machine Learning Molecular Oncology Tumor Microenvironment and Metastasis
Center of Excellence Select Center for Infection Research in Cancer DeBartolo Family Personalized Medicine Institute Evolutionary Therapy Lung Cancer Center of Excellence Melanoma Research Center of Excellence
Work Group Select Cancer Chemoprevention Research Interest Group Myeloma Systems Medicine Working Group Tobacco Research & Intervention Program
Keyword
Search
[ ![Moffitt Cancer Center](https://www.moffitt.org/globalassets/images/logos/moffitt-logo-full-white.svg) ](https://www.moffitt.org/ "Logo for Moffitt Cancer Center") [ ![](https://www.moffitt.org/globalassets/images/logos/moffitt-logo-mobile-white.svg) ](https://www.moffitt.org/ "Logo for Moffitt Cancer Center")
Our Mission
To contribute to the prevention and cure of cancer.
[Connect with a Cancer Expert](https://www.moffitt.org/eforms/patientregistrationform/)
[ ![Designated Comprehensive Cancer Center](https://www.moffitt.org/globalassets/images/logos/nci.png) ](https://www.moffitt.org/about-moffitt/nci-designation/?source=footer "Designated Comprehensive Cancer Center") [ ![Florida Health Cancer Center of Excellence](https://www.moffitt.org/globalassets/global-blocks/navigation/footer/moffitt-cancer-center-of-excellence-2.png) ](https://www.floridahealth.gov/provider-and-partner-resources/research/cancer-center-of-excellence-award.html "Florida Health Cancer Center of Excellence") [ ![Magnet Recognized](https://www.moffitt.org/globalassets/images/logos/magnet.png) ](https://www.moffitt.org/about-moffitt/medical/nursing/?source=footer "Magnet Recognized") [ ![National Comprehensive Cancer Network](https://www.moffitt.org/globalassets/global-blocks/navigation/footer/nccn.png) ](https://www.nccn.org/patients/ "National Comprehensive Cancer Network")
Careers
    * [Careers at Moffitt](https://www.moffitt.org/careers/)
    * [Search Jobs](https://moffitt-cancer-center-careers.hctsportals.com/)
    * [Training & Education](https://www.moffitt.org/education/)


Emerging Cancer Therapies
    * [CAR T Therapy](https://www.moffitt.org/treatments/immunotherapy/car-t-therapy/)
    * [Immunotherapy](https://www.moffitt.org/treatments/immunotherapy/)
    * [TIL Therapy](https://www.moffitt.org/treatments/immunotherapy/til-therapy/)


Cancers & Treatments
    * [Cancers We Treat](https://www.moffitt.org/cancers/)
    * [Clinical Trials](https://www.moffitt.org/clinical-trials-research/clinical-trials/)
    * [Diagnostic Services](https://www.moffitt.org/diagnostic-services/)
    * [Treatments We Offer](https://www.moffitt.org/treatments/)


Get Involved
    * [Donate](https://fundraise.moffitt.org/give/563959/#!/donation/checkout)
    * [Volunteer](https://www.moffitt.org/give/get-involved/volunteer-your-time/)
    * [Ways to Give](https://www.moffitt.org/give/ways-to-give/)


Cancer Screening
    * [Head and Neck Cancer Screening](https://www.moffitt.org/diagnostic-services/cancer-screenings/head-and-neck-cancer-screening/)
    * [Lung CT Screening](https://www.moffitt.org/cancers/lung-cancer/lung-cancer-screening-and-surveillance-program/)
    * [Mammogram](https://www.moffitt.org/cancers/breast-cancer/diagnosis/screening/mammogram/)
    * [Skin Cancer Mole Patrol](https://www.moffitt.org/diagnostic-services/cancer-screenings/mole-patrol/)


Patients & Family
    * [Appointments](https://www.moffitt.org/eforms/patientregistrationform/)
    * [Find a Doctor](https://www.moffitt.org/find-a-doctor/)
    * [Insurance & Financial Info](https://www.moffitt.org/patient-family/insurance-financial-information/)
    * [Moffitt Blog for Patients](https://www.moffitt.org/taking-care-of-your-health/)
    * [Patient & Family Resources](https://www.moffitt.org/patient-family/)


About Moffitt
    * [About](https://www.moffitt.org/about-moffitt/)
    * [Community Benefit](https://www.moffitt.org/publications/community-benefit/)
    * [Patient Outcomes](https://www.moffitt.org/about-moffitt/outcomes/)
    * [Research](https://www.moffitt.org/research-science/)


Industry Partnerships
    * [Available Emerging Technologies](https://www.moffitt.org/research-science/academic-and-industry-partnerships/office-of-innovation/available-technologies/)
    * [Business of Biotech](https://www.moffitt.org/research-science/academic-and-industry-partnerships/office-of-innovation/business-of-biotech/)
    * [Cell Therapy Facility](https://www.moffitt.org/research-science/academic-and-industry-partnerships/office-of-innovation/cell-therapy-gene-engineering/)
    * [Office of Innovation](https://www.moffitt.org/research-science/academic-and-industry-partnerships/office-of-innovation/)


Resources
    * [Calendar of Events](https://www.moffitt.org/calendar/)
    * [Endeavor](https://www.moffitt.org/endeavor/)
    * [Newsroom](https://www.moffitt.org/newsroom/)
    * [Partnerships](https://www.moffitt.org/about-moffitt/strategic-alliances-and-partnerships/)
    * [Publications](https://www.moffitt.org/publications/)


Call Today
[1-888-663-3488](tel:1-888-663-3488 "Call Today")
[ ](https://www.facebook.com/MoffittCancerCenter "Facebook") [ ](https://twitter.com/MoffittNews "Twitter") [ ](https://www.instagram.com/moffittcancercenter/ "Instagram") [ ](https://www.youtube.com/user/MoffittNews "YouTube")
[ Getting Here ](https://www.moffitt.org/locations-directions/) [ Patient Portal ](https://www.moffitt.org/patient-family/preparing-for-your-appointment/mymoffitt-patient-portal/) [ Refer a Patient ](https://www.moffitt.org/eforms/referapatient/) [ Provider Portal ](https://rpp.moffitt.org/) [ Staff Login ](https://hlmconnect.moffitt.org/dana-na/auth/url_default/welcome.cgi?source=footer&_ga=2.192849257.2128654650.1660063894-1522311918.1659049215)
  * [Privacy Policy](https://www.moffitt.org/legal-statements-and-policies/privacy-policy/)
  * [Terms & Conditions](https://www.moffitt.org/terms-conditions/ "Terms & Condition")
  * [Unsubscribe](https://www.moffitt.org/eforms/unsubscribe/ "Unsubscribe")
  * [State Nonprofit Disclosures](https://www.moffitt.org/globalassets/pdfs/footer/state-registration-for-web.pdf "State Nonprofit Disclosures")
  * [Donor Privacy](https://www.moffitt.org/give/donor-privacy/ "Donor Privacy")
  * [Notice of Privacy Practices](https://www.moffitt.org/legal-statements-and-policies/notice-of-privacy-practices/ "Notice of Privacy Practices")
  * [Visitor Policy](https://www.moffitt.org/globalassets/pdfs/patient--family/preparing-for-your-appointment/visitation-and-family-presence-policy.pdf "Visitor Policy")
  * [Moffitt Masking Policy](https://www.moffitt.org/globalassets/pdfs/footer/ic-085-moffitt-masking-policy.pdf)
  * [Price Transparency](https://eforms.moffitt.org/Moffittcancercenter_standardcharges/593238634_H.-Lee-Moffitt-Cancer-Center-and-Research-Institute-Hospital,-Inc._standardcharges.json)
  * [Sitemap](https://www.moffitt.org/sitemap.xml)


©Copyright 2025 Moffitt Cancer Center
Discover More
  * [Individualized Cancer Treatment in Florida](https://moffitt.org/patient-family/)
  * [Cancer Second Opinion Appointment in Florida](https://moffitt.org/diagnostic-services/second-opinion/)
  * [Cancer Healthcare Professionals in Florida](https://moffitt.org/for-healthcare-professionals/)


### Cambiar el idioma
Si no encuentra la información que busca o si desea programar una cita, llámenos gratis al [1-888-663-3488](tel:1-888-663-3488).
Gracias.
[Cancel | Cancelar](https://www.moffitt.org/research-science/researchers/taiga-nishihori) [OK](https://www.moffitt.org/research-science/researchers/taiga-nishihori)
[ ![Moffitt Cancer Center](https://www.moffitt.org/globalassets/images/logos/moffitt-logo-full-white.svg) ](https://www.moffitt.org/ "Moffitt Cancer Center")
Search
Menu
  * [Cancer Types & Treatments](https://www.moffitt.org/research-science/researchers/taiga-nishihori) [](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-3)
  * [Patients & Families](https://www.moffitt.org/research-science/researchers/taiga-nishihori) [](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-13)
  * [For Healthcare Professionals](https://www.moffitt.org/research-science/researchers/taiga-nishihori) [](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-31)
  * [Research](https://www.moffitt.org/research-science/researchers/taiga-nishihori) [](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-37)
  * [Training & Education](https://www.moffitt.org/research-science/researchers/taiga-nishihori) [](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-53)
  * [Give](https://www.moffitt.org/research-science/researchers/taiga-nishihori) [](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-63)


Schedule
[New Patients](https://www.moffitt.org/eforms/patientregistrationform/ "New Patients") [Referring Physicians](https://www.moffitt.org/eforms/referapatient/ "Referring Physicians")
[ Find a Doctor ](https://www.moffitt.org/find-a-doctor/ "Find a Doctor")
Patient Portal
[Log In](https://mymoffitt.iqhealth.com/ "Log In") [Enroll](https://mymoffitt.iqhealth.com/self-enroll/)
[ Careers ](https://www.moffitt.org/careers/ "Careers")
[ Locations ](https://www.moffitt.org/locations-directions/ "Locations")
[ 1-888-663-3488 ](tel:1-888-663-3488 "Call 1-888-663-3488")
English
[English](https://www.moffitt.org/research-science/researchers/taiga-nishihori/ "English") [Spanish](https://www.moffitt.org/es/research-science/researchers/taiga-nishihori/ "Spanish")
[ ](https://www.moffitt.org/research-science/researchers/?campaign=567103 "Donate")
[](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-1)[Cancer Types & Treatments](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-1)
  * [ Cancers ](https://www.moffitt.org/cancers/) [](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-5)
  * [ Treatments ](https://www.moffitt.org/treatments/) [](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-7)
  * [ Clinical Trials ](https://www.moffitt.org/clinical-trials-research/clinical-trials/) [](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-9)
  * [ Diagnostic Services ](https://www.moffitt.org/diagnostic-services/) [](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-11)


[](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-3)[Cancers](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-3)
  * [Acute Lymphocytic Leukemia (ALL)](https://www.moffitt.org/cancers/acute-lymphocytic-leukemia-all/ "Acute Lymphocytic Leukemia \(ALL\)")
  * [Acute Myeloid Leukemia (AML)](https://www.moffitt.org/cancers/acute-myelogenous-leukemia/ "Acute Myeloid Leukemia \(AML\)")
  * [Acute Promyelocytic Leukemia (APL)](https://www.moffitt.org/cancers/acute-promyelocytic-leukemia-apl/ "Acute Promyelocytic Leukemia \(APL\)")
  * [Adrenal Cancer](https://www.moffitt.org/cancers/adrenal-cancer/ "Adrenal Cancer")
  * [Anal Cancer](https://www.moffitt.org/cancers/anal-cancer/ "Anal Cancer")
  * [Appendiceal (Appendix) Cancer](https://www.moffitt.org/cancers/appendiceal-appendix-cancer/ "Appendiceal \(Appendix\) Cancer")
  * [Astrocytoma](https://www.moffitt.org/cancers/astrocytoma/ "Astrocytoma")
  * [Basal Cell Carcinoma](https://www.moffitt.org/cancers/basal-cell-carcinoma/ "Basal Cell Carcinoma")
  * [Bladder Cancer](https://www.moffitt.org/cancers/bladder-cancer/ "Bladder Cancer")
  * [Bone Metastasis](https://www.moffitt.org/cancers/bone-metastasis/ "Bone Metastasis")
  * [Brain Cancer](https://www.moffitt.org/cancers/brain-cancer/ "Brain Cancer")
  * [Brain Tumor](https://www.moffitt.org/cancers/brain-tumor/ "Brain Tumor")
  * [Brain Metastases](https://www.moffitt.org/cancers/brain-metastases/ "Brain Metastases")
  * [Breast Cancer](https://www.moffitt.org/cancers/breast-cancer/ "Breast Cancer")
  * [Cervical Cancer](https://www.moffitt.org/cancers/cervical-cancer/ "Cervical Cancer")
  * [Cholangiocarcinoma (Bile Duct Cancer)](https://www.moffitt.org/cancers/cholangiocarcinoma-bile-duct-cancer/ "Cholangiocarcinoma \(Bile Duct Cancer\)")
  * [Chronic Lymphocytic Leukemia (CLL)](https://www.moffitt.org/cancers/chronic-lymphocytic-leukemia/ "Chronic Lymphocytic Leukemia \(CLL\)")
  * [Colon Cancer](https://www.moffitt.org/cancers/colon-cancer/ "Colon Cancer")
  * [Colorectal Cancer](https://www.moffitt.org/cancers/colorectal-cancer/ "Colorectal Cancer")
  * [Chronic Myeloid Leukemia (CML)](https://www.moffitt.org/cancers/chronic-myelogenous-leukemia-cml/ "Chronic Myeloid Leukemia \(CML\)")
  * [Cutaneous Lymphoma (CTCL)](https://www.moffitt.org/cancers/cutaneous-t-cell-lymphoma/ "Cutaneous Lymphoma \(CTCL\)")
  * [Diffuse Large B-Cell Lymphoma](https://www.moffitt.org/cancers/diffuse-large-b-cell-lymphoma/ "Diffuse Large B-Cell Lymphoma")
  * [Ductal Carcinoma In Situ](https://www.moffitt.org/cancers/ductal-carcinoma-in-situ/ "Ductal Carcinoma In Situ")
  * [Endometrial (Uterine) Cancer](https://www.moffitt.org/cancers/endometrial-uterine-cancer/ "Endometrial \(Uterine\) Cancer")
  * [Esophageal Cancer](https://www.moffitt.org/cancers/esophageal-cancer/ "Esophageal Cancer")
  * [Follicular Lymphoma](https://www.moffitt.org/cancers/follicular-lymphoma/ "Follicular Lymphoma")
  * [Gallbladder Cancer](https://www.moffitt.org/cancers/gallbladder-cancer/ "Gallbladder Cancer")
  * [Gastrointestinal Carcinoid Tumor](https://www.moffitt.org/cancers/gastrointestinal-carcinoid-tumor/ "Gastrointestinal Carcinoid Tumor")
  * [GIST (Gastrointestinal Stromal Tumor)](https://www.moffitt.org/cancers/gist-gastrointestinal-stromal-tumor/ "GIST \(Gastrointestinal Stromal Tumor\)")
  * [Glioblastoma](https://www.moffitt.org/cancers/glioblastoma/ "Glioblastoma")
  * [Head and Neck Cancer](https://www.moffitt.org/cancers/head-and-neck-cancer/ "Head and Neck Cancer")
  * [HER2 Positive Breast Cancer](https://www.moffitt.org/cancers/her2-positive-breast-cancer/ "HER2 Positive Breast Cancer")
  * [Hodgkin Lymphoma](https://www.moffitt.org/cancers/hodgkin-lymphoma/ "Hodgkin Lymphoma")
  * [Inflammatory Breast Cancer](https://www.moffitt.org/cancers/inflammatory-breast-cancer/ "Inflammatory Breast Cancer")
  * [Invasive Ductal Carcinoma](https://www.moffitt.org/cancers/invasive-ductal-carcinoma/ "Invasive Ductal Carcinoma")
  * [Kidney (Renal Cell) Cancer](https://www.moffitt.org/cancers/kidney-renal-cell-cancer/ "Kidney \(Renal Cell\) Cancer")
  * [Leukemia](https://www.moffitt.org/cancers/leukemia/ "Leukemia")
  * [Liver (Hepatocellular) Cancer](https://www.moffitt.org/cancers/liver-hepatocellular-cancer/ "Liver \(Hepatocellular\) Cancer")
  * [Low-Grade Glioma](https://www.moffitt.org/cancers/low-grade-glioma/ "Low-Grade Glioma")
  * [Lung Cancer](https://www.moffitt.org/cancers/lung-cancer/ "Lung Cancer")
  * [Lymphomas (Hodgkin and Non-Hodgkin)](https://www.moffitt.org/cancers/lymphomas-hodgkin-and-non-hodgkin/ "Lymphomas \(Hodgkin and Non-Hodgkin\)")
  * [Mantle Cell Lymphoma](https://www.moffitt.org/cancers/mantle-cell-lymphoma/ "Mantle Cell Lymphoma")
  * [Melanoma](https://www.moffitt.org/cancers/melanoma/ "Melanoma")
  * [Meningioma](https://www.moffitt.org/cancers/meningioma/ "Meningioma")
  * [Merkel Cell Carcinoma](https://www.moffitt.org/cancers/merkel-cell-carcinoma/ "Merkel Cell Carcinoma")
  * [Mesothelioma](https://www.moffitt.org/cancers/mesothelioma/ "Mesothelioma")
  * [Metastatic Breast Cancer](https://www.moffitt.org/cancers/metastatic-breast-cancer/ "Metastatic Breast Cancer")
  * [Monoclonal Gammopathy of Undetermined Significance (MGUS)](https://www.moffitt.org/cancers/monoclonal-gammopathy-of-undetermined-significance-mgus/ "Monoclonal Gammopathy of Undetermined Significance \(MGUS\)")
  * [Multiple Myeloma-Plasma Cell Tumor](https://www.moffitt.org/cancers/multiple-myeloma-plasma-cell-tumor/ "Multiple Myeloma-Plasma Cell Tumor")
  * [Myelodysplastic Syndromes (MDS)](https://www.moffitt.org/cancers/myelodysplastic-syndromes-mds/ "Myelodysplastic Syndromes \(MDS\)")
  * [Neuroendocrine Tumor](https://www.moffitt.org/cancers/neuroendocrine-tumor/ "Neuroendocrine Tumor")
  * [Neurofibromatosis](https://www.moffitt.org/cancers/neurofibromatosis/ "Neurofibromatosis")
  * [Non-Hodgkin Lymphoma](https://www.moffitt.org/cancers/non-hodgkin-lymphoma/ "Non-Hodgkin Lymphoma")
  * [Oral Cavity (Mouth) Cancer](https://www.moffitt.org/cancers/oral-cavity-mouth-cancer/ "Oral Cavity \(Mouth\) Cancer")
  * [Insurance and Financial Information](https://www.moffitt.org/patient-family/insurance-financial-information/ "Insurance and Financial Information")
  * [Oral Cavity or Throat Cancer](https://www.moffitt.org/cancers/oral-cavity-or-throat-cancer/ "Oral Cavity or Throat Cancer")
  * [Osteosarcoma](https://www.moffitt.org/cancers/osteosarcoma/ "Osteosarcoma")
  * [Ovarian Cancer](https://www.moffitt.org/cancers/ovarian-cancer/ "Ovarian Cancer")
  * [Pancoast Tumor](https://www.moffitt.org/cancers/pancoast-tumor/ "Pancoast Tumor")
  * [Pancreatic Cancer](https://www.moffitt.org/cancers/pancreatic-cancer/ "Pancreatic Cancer")
  * [Penile Cancer](https://www.moffitt.org/cancers/penile-cancer/ "Penile Cancer")
  * [Pituitary Adenoma](https://www.moffitt.org/cancers/pituitary-adenoma/ "Pituitary Adenoma")
  * [Prostate Cancer](https://www.moffitt.org/cancers/prostate-cancer/ "Prostate Cancer")
  * [Rectal Cancer](https://www.moffitt.org/cancers/rectal-cancer/ "Rectal Cancer")
  * [Sarcoma](https://www.moffitt.org/cancers/sarcoma/ "Sarcoma")
  * [Skin Cancer (Nonmelanoma)](https://www.moffitt.org/cancers/skin-cancer-nonmelanoma/ "Skin Cancer \(Nonmelanoma\)")
  * [Skull Base Tumors](https://www.moffitt.org/cancers/skull-base-tumors/ "Skull Base Tumors")
  * [Small Intestine Cancer](https://www.moffitt.org/cancers/small-intestine-cancer/ "Small Intestine Cancer")
  * [Spinal Tumor](https://www.moffitt.org/cancers/spinal-tumor/ "Spinal Tumor")
  * [Squamous Cell Carcinoma](https://www.moffitt.org/cancers/squamous-cell-carcinoma/ "Squamous Cell Carcinoma")
  * [Smoldering Multiple Myeloma](https://www.moffitt.org/cancers/smoldering-multiple-myeloma-smm/ "Smoldering Multiple Myeloma")
  * [Stomach (Gastric) Cancer](https://www.moffitt.org/cancers/stomach-gastric-cancer/ "Stomach \(Gastric\) Cancer")
  * [Testicular Cancer](https://www.moffitt.org/cancers/testicular-cancer/ "Testicular Cancer")
  * [Throat Cancer](https://www.moffitt.org/cancers/throat-cancer/ "Throat Cancer")
  * [Thymoma](https://www.moffitt.org/cancers/thymoma/ "Thymoma")
  * [Thyroid Cancer](https://www.moffitt.org/cancers/thyroid-cancer/ "Thyroid Cancer")
  * [Tongue Cancer](https://www.moffitt.org/cancers/tongue-cancer/ "Tongue Cancer")
  * [Tracheal Cancer](https://www.moffitt.org/cancers/tracheal-cancer/ "Tracheal Cancer")
  * [Triple Negative Breast Cancer](https://www.moffitt.org/cancers/triple-negative-breast-cancer/ "Triple Negative Breast Cancer")
  * [Vaginal Cancer](https://www.moffitt.org/cancers/vaginal-cancer/ "Vaginal Cancer")
  * [Vulvar Cancer](https://www.moffitt.org/cancers/vulvar-cancer/ "Vulvar Cancer")


[](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-3)[Treatments](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-3)
  * [Blood Bone Marrow Transplant](https://www.moffitt.org/treatments/blood-bone-marrow-transplant/ "Blood Bone Marrow Transplant")
  * [Bloodless Medicine and Surgery](https://www.moffitt.org/treatments/bloodless-medicine-and-surgery/ "Bloodless Medicine and Surgery")
  * [Cardio-Oncology](https://www.moffitt.org/treatments/cardio-oncology/ "Cardio-Oncology")
  * [Chemotherapy](https://www.moffitt.org/treatments/chemotherapy/ "Chemotherapy")
  * [Clinical Pathways](https://www.moffitt.org/treatments/clinical-pathways/ "Clinical Pathways")
  * [Clinical Trials](https://www.moffitt.org/clinical-trials-research/clinical-trials/ "Clinical Trials")
  * [Diagnostic Services](https://www.moffitt.org/diagnostic-services/ "Diagnostic Services")
  * [Endoscopic Procedures](https://www.moffitt.org/treatments/endoscopic-procedures/ "Endoscopic Procedures")
  * [Fertility Preservation](https://www.moffitt.org/treatments/fertility-preservation/ "Fertility Preservation")
  * [Gynecologic Oncology](https://www.moffitt.org/treatments/gynecologic-oncology/ "Gynecologic Oncology")
  * [Immunotherapy](https://www.moffitt.org/treatments/immunotherapy/ "Immunotherapy")
  * [Interventional Pain Management](https://www.moffitt.org/treatments/interventional-pain-management/ "Interventional Pain Management")
  * [Interventional Radiology](https://www.moffitt.org/treatments/interventional-radiology/ "Interventional Radiology")
  * [Precision Medicine](https://www.moffitt.org/treatments/precision-medicine/ "Precision Medicine")
  * [Pharmacy](https://www.moffitt.org/treatments/pharmacy/ "Pharmacy")
  * [Radiation Therapy](https://www.moffitt.org/treatments/radiation-therapy/ "Radiation Therapy")
  * [Rehabilitation Services](https://www.moffitt.org/treatments/rehabilitation-services/ "Rehabilitation Services")
  * [Supportive Care Medicine](https://www.moffitt.org/treatments/supportive-care-medicine/ "Supportive Care Medicine")
  * [Surgical Care](https://www.moffitt.org/treatments/surgical-care/ "Surgical Care")
  * [Systemic Therapy](https://www.moffitt.org/treatments/systemic-therapy/ "Systemic Therapy")
  * [Targeted Therapy](https://www.moffitt.org/treatments/targeted-therapy/ "Targeted Therapy")
  * [Tumor Board](https://www.moffitt.org/treatments/tumor-board/ "Tumor Board")


[](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-3)[Clinical Trials](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-3)
  * [Am I A Candidate?](https://www.moffitt.org/clinical-trials-research/clinical-trials/am-i-a-candidate/ "Am I A Candidate?")
  * [Clinical Research Unit](https://www.moffitt.org/clinical-trials-research/clinical-trials/clinical-research-unit/ "Clinical Research Unit")
  * [Clinical Trials Administration](https://www.moffitt.org/clinical-trials-research/clinical-trials/clinical-trials-administration/ "Clinical Trials Administration")
  * [Clinical Trials: Are They Right for You?](https://www.moffitt.org/clinical-trials-research/clinical-trials/clinical-trials-are-they-right-for-you/ "Clinical Trials: Are They Right for You?")
  * [Patient Protection](https://www.moffitt.org/clinical-trials-research/clinical-trials/patient-protection/ "Patient Protection")
  * [Phase 1 Clinical Trials](https://www.moffitt.org/clinical-trials-research/clinical-trials/phase-1-clinical-trials/ "Phase 1 Clinical Trials")


[](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-3)[Diagnostic Services](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-3)
  * [Cancer Screenings](https://www.moffitt.org/diagnostic-services/cancer-screenings/ "Cancer Screenings")
  * [Genetic Counseling and Genetic Testing](https://www.moffitt.org/diagnostic-services/genetic-counseling-and-genetic-testing/ "Genetic Counseling and Genetic Testing")
  * [Labwork and Bloodwork](https://www.moffitt.org/diagnostic-services/labwork-and-bloodwork/ "Labwork and Bloodwork")
  * [Pathology](https://www.moffitt.org/diagnostic-services/pathology/ "Pathology")
  * [Radiology – Diagnostic Imaging and Interventional Radiology](https://www.moffitt.org/diagnostic-services/radiology-diagnostic-imaging-and-interventional-radiology/ "Radiology – Diagnostic Imaging and Interventional Radiology")
  * [Cancer Treatments](https://www.moffitt.org/treatments/ "Cancer Treatments")


[](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-1)[Patients & Families](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-1)
  * [ Patient & Family ](https://www.moffitt.org/patient-family/)
  * [ Preparing For Your Appointment ](https://www.moffitt.org/patient-family/preparing-for-your-appointment/) [](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-15)
  * [ Insurance & Financial Information ](https://www.moffitt.org/patient-family/insurance-financial-information/) [](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-17)
  * [ Programs & Support Services ](https://www.moffitt.org/patient-family/programs-support-services/) [](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-19)
  * [ Patient and Family Centered Care ](https://www.moffitt.org/patient-family/patient-and-family-centered-care/) [](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-21)
  * [ Cancer Survivorship ](https://www.moffitt.org/patient-family/cancer-survivorship/) [](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-23)
  * [ International Patient Services ](https://www.moffitt.org/patient-family/international-patient-services/) [](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-25)
  * [ Moffitt Virtual Care ](https://www.moffitt.org/patient-family/moffitt-virtual-care/) [](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-27)
  * [ Inspiring Stories ](https://www.moffitt.org/inspiring-stories/) [](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-29)


[](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-13)[Preparing For Your Appointment](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-13)
  * [Patient and Family Orientation](https://www.moffitt.org/patient-family/preparing-for-your-appointment/patient-and-family-orientation/ "Patient and Family Orientation")
  * [Medical Records](https://www.moffitt.org/patient-family/preparing-for-your-appointment/medical-records/ "Medical Records")
  * [Appointment Reminder Service](https://www.moffitt.org/patient-family/preparing-for-your-appointment/appointment-reminder-service/ "Appointment Reminder Service")
  * [MyMoffitt Patient Portal](https://www.moffitt.org/patient-family/preparing-for-your-appointment/mymoffitt-patient-portal/ "MyMoffitt Patient Portal")
  * [New Cancer Diagnosis](https://www.moffitt.org/patient-family/preparing-for-your-appointment/new-cancer-diagnosis/ "New Cancer Diagnosis")
  * [Online Registration Frequently Asked Questions](https://www.moffitt.org/patient-family/preparing-for-your-appointment/online-registration-frequently-asked-questions/ "Online Registration Frequently Asked Questions")
  * [Scheduling Your Appointment](https://www.moffitt.org/patient-family/preparing-for-your-appointment/scheduling-your-appointment/ "Scheduling Your Appointment")
  * [Traveling for Cancer Treatment](https://www.moffitt.org/patient-family/preparing-for-your-appointment/traveling-for-cancer-treatment/ "Traveling for Cancer Treatment")
  * [Preparing For Your Hospitalization](https://www.moffitt.org/patient-family/preparing-for-your-hospitalization/ "Preparing For Your Hospitalization")
  * [Preparing For Your Surgery](https://www.moffitt.org/patient-family/preparing-for-your-surgery/ "Preparing For Your Surgery")
  * [Visitor Policy](https://www.moffitt.org/patient-family/preparing-for-your-appointment/visitor-policy/ "Visitor Policy")
  * [Patient Rights and Responsibilities](https://www.moffitt.org/patient-family/preparing-for-your-appointment/patient-rights-and-responsibilities/ "Patient Rights and Responsibilities")
  * [What to Know About Your Appointments During Hurricane Season](https://www.moffitt.org/patient-family/hurricane/appointments-during-hurricane-season/ "What to Know About Your Appointments During Hurricane Season")


[](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-13)[Insurance & Financial Information](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-13)
  * [Copay Assistance Program](https://www.moffitt.org/patient-family/insurance-financial-information/copay-assistance-program/ "Copay Assistance Program")
  * [Financial Assistance](https://www.moffitt.org/patient-family/insurance-financial-information/financial-assistance/ "Financial Assistance")
  * [Glossary of Terms](https://www.moffitt.org/patient-family/insurance-financial-information/glossary-of-terms/ "Glossary of Terms")
  * [Health Exchange](https://www.moffitt.org/patient-family/insurance-financial-information/health-exchange/ "Health Exchange")
  * [Insurance Coverage](https://www.moffitt.org/patient-family/insurance-financial-information/insurance-coverage/ "Insurance Coverage")
  * [Medicare Coverage](https://www.moffitt.org/patient-family/insurance-financial-information/medicare-coverage/ "Medicare Coverage")
  * [Obtain a Cost Estimate](https://www.moffitt.org/patient-family/insurance-financial-information/obtain-a-cost-estimate/ "Obtain a Cost Estimate")
  * [Questions to Ask Your Insurance Company](https://www.moffitt.org/patient-family/insurance-financial-information/questions-to-ask-your-insurance-company/ "Questions to Ask Your Insurance Company")
  * [Understanding Your Bill](https://www.moffitt.org/patient-family/insurance-financial-information/understanding-your-bill/ "Understanding Your Bill")
  * [Frequently Asked Questions](https://www.moffitt.org/patient-family/insurance-financial-information/frequently-asked-questions/ "Frequently Asked Questions")
  * [Financial Information](https://www.moffitt.org/patient-family/insurance-financial-information/financial-information/ "Financial Information")


[](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-13)[Programs & Support Services](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-13)
  * [Advance Care Planning](https://www.moffitt.org/patient-family/programs-support-services/advance-care-planning/ "Advance Care Planning")
  * [AYA: Adolescent Young Adult Program](https://www.moffitt.org/patient-family/programs-support-services/aya-adolescent-young-adult-program/ "AYA: Adolescent Young Adult Program")
  * [Chaplaincy Spiritual Care](https://www.moffitt.org/patient-family/programs-support-services/chaplaincy-spiritual-care/ "Chaplaincy Spiritual Care")
  * [Community Resources](https://www.moffitt.org/patient-family/programs-support-services/online-resources/ "Community Resources")
  * [Counseling and Support](https://www.moffitt.org/patient-family/programs-support-services/counseling-and-support/ "Counseling and Support")
  * [Language Services](https://www.moffitt.org/patient-family/programs-support-services/language-services/ "Language Services")
  * [Nutrition](https://www.moffitt.org/patient-family/programs-support-services/nutrition/ "Nutrition")
  * [Senior Adult Oncology Program](https://www.moffitt.org/patient-family/programs-support-services/senior-adult-oncology-program/ "Senior Adult Oncology Program")
  * [Share Gratitude for Moffitt Team Members](https://www.moffitt.org/patient-family/patient-and-family-centered-care/share-gratitude-for-moffitt-team-members/ "Share Gratitude for Moffitt Team Members")
  * [Specialty Pharmacy at Moffitt](https://www.moffitt.org/patient-family/programs-support-services/specialty-pharmacy/ "Specialty Pharmacy at Moffitt")


[](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-13)[Patient and Family Centered Care](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-13)
  * [Demonstrating Respect at Moffitt](https://www.moffitt.org/patient-family/patient-and-family-centered-care/demonstrating-respect-at-moffitt/ "Demonstrating Respect at Moffitt")
  * [Daisy and Sunflower Awards](https://www.moffitt.org/patient-family/patient-and-family-centered-care/daisy-and-sunflower-awards/ "Daisy and Sunflower Awards")
  * [Patient and Family Advisory Program](https://www.moffitt.org/patient-family/patient-and-family-centered-care/patient-and-family-advisory-program/ "Patient and Family Advisory Program")
  * [Patient Relations](https://www.moffitt.org/patient-family/patient-and-family-centered-care/patient-relations/ "Patient Relations")
  * [Patient Researcher Forum](https://www.moffitt.org/patient-family/patient-and-family-centered-care/patient-researcher-forum/ "Patient Researcher Forum")
  * [Patti K Halula Legacy Award](https://www.moffitt.org/patient-family/patient-and-family-centered-care/patti-k-halula-legacy-award/ "Patti K Halula Legacy Award")
  * [Share Gratitude for Moffitt Team Members](https://www.moffitt.org/patient-family/patient-and-family-centered-care/share-gratitude-for-moffitt-team-members/ "Share Gratitude for Moffitt Team Members")


[](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-13)[Cancer Survivorship](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-13)
  * [Cancer Survivorship Program](https://www.moffitt.org/patient-family/cancer-survivorship/cancer-survivorship-program/ "Cancer Survivorship Program")


[](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-13)[International Patient Services](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-13)
  * [Frequently Asked Questions](https://www.moffitt.org/patient-family/international-patient-services/frequently-asked-questions/ "Frequently Asked Questions")
  * [Online Consult Forms](https://www.moffitt.org/patient-family/international-patient-services/online-consult-forms/ "Online Consult Forms")
  * [Online Consults](https://www.moffitt.org/patient-family/international-patient-services/online-consults/ "Online Consults")
  * [Moffitt Outreach in Puerto Rico](https://www.moffitt.org/patient-family/international-patient-services/puerto-rico/ "Moffitt Outreach in Puerto Rico")


[](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-13)[Moffitt Virtual Care](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-13)
  * [All About Virtual Care](https://www.moffitt.org/patient-family/moffitt-virtual-care/all-about-virtual-care/ "All About Virtual Care")
  * [Informed Consent for Telemedicine](https://www.moffitt.org/patient-family/moffitt-virtual-care/informed-consent-for-telemedicine/ "Informed Consent for Telemedicine")
  * [New Cancer Patients](https://www.moffitt.org/patient-family/moffitt-virtual-care/new-cancer-patients/ "New Cancer Patients")
  * [Virtual Care Success Checklist](https://www.moffitt.org/patient-family/moffitt-virtual-care/virtual-care-success-checklist/ "Virtual Care Success Checklist")


[](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-13)[Inspiring Stories](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-13)
  * [Isabel's Story](https://www.moffitt.org/inspiring-stories/isabels-story/ "Isabel's Story")
  * [Amanda's Story](https://www.moffitt.org/inspiring-stories/amandas-story/ "Amanda's Story")
  * [Rick's Story](https://www.moffitt.org/inspiring-stories/ricks-story-my-prostate-cancer-journey/ "Rick's Story")
  * [Vondalyn's Story: From Adversity to Advocacy](https://www.moffitt.org/inspiring-stories/vondalyns-story-from-adversity-to-advocacy/ "Vondalyn's Story: From Adversity to Advocacy")
  * [Cayla’s Story: Cancer Never Cares About Anything Like That](https://www.moffitt.org/inspiring-stories/caylas-story-cancer-never-cares-about-anything-like-that/ "Cayla’s Story: Cancer Never Cares About Anything Like That")
  * [Rick's Story: Now What?](https://www.moffitt.org/inspiring-stories/ricks-story-now-what/ "Rick's Story: Now What?")
  * [Amy's Story: No Longer Alone](https://www.moffitt.org/inspiring-stories/no-longer-alone/ "Amy's Story: No Longer Alone")
  * [Zoe's Story](https://www.moffitt.org/inspiring-stories/zoeys-story/ "Zoe's Story")
  * [Erma's Story](https://www.moffitt.org/inspiring-stories/ermas-story/ "Erma's Story")
  * [Donna's Story](https://www.moffitt.org/inspiring-stories/donnas-story/ "Donna's Story")
  * [Dr. Vadaparampil's Story](https://www.moffitt.org/inspiring-stories/dr.-vadaparampils-story "Dr. Vadaparampil's Story")
  * [Mark's Story](https://www.moffitt.org/inspiring-stories/marks-story/ "Mark's Story")
  * [Heather's Story](https://www.moffitt.org/inspiring-stories/heathers-story/ "Heather's Story")
  * [Ellen's Story](https://www.moffitt.org/inspiring-stories/ellens-story/ "Ellen's Story")
  * [Dr. Tran's Story](https://www.moffitt.org/inspiring-stories/dr.-trans-story "Dr. Tran's Story")
  * [Dr. Toloza's Story](https://www.moffitt.org/inspiring-stories/dr.-tolozas-story "Dr. Toloza's Story")
  * [Dr. Silva's Story](https://www.moffitt.org/inspiring-stories/dr.-silvas-story "Dr. Silva's Story")
  * [Dr. Fernandez's Story](https://www.moffitt.org/inspiring-stories/dr.-fernandezs-story "Dr. Fernandez's Story")
  * [Dr. Robinson's Story](https://www.moffitt.org/inspiring-stories/dr.-robinsons-story "Dr. Robinson's Story")
  * [Dr. Pow-Sang's Story](https://www.moffitt.org/inspiring-stories/dr.-pow-sangs-story "Dr. Pow-Sang's Story")
  * [Mike's Volunteer Story](https://www.moffitt.org/inspiring-stories/mikes-volunteer-story/ "Mike's Volunteer Story")
  * [Mike's Story](https://www.moffitt.org/inspiring-stories/mikes-story/ "Mike's Story")
  * [Mary Beth's Story](https://www.moffitt.org/inspiring-stories/mary-beths-story/ "Mary Beth's Story")
  * [Malcolm's Story](https://www.moffitt.org/inspiring-stories/malcolms-story/ "Malcolm's Story")
  * [Lori's Story](https://www.moffitt.org/inspiring-stories/loris-story2/ "Lori's Story")
  * [Miriam's Story](https://www.moffitt.org/inspiring-stories/miriams-story/ "Miriam's Story")
  * [Nick's Story](https://www.moffitt.org/inspiring-stories/nicks-story/ "Nick's Story")
  * [Nadine's Story](https://www.moffitt.org/inspiring-stories/nadines-story/ "Nadine's Story")
  * [Nancy's Story](https://www.moffitt.org/inspiring-stories/nancys-story/ "Nancy's Story")
  * [Madison's Story](https://www.moffitt.org/inspiring-stories/madisons-story/ "Madison's Story")
  * [Lori's Story](https://www.moffitt.org/inspiring-stories/loris-story/ "Lori's Story")
  * [Lloyd's Story](https://www.moffitt.org/inspiring-stories/lloyds-story/ "Lloyd's Story")
  * [Lanse's Story](https://www.moffitt.org/inspiring-stories/lanses-story/ "Lanse's Story")
  * [Kevin's Story](https://www.moffitt.org/inspiring-stories/kevins-story/ "Kevin's Story")
  * [Dr. Mooney's Story](https://www.moffitt.org/inspiring-stories/dr.-mooneys-story "Dr. Mooney's Story")
  * [Ken's Story](https://www.moffitt.org/inspiring-stories/kens-story/ "Ken's Story")
  * [Dr. Lee's Story](https://www.moffitt.org/inspiring-stories/dr.-lees-story "Dr. Lee's Story")
  * [Dr. Kumar's Story](https://www.moffitt.org/inspiring-stories/dr.-kumars-story "Dr. Kumar's Story")
  * [Keith's Story](https://www.moffitt.org/inspiring-stories/keiths-story2/ "Keith's Story")
  * [Dr. Latifi's Story](https://www.moffitt.org/inspiring-stories/dr.-latifis-story "Dr. Latifi's Story")
  * [Keith's Story](https://www.moffitt.org/inspiring-stories/keiths-story/ "Keith's Story")
  * [Dr. Kubal's Story](https://www.moffitt.org/inspiring-stories/dr.-kubals-story "Dr. Kubal's Story")
  * [Dr. Khakpour's Story](https://www.moffitt.org/inspiring-stories/dr.-khakpours-story "Dr. Khakpour's Story")
  * [Dr. Keenan's Story](https://www.moffitt.org/inspiring-stories/dr.-keenans-story "Dr. Keenan's Story")
  * [Dr. Kanetsky's Story](https://www.moffitt.org/inspiring-stories/dr.-kanetskys-story "Dr. Kanetsky's Story")
  * [Dr. Hoffe's Story](https://www.moffitt.org/inspiring-stories/dr.-hoffes-story "Dr. Hoffe's Story")
  * [Dr. Harrison's Story](https://www.moffitt.org/inspiring-stories/dr.-harrisons-story "Dr. Harrison's Story")
  * [Dr. Gwede's Story](https://www.moffitt.org/inspiring-stories/dr.-gwedes-story "Dr. Gwede's Story")
  * [Dr. Giuliano's Story](https://www.moffitt.org/inspiring-stories/dr.-giulianos-story "Dr. Giuliano's Story")
  * [Juli's Story](https://www.moffitt.org/inspiring-stories/julis-story/ "Juli's Story")
  * [Dr. Gonzalez's Story](https://www.moffitt.org/inspiring-stories/dr.-gonzalezs-story "Dr. Gonzalez's Story")
  * [Dr. Gatenby's Story](https://www.moffitt.org/inspiring-stories/dr.-gatenbys-story "Dr. Gatenby's Story")
  * [Dr. Etame's Story](https://www.moffitt.org/inspiring-stories/dr.-etames-story "Dr. Etame's Story")
  * [Dr. Cleveland's Story](https://www.moffitt.org/inspiring-stories/dr.-clevelands-story "Dr. Cleveland's Story")
  * [John and Whitney's Story](https://www.moffitt.org/inspiring-stories/john-and-whitneys-story/ "John and Whitney's Story")
  * [Liz's Story](https://www.moffitt.org/inspiring-stories/lizs-story/ "Liz's Story")
  * [Meet Lloyd](https://www.moffitt.org/inspiring-stories/meet-lloyd/ "Meet Lloyd")
  * [Paul and Gina's Story](https://www.moffitt.org/inspiring-stories/pauls-and-ginas-story/ "Paul and Gina's Story")
  * [Marvin's Story](https://www.moffitt.org/inspiring-stories/marvins-story/ "Marvin's Story")
  * [Meet Melissa](https://www.moffitt.org/inspiring-stories/meet-melissa/ "Meet Melissa")
  * [Muriel's Story](https://www.moffitt.org/inspiring-stories/muriels-story/ "Muriel's Story")
  * [John's and David's Story](https://www.moffitt.org/inspiring-stories/johns-and-davids-story/ "John's and David's Story")
  * [Melissa's Story](https://www.moffitt.org/inspiring-stories/melissas-story/ "Melissa's Story")
  * [Dr. Alexander Anderson's Story](https://www.moffitt.org/inspiring-stories/dr.-alexander-andersons-story "Dr. Alexander Anderson's Story")
  * [Pam's Story](https://www.moffitt.org/inspiring-stories/pams-story/ "Pam's Story")
  * [Yolanda's Story](https://www.moffitt.org/inspiring-stories/yolandas-story/ "Yolanda's Story")
  * [Wilbur's Story](https://www.moffitt.org/inspiring-stories/wilburs-story/ "Wilbur's Story")
  * [Vikki's Story](https://www.moffitt.org/inspiring-stories/vikkis-story/ "Vikki's Story")
  * [Tiffany's Story](https://www.moffitt.org/inspiring-stories/tiffanys-story/ "Tiffany's Story")
  * [Theresa's Story](https://www.moffitt.org/inspiring-stories/theresas-story/ "Theresa's Story")
  * [Joanna's Story](https://www.moffitt.org/inspiring-stories/joannas-story/ "Joanna's Story")
  * [Jenifer's Story](https://www.moffitt.org/inspiring-stories/jenifers-story/ "Jenifer's Story")
  * [Jeanine's Story](https://www.moffitt.org/inspiring-stories/jeanines-story/ "Jeanine's Story")
  * [Meet Jackie](https://www.moffitt.org/inspiring-stories/meet-jackie/ "Meet Jackie")
  * [Ian's Story](https://www.moffitt.org/inspiring-stories/ians-story/ "Ian's Story")
  * [Howard's Story](https://www.moffitt.org/inspiring-stories/howards-story/ "Howard's Story")
  * [Ryan's Story](https://www.moffitt.org/inspiring-stories/ryans-story/ "Ryan's Story")
  * [Robert's Story](https://www.moffitt.org/inspiring-stories/roberts-story/ "Robert's Story")
  * [Rick's Story](https://www.moffitt.org/inspiring-stories/ricks-story/ "Rick's Story")
  * [Richard's Story](https://www.moffitt.org/inspiring-stories/richards-story/ "Richard's Story")
  * [Rena's Story](https://www.moffitt.org/inspiring-stories/renas-story/ "Rena's Story")
  * [Rebecca's Story](https://www.moffitt.org/inspiring-stories/rebeccas-story/ "Rebecca's Story")
  * [Ray's and Dr. Bui's story](https://www.moffitt.org/inspiring-stories/rays-and-dr.-buis-story "Ray's and Dr. Bui's story")
  * [Patti's Story](https://www.moffitt.org/inspiring-stories/pattis-story/ "Patti's Story")
  * [Pam and Jonathan's story](https://www.moffitt.org/inspiring-stories/pams-and-jonathans-story/ "Pam and Jonathan's story")
  * [Sarah's Story](https://www.moffitt.org/inspiring-stories/sarahs-story/ "Sarah's Story")
  * [Steve and Laura's Story](https://www.moffitt.org/inspiring-stories/steve-and-lauras-story/ "Steve and Laura's Story")
  * [Donna's Story](https://www.moffitt.org/inspiring-stories/donna/ "Donna's Story")
  * [Tommy's Story](https://www.moffitt.org/inspiring-stories/tommys-story/ "Tommy's Story")
  * [Viviana's Story](https://www.moffitt.org/inspiring-stories/vivianas-story/ "Viviana's Story")
  * [Craig's Story](https://www.moffitt.org/inspiring-stories/craigs-story/ "Craig's Story")
  * [William's Story](https://www.moffitt.org/inspiring-stories/williams-story/ "William's Story")
  * [The Wilson - Jones's Family Story](https://www.moffitt.org/inspiring-stories/the-joness-family-story/ "The Wilson - Jones's Family Story")
  * [Woodrow's Story](https://www.moffitt.org/inspiring-stories/woodrows-story/ "Woodrow's Story")
  * [Cathy's Story](https://www.moffitt.org/inspiring-stories/cathys-story2/ "Cathy's Story")
  * [Cathy's Story](https://www.moffitt.org/inspiring-stories/cathys-story/ "Cathy's Story")
  * [Carolyn's Story](https://www.moffitt.org/inspiring-stories/carolyn/ "Carolyn's Story")
  * [Beth's Story](https://www.moffitt.org/inspiring-stories/beths-story/ "Beth's Story")
  * [Benita's Story](https://www.moffitt.org/inspiring-stories/benitas-story/ "Benita's Story")
  * [Barney's Story](https://www.moffitt.org/inspiring-stories/barneys-story/ "Barney's Story")
  * [Joel's Story](https://www.moffitt.org/inspiring-stories/joels-story/ "Joel's Story")
  * [Jessica's Story](https://www.moffitt.org/inspiring-stories/jessicas-story/ "Jessica's Story")
  * [Jen's Story](https://www.moffitt.org/inspiring-stories/jens-story/ "Jen's Story")
  * [Jay's Story](https://www.moffitt.org/inspiring-stories/jays-story/ "Jay's Story")
  * [Janelle's Story](https://www.moffitt.org/inspiring-stories/janelles-story/ "Janelle's Story")
  * [Greg's Story](https://www.moffitt.org/inspiring-stories/gregs-story2/ "Greg's Story")
  * [Gayle's Story](https://www.moffitt.org/inspiring-stories/gayles-story/ "Gayle's Story")
  * [Francis' Story](https://www.moffitt.org/inspiring-stories/francis-story/ "Francis' Story")
  * [Dr. Lau's Story](https://www.moffitt.org/inspiring-stories/dr.-laus-story "Dr. Lau's Story")
  * [Dr. Roberto Diaz's Story](https://www.moffitt.org/inspiring-stories/dr.-roberto-diazs-story "Dr. Roberto Diaz's Story")
  * [Dimas' Story](https://www.moffitt.org/inspiring-stories/dimas-story/ "Dimas' Story")
  * [David and Vesta's Story](https://www.moffitt.org/inspiring-stories/david-and-vestas-story/ "David and Vesta's Story")
  * [Cydney's Story](https://www.moffitt.org/inspiring-stories/cydneys-story/ "Cydney's Story")
  * [Charles' Story](https://www.moffitt.org/inspiring-stories/charless-story/ "Charles' Story")
  * [Cammie's Story](https://www.moffitt.org/inspiring-stories/cammies-story/ "Cammie's Story")
  * [Joanne's Story](https://www.moffitt.org/inspiring-stories/joannes-story/ "Joanne's Story")
  * [Neisha's Story](https://www.moffitt.org/inspiring-stories/neishas-story/ "Neisha's Story")
  * [Greg's Story](https://www.moffitt.org/inspiring-stories/gregs-story/ "Greg's Story")
  * [Joshua's Story](https://www.moffitt.org/inspiring-stories/joshuas-story/ "Joshua's Story")
  * [Bridget's Story](https://www.moffitt.org/inspiring-stories/bridgets-story/ "Bridget's Story")
  * [Barbara's Story](https://www.moffitt.org/inspiring-stories/barbaras-story/ "Barbara's Story")
  * [Abrianna's Story](https://www.moffitt.org/inspiring-stories/abriannas-story/ "Abrianna's Story")


[](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-1)[For Healthcare Professionals](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-1)
  * [ For Healthcare Professionals ](https://www.moffitt.org/for-healthcare-professionals/)
  * [ Clinical Programs and Services ](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/) [](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-33)
  * [ Physician Relations ](https://www.moffitt.org/for-healthcare-professionals/physician-relations/)
  * [ Continuing Education ](https://www.moffitt.org/for-healthcare-professionals/continuing-education/) [](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-35)


[](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-31)[Clinical Programs and Services](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-31)
  * [Adolescent Young Adult (AYA) Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/adolescent-young-adult-aya-program/ "Adolescent Young Adult \(AYA\) Program")
  * [Anesthesiology and Critical Care Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/anesthesiology-program/ "Anesthesiology and Critical Care Program")
  * [BMT and Cellular Immunotherapy Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/bmt-and-cellular-immunotherapy-program/ "BMT and Cellular Immunotherapy Program")
  * [Breast Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/breast-oncology-program/ "Breast Oncology Program")
  * [Cardio-Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/cardio-oncology-program/ "Cardio-Oncology Program")
  * [Cutaneous Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/cutaneous-oncology-program/ "Cutaneous Oncology Program")
  * [Diagnostic Imaging and Interventional Radiology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/diagnostic-imaging-and-interventional-radiology-program/ "Diagnostic Imaging and Interventional Radiology Program")
  * [Endocrine Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/endocrine-oncology-program/ "Endocrine Oncology Program")
  * [Endoscopic Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/endoscopic-oncology-program/ "Endoscopic Oncology Program")
  * [Gastrointestinal Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/gastrointestinal-oncology-program/ "Gastrointestinal Oncology Program")
  * [Genetic Counseling Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/genetic-counseling-program/ "Genetic Counseling Program")
  * [Genitourinary Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/genitourinary-oncology-program/ "Genitourinary Oncology Program")
  * [Gynecologic Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/gynecologic-oncology-program/ "Gynecologic Oncology Program")
  * [Head and Neck Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/head-and-neck-oncology-program/ "Head and Neck Oncology Program")
  * [Immunotherapy Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/immunotherapy-program/ "Immunotherapy Program")
  * [Malignant Hematology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/malignant-hematology-program/ "Malignant Hematology Program")
  * [Moffitt Malignant Hematology Cellular Therapy at Memorial Healthcare System](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/moffitt-malignant-hematology-cellular-therapy-at-memorial-healthcare-system/ "Moffitt Malignant Hematology Cellular Therapy at Memorial Healthcare System")
  * [Neuro-Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/neuro-oncology-program/ "Neuro-Oncology Program")
  * [Pathology](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/pathology/ "Pathology")
  * [Pharmacy](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/pharmacy/ "Pharmacy")
  * [Radiation Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/radiation-oncology-program/ "Radiation Oncology Program")
  * [Sarcoma Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/sarcoma-program/ "Sarcoma Program")
  * [Screening Prevention](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/screening-prevention/ "Screening Prevention")
  * [Senior Adult Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/senior-adult-oncology-program/ "Senior Adult Oncology Program")
  * [Supportive Care Medicine Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/supportive-care-medicine-program/ "Supportive Care Medicine Program")
  * [Thoracic Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/thoracic-oncology-program/ "Thoracic Oncology Program")
  * [Translational Pathology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/translational-pathology/ "Translational Pathology Program")


[](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-31)[Continuing Education](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-31)
  * [Moffitt Grand Rounds](https://www.moffitt.org/for-healthcare-professionals/continuing-education/moffitt-grand-rounds/ "Moffitt Grand Rounds")
  * [Provider Conferences](https://www.moffitt.org/for-healthcare-professionals/continuing-education/provider-conferences/ "Provider Conferences")


[](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-1)[Research](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-1)
  * [ Research Science ](https://www.moffitt.org/research-science/)
  * [ Research Programs ](https://www.moffitt.org/research-science/research-programs/) [](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-39)
  * [ Divisions and Departments ](https://www.moffitt.org/research-science/divisions-and-departments/) [](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-41)
  * [ Centers and Institutes ](https://www.moffitt.org/research-science/centers-and-institutes/) [](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-43)
  * [ Community Outreach and Engagement ](https://www.moffitt.org/research-science/community-outreach-and-engagement/) [](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-45)
  * [ Shared Resources ](https://www.moffitt.org/research-science/shared-resources/) [](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-47)
  * [ Academic and Industry Partnerships ](https://www.moffitt.org/research-science/academic-and-industry-partnerships/) [](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-49)
  * [ Administration ](https://www.moffitt.org/research-science/administration/) [](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-51)


[](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-37)[Research Programs](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-37)
  * [Cancer Biology and Evolution](https://www.moffitt.org/research-science/research-programs/cancer-biology-and-evolution/ "Cancer Biology and Evolution")
  * [Cancer Epidemiology](https://www.moffitt.org/research-science/research-programs/cancer-epidemiology/ "Cancer Epidemiology")
  * [Health Outcomes and Behavior](https://www.moffitt.org/research-science/research-programs/health-outcomes-behavior/ "Health Outcomes and Behavior")
  * [Immuno-Oncology](https://www.moffitt.org/research-science/research-programs/immuno-oncology/ "Immuno-Oncology")
  * [Molecular Medicine](https://www.moffitt.org/research-science/research-programs/molecular-medicine/ "Molecular Medicine")


[](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-37)[Divisions and Departments](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-37)
  * [Basic Science](https://www.moffitt.org/research-science/divisions-and-departments/basic-science/ "Basic Science")
  * [BioEngineering](https://www.moffitt.org/research-science/divisions-and-departments/bioengineering/ "BioEngineering")
  * [Clinical Science](https://www.moffitt.org/research-science/divisions-and-departments/clinical-science/ "Clinical Science")
  * [Population Science](https://www.moffitt.org/research-science/divisions-and-departments/population-science/ "Population Science")
  * [Quantitative Science](https://www.moffitt.org/research-science/divisions-and-departments/quantitative-science/ "Quantitative Science")


[](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-37)[Centers and Institutes](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-37)
  * [Centers of Excellence](https://www.moffitt.org/research-science/centers-and-institutes/centers-of-excellence/ "Centers of Excellence")
  * [Institutes](https://www.moffitt.org/research-science/centers-and-institutes/institutes/ "Institutes")


[](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-37)[Community Outreach and Engagement](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-37)
  * [About COE](https://www.moffitt.org/research-science/community-outreach-and-engagement/about-coe/ "About COE")
  * [Advisory Boards](https://www.moffitt.org/research-science/community-outreach-and-engagement/community-advisory-boards/ "Advisory Boards")
  * [Catchment Area](https://www.moffitt.org/research-science/community-outreach-and-engagement/catchment-area/ "Catchment Area")
  * [Data](https://www.moffitt.org/research-science/community-outreach-and-engagement/data/ "Data")
  * [Outreach](https://www.moffitt.org/research-science/community-outreach-and-engagement/outreach/ "Outreach")
  * [Research and Clinical Trials](https://www.moffitt.org/research-science/community-outreach-and-engagement/research-and-clinical-trials/ "Research and Clinical Trials")
  * [Get Involved With COE](https://www.moffitt.org/research-science/community-outreach-and-engagement/get-involved-with-coe/ "Get Involved With COE")


[](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-37)[Shared Resources](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-37)
  * [Analytic Microscopy](https://www.moffitt.org/research-science/shared-resources/analytic-microscopy/ "Analytic Microscopy")
  * [Biostatistics and Bioinformatics](https://www.moffitt.org/research-science/shared-resources/biostatistics-and-bioinformatics/ "Biostatistics and Bioinformatics")
  * [Cancer Pharmacokinetics and Pharmacodynamics](https://www.moffitt.org/research-science/shared-resources/cancer-pharmacokinetics-and-pharmacodynamics/ "Cancer Pharmacokinetics and Pharmacodynamics")
  * [Chemical Biology](https://www.moffitt.org/research-science/shared-resources/chemical-biology/ "Chemical Biology")
  * [Collaborative Data Services](https://www.moffitt.org/research-science/shared-resources/collaborative-data-services/ "Collaborative Data Services")
  * [Flow Cytometry](https://www.moffitt.org/research-science/shared-resources/flow-cytometry/ "Flow Cytometry")
  * [Gene Targeting](https://www.moffitt.org/research-science/shared-resources/gene-targeting/ "Gene Targeting")
  * [Molecular Genomics](https://www.moffitt.org/research-science/shared-resources/molecular-genomics/ "Molecular Genomics")
  * [Participant Research, Interventions, and Measurement Core (PRISM)](https://www.moffitt.org/research-science/shared-resources/participant-research-interventions-and-measurement-core-prism/ "Participant Research, Interventions, and Measurement Core \(PRISM\)")
  * [Proteomics and Metabolomics](https://www.moffitt.org/research-science/shared-resources/proteomics-and-metabolomics/ "Proteomics and Metabolomics")
  * [Quantitative Imaging Core](https://www.moffitt.org/research-science/shared-resources/quantitative-imaging-core/ "Quantitative Imaging Core")
  * [Small Animal Imaging Lab](https://www.moffitt.org/research-science/shared-resources/small-animal-imaging-lab/ "Small Animal Imaging Lab")
  * [Tissue](https://www.moffitt.org/research-science/shared-resources/tissue/ "Tissue")


[](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-37)[Academic and Industry Partnerships](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-37)
  * [Office of Innovation](https://www.moffitt.org/research-science/academic-and-industry-partnerships/office-of-innovation/ "Office of Innovation")
  * [Academic Partnerships](https://www.moffitt.org/research-science/academic-and-industry-partnerships/academic-partnerships/ "Academic Partnerships")


[](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-37)[Administration](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-37)
  * [Non-Therapeutic Research Office](https://www.moffitt.org/research-science/administration/non-therapeutic-research-office/ "Non-Therapeutic Research Office")


[](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-1)[Training & Education](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-1)
  * [ Education ](https://www.moffitt.org/education/)
  * [ Medical Education ](https://www.moffitt.org/education/medical-education/) [](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-55)
  * [ Research Education and Training ](https://www.moffitt.org/education/research-education-and-training/) [](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-57)
  * [ Nursing Education ](https://www.moffitt.org/education/nursing-education/) [](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-59)
  * [ Health Professional Education ](https://www.moffitt.org/education/health-professional-education/) [](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-61)
  * [ Other Educational Programs ](https://www.moffitt.org/education/other-educational-programs/)


[](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-53)[Medical Education](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-53)
  * [Our Training Programs](https://www.moffitt.org/education/medical-education/our-training-programs/ "Our Training Programs")
  * [Program Staff/Contact Us](https://www.moffitt.org/education/medical-education/program-staffcontact-us/ "Program Staff/Contact Us")
  * [Salary and Benefits](https://www.moffitt.org/education/medical-education/salary-and-benefits/ "Salary and Benefits")
  * [About Tampa Bay](https://www.moffitt.org/careers/about-tampa-bay/ "About Tampa Bay")


[](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-53)[Research Education and Training](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-53)
  * [Office of Postdoctoral Affairs](https://www.moffitt.org/education/research-education-and-training/office-of-postdoctoral-affairs/ "Office of Postdoctoral Affairs")
  * [Office of Graduate Affairs](https://www.moffitt.org/education/research-education-and-training/office-of-graduate-affairs/ "Office of Graduate Affairs")
  * [Office of Undergraduate and Visiting Scholar Affairs](https://www.moffitt.org/education/research-education-and-training/office-of-undergraduate-and-visiting-scholar-affairs/ "Office of Undergraduate and Visiting Scholar Affairs")
  * [Pre-College Programs](https://www.moffitt.org/education/research-education-and-training/pre-college-programs/ "Pre-College Programs")
  * [What We Provide](https://www.moffitt.org/education/research-education-and-training/what-we-provide/ "What We Provide")
  * [Contact Us](https://www.moffitt.org/education/research-education-and-training/contact-us/ "Contact Us")
  * [About Tampa Bay](https://www.moffitt.org/careers/about-tampa-bay/ "About Tampa Bay")
  * [News](https://www.moffitt.org/education/research-education-and-training/news/ "News")
  * [Where Are They Now](https://www.moffitt.org/education/research-education-and-training/where-are-they-now/ "Where Are They Now")


[](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-53)[Nursing Education](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-53)
  * [Ambulatory Care Oncology Nurse Residency Program](https://www.moffitt.org/education/nursing-education/ambulatory-care-oncology-nurse-residency-program/ "Ambulatory Care Oncology Nurse Residency Program")
  * [Nurse Anesthetist](https://www.moffitt.org/education/nursing-education/nurse-anesthetist/ "Nurse Anesthetist")
  * [Nurse Practitioner](https://www.moffitt.org/education/nursing-education/nurse-practitioner/ "Nurse Practitioner")
  * [Oncology Nurse Residency Program](https://www.moffitt.org/education/nursing-education/oncology-nurse-residency-program/ "Oncology Nurse Residency Program")
  * [Registered Nurse](https://www.moffitt.org/education/nursing-education/registered-nurse/ "Registered Nurse")


[](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-53)[Health Professional Education](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-53)
  * [Advanced Pharmacy Practice (APPE)](https://www.moffitt.org/education/health-professional-education/advanced-pharmacy-practice-appe/ "Advanced Pharmacy Practice \(APPE\)")
  * [Anesthesiology Assistant](https://www.moffitt.org/education/health-professional-education/anesthesiology-assistant/ "Anesthesiology Assistant")
  * [Dietetic Technician](https://www.moffitt.org/education/health-professional-education/dietetic-technician/ "Dietetic Technician")
  * [Dietitian](https://www.moffitt.org/education/health-professional-education/dietitian/ "Dietitian")
  * [Genetic Counseling](https://www.moffitt.org/education/health-professional-education/genetic-counseling/ "Genetic Counseling")
  * [Introductory Pharmacy Practice (IPPE)](https://www.moffitt.org/education/health-professional-education/introductory-pharmacy-practice-ippe/ "Introductory Pharmacy Practice \(IPPE\)")
  * [Master of Public Health Field Experience](https://www.moffitt.org/education/health-professional-education/master-of-public-health-field-experience/ "Master of Public Health Field Experience")
  * [Medical Assistants](https://www.moffitt.org/education/health-professional-education/medical-assistants/ "Medical Assistants")
  * [Nuclear Medicine](https://www.moffitt.org/education/health-professional-education/nuclear-medicine/ "Nuclear Medicine")
  * [Occupational Therapy Intern](https://www.moffitt.org/education/health-professional-education/occupational-therapy-intern/ "Occupational Therapy Intern")
  * [PGY1 Pharmacy Residency](https://www.moffitt.org/education/health-professional-education/pgy-1-residency/ "PGY1 Pharmacy Residency")
  * [PGY2 Oncology Pharmacy Residency](https://www.moffitt.org/education/health-professional-education/pgy-2-oncology-residency/ "PGY2 Oncology Pharmacy Residency")
  * [Oncology Pharmacy Technician Trainee Program](https://www.moffitt.org/education/health-professional-education/pharmacy-technician-extern/ "Oncology Pharmacy Technician Trainee Program")
  * [Physical Therapy](https://www.moffitt.org/education/health-professional-education/physical-therapy/ "Physical Therapy")
  * [Physical Therapy Assistant](https://www.moffitt.org/education/health-professional-education/physical-therapy-assistant/ "Physical Therapy Assistant")
  * [Physician Assistant](https://www.moffitt.org/education/health-professional-education/physician-assistant/ "Physician Assistant")
  * [Psychology](https://www.moffitt.org/education/health-professional-education/psychology/ "Psychology")
  * [Radiation Therapy](https://www.moffitt.org/education/health-professional-education/radiation-therapy/ "Radiation Therapy")
  * [Radiography Therapy](https://www.moffitt.org/education/health-professional-education/radiography-therapy/ "Radiography Therapy")
  * [Respiratory Therapy](https://www.moffitt.org/education/health-professional-education/respiratory-therapy/ "Respiratory Therapy")
  * [Social Work](https://www.moffitt.org/education/health-professional-education/social-work/ "Social Work")
  * [Sonography/Ultrasound Student](https://www.moffitt.org/education/health-professional-education/sonographyultrasound-student/ "Sonography/Ultrasound Student")
  * [Speech Therapy](https://www.moffitt.org/education/health-professional-education/speech-therapy/ "Speech Therapy")
  * [Wound Ostomy](https://www.moffitt.org/education/health-professional-education/wound-ostomy/ "Wound Ostomy")


[](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-1)[Give](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-1)
  * [ Give ](https://www.moffitt.org/give/)
  * [ Why Give? ](https://www.moffitt.org/give/why-give/) [](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-65)
  * [ Ways to Give ](https://www.moffitt.org/give/ways-to-give/) [](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-67)
  * [ Get Involved ](https://www.moffitt.org/give/get-involved/) [](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-69)


[](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-63)[Why Give?](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-63)
  * [About the Moffitt Foundation](https://www.moffitt.org/give/why-give/about-the-moffitt-foundation/ "About the Moffitt Foundation")
  * [FAQ](https://www.moffitt.org/give/why-give/faq/ "FAQ")
  * [Financials and Stewardship](https://www.moffitt.org/give/why-give/financials-and-stewardship/ "Financials and Stewardship")
  * [Contact the Foundation](https://www.moffitt.org/give/why-give/contact-the-foundation/ "Contact the Foundation")
  * [You Can Make a Difference](https://www.moffitt.org/give/why-give/you-can-make-a-difference/ "You Can Make a Difference")
  * [Impact Report](https://www.moffitt.org/give/your-impact/2022-annual-foundation-impact-report/ "Impact Report")


[](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-63)[Ways to Give](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-63)
  * [Cash, Stock or Other Assets](https://www.moffitt.org/give/ways-to-give/cash-stock-or-other-assets/ "Cash, Stock or Other Assets")
  * [Planned Giving](https://mymoffittlegacy.org/ "Planned Giving")
  * [Philanthropic Foundation Giving](https://www.moffitt.org/give/ways-to-give/philanthropic-foundation-giving/ "Philanthropic Foundation Giving")
  * [Corporate Partnership](https://www.moffitt.org/give/ways-to-give/corporate-partnership/ "Corporate Partnership")
  * [Employer Matching Gifts](https://www.moffitt.org/give/ways-to-give/employer-matching-gifts/ "Employer Matching Gifts")
  * [Endowment Gifts](https://www.moffitt.org/give/ways-to-give/endowment-gifts/ "Endowment Gifts")
  * [Other Ways to Donate](https://www.moffitt.org/give/ways-to-give/other-ways-to-donate/ "Other Ways to Donate")
  * [Breast Cancer Funding Opportunities](https://www.moffitt.org/give/ways-to-give/breast-cancer-funding-opportunities/ "Breast Cancer Funding Opportunities")
  * [Support the Pentecost Family Myeloma Research Center](https://www.moffitt.org/give/ways-to-give/support-the-pentecost-family-myeloma-research-center/ "Support the Pentecost Family Myeloma Research Center")
  * [Partners In Discovery](https://www.moffitt.org/give/ways-to-give/partners-in-discovery/ "Partners In Discovery")


[](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-63)[Get Involved](https://www.moffitt.org/research-science/researchers/taiga-nishihori#mm-63)
  * [Become a Member](https://www.moffitt.org/give/get-involved/become-a-member/ "Become a Member")
  * [Volunteer Your Time](https://www.moffitt.org/give/get-involved/volunteer-your-time/ "Volunteer Your Time")
  * [Miles for Moffitt](https://www.moffitt.org/give/get-involved/miles-for-moffitt/ "Miles for Moffitt")
  * [Magnolia](https://www.moffitt.org/give/get-involved/magnolia/ "Magnolia")
  * [Mission Possible Sarasota Luncheon](https://www.moffitt.org/give/get-involved/mission-possible-sarasota-luncheon/ "Mission Possible Sarasota Luncheon")
  * [Discovery Series Webinars](https://www.moffitt.org/give/get-involved/discovery-series-webinars/ "Discovery Series Webinars")
  * [Fundraise for Moffitt](https://www.moffitt.org/give/get-involved/fundraise-for-moffitt/ "Fundraise for Moffitt")


[](https://www.moffitt.org/research-science/researchers/taiga-nishihori#page)
